REQUEST FOR PROPOSAL

Third party evaluation on availability of free drugs under FDSI in selected primary and secondary public health care facilities in Six states and one UT in India.

NATIONAL HEALTH SYSTEMS RESOURCE CENTRE,
MINISTRY OF HEALTH & FAMILY WELFARE,
GOVERNMENT OF INDIA.

30/11/2025

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India.

****

RFP No: NHSRC/25-26/QPS/DU/RFP/615 **Date of Issue: 30/11/2025**

REQUEST FOR PROPOSAL(RFP)

THIRD PARTY EVALUATION OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATE S AND ONE UT IN INDIA

National Health Systems Resource Centre (NHSRC) a technical support wing of Ministry of Health & Family Welfare, Govt. of India, invites sealed proposals from the research/ academic organizations/ institutions/ consulting agencies/ Non-Govt. Organizations for **"THIRD PARTY EVALUATION OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA".** Bidders fulfilling the prescribed eligibility criteria of the RFP can access and download the complete RFP Document and other details from https://nhsrcindia.org/. Details of the schedule are given below:

Sl. No	List of Key Events	Schedule Dates
1.	Date & Time of issue of RFP	30/11/2025
2.	Pre bid meeting	08/12/2025 at 1500 Hours
3.	Last date and time for receipt of Bids	21/12/2025 up to 1400 Hours
4.	Date and time for opening of technical bid.	22/12/2025 at 1500 Hours
5.	Date and time for opening of Financial bid.	24/12/2025 at 1500 Hours
6.	Website for downloading RFP documents, corrigendum etc.	www.nhsrcindia.org
7.	Validity of bid offers	180 days from date of opening of pre-qualification-cum-technical bid.

8.	Method of selection	Quality and Cost Based Selection (QCBS) (70:30) (Technical- **70,** financial- **30**)
9.	Bids/queries to be addressed to	Advisor Quality & Patient Safety National Health Systems Resource Centre, NIHFW Campus, Baba Gang Nath Marg, Munirka, New Delhi- 110067 e-mail: drug.cell@nhsrcindia.org
10.	Performance Security total cost of Bid (for Finalized Bidder only)	03% of contract value

Interested bidders fulfilling the eligibility/essential criteria shall submit the bid along with all requisite documents will be considered for technical bid evaluation. The bidders who qualify for the technical bid will only be considered for the financial bid evaluation. The detailed proposal containing the Technical and Financial proposals separately under sealed cover clearly indicating **Technical bid for RFP,** "**THIRD PARTY EVALUATION OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" and **Financial bid for RFP**, "**THIRD PARTY AUDIT OF AVAILABILITY OF FREE DRUGS SERVICES UNDER FDSI IN SELECTED PRIMARY AND SECONDARY CARE PUBLIC**
HEALTH FACILITIES IN SIX STATES AND ONE UT IN INDIA" on the right-hand upper corner of each envelope, placed in one covering envelope clearly mentioning on the top of it "**THIRD PARTY EVALUATION OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" in the tender box, addressed to the Principal Administrative Officer, National Health Systems Resource Centre by 21/12/2025 by 14:00 Hours.

The detailed terms and conditions of the RFP may be downloaded from the NHSRC website https://nhsrcindia.org/ and the same shall be read as part and parcel of this RFP

1. Overview

1.1. Background

The National Health Mission (NHM) launched the "Free Drugs Service Initiative" (FDSI) in July 2015 to ensure access to essential medicines services free of cost to all patients visiting the public health facilities.

Uninterrupted availability of essential medicines in public health systems facilitates to achieve Sustainable development goal (SDG) Target- 3.8 i.e. achievement of Universal Health Coverage (UHC), including financial risk protection and access to safe, effective, quality and affordable essential medicines and vaccines for all and (SDG) Target- 3.4 i.e. reduction of one third premature mortality (33 %) from non-communicable diseases by 2030 by ensuring accessibility of NCD Medicines. MoHFW has defined the EML for all levels of health facilities accordingly states are having their state specific EDL. Many states are having established central procuring agency for timely and cost-effective procurement of medicines. States are also having their IT enabled supply chain management system and at national level the supply chain is monitored through DVDMS central dashboard.

Despite several interventions, the last-mile delivery and availability of free quality medicines across the health facilities remain a challenge. The underlying causes are multifaceted.

Though there has been a gradual decrease in Out-of-Pocket Expenditure (OOPE) which was 62.6 % in 2014 and now stand at 39.4 % in 2022, still drugs constitute over 67% of OOPE on healthcare. The total Pharmaceutical Expenditure (TPE) is 30. 84% of the Current Health Expenditure (CHE), which includes prescribed medicines and over-the-counter drugs.

1.2. Context

The Indian Public Health Standard EML recommends 381 medicines for District hospitals (DH), 318 medicines for Sub district hospitals (SDH), 300 medicines for Community health centers (CHC), 172 medicines for Ayushman Arogya Mandir primary health centers (AAM-PHC)/ Ayushman Arogya Mandir urban primary health centers (AAM-UPHC) and 105 medicines for Ayushman Arogya Mandir sub health centers (AAM-SHC). Hydroxyurea is also recommended essential for sickle cell prevalent states. States and UTs have developed their Essential Drugs List (EDL) by considering the medicines recommended in IPHS EML and disease prevalence in their respective State/UT. Under the said scheme, Government of India (GoI) have been providing both technical and financial support to States/UTs for strengthening various components under FDSI to ensure uninterrupted access of essential medicines to public across primary and secondary level public health facilities.

Providing equitable availability of essential medicines in all primary and secondary care public health facilities i.e. DH, SDH, CHC, AAM-PHC/AAM-UPHC and AAM-SHC/AAM-USHC, a major challenge in a larger country like India.

Hence it necessitates to engage an independent organization to collect information on medicine availability at various levels of public health facilities-DH, SDH, CHC, AAM-PHC/AAM-UPHC and

AAM-SHC/AAM-USHC to assess the availability of free medicines as per under the Free Drugs Service Initiative (FDSI Scheme) and their inventory trends.

Note - "This RFP does not alter or amend any statutory procurement, licensing, or clinical protocol of MoHFW or State Government; it is purely for data collection and evaluation purposes."

2. Objectives & Scope of work

2.1 Objective: To engage an independent qualified organization to collect, verify and analyze data regarding medicine availability of essential medicines under Free Drugs Service Initiative (FDSI) across selected public health facilities as per IPHS and states-specific EMLs on:

Primary objective: To study the Availability of free drugs under Free Drugs Service Initiative (FDSI)

Secondary Objectives: To assess the following

- Number of medicines dispensed to the patient against prescribed prescriptions
- Transportation system in use to supply the medicines in the visited facility
- Availability of locally procured medicines
- Indent verses supply of medicines
- Number and percentage of expired medicines
- Number and percentage of wastage medicines
- Prescription of medicines in generic names
- Patient satisfaction on availability of medicines
- Perspective of service provider and patient towards quality of medicines

2.2 SCOPE OF WORK:

To achieve the objectives, the scope of 3rd Party Evaluation is as follows:

2.2.1 Detailed Scope of Work (Methods)

2.2.1.1 Sampling strategy:

- Purposive Sampling: One state from each zone (07 zones including EAG State) for selection of States/UT. In each selected state, 10% of the total number of districts {or at least two districts in each state (one best performing and one comparatively poor performing)} are considered as sample districts for data collection.
- Selection of secondary level Health Facilities in selected sample districts: One DH, One SDH and two CHCs (one FRU and one Non-FRU, one nearest to the District Headquarter and one farthest from the District Headquarter)} of each sample district.
- Selection of primary level Health Facilities: one AAM PHC/UPHC in each block and two AAM-SHC/AAM-USHC under each selected AAM PHC/ AAM UPHC) to be considered for the data collection. The blocks will be selected based on the distance from the District Headquarter:

- 1st block- located nearest to the District Headquarter.
- 2nd block- located farthest from the District Headquarter.

- The AAM-PHCs and AAM-SHCs within the block will also be selected by considering the nearest and farthest distance to/from the Block headquarters.
- The name of sample facilities will be shared with the selected bidders along with the Notification of Award
- Drug availability will primarily be assessed retrospectively through stock registers, bin cards, DVDMS/State LMIS entries, and issue vouchers for the reference period 1st April – 30th September 2025. To triangulate the record-based findings and strengthen validity, exiting OPD patients and patients at the time of discharge (IPD) will be briefly interviewed (3–4 questions) on whether they actually received the prescribed medicines free of cost and in full quantity on the day of visit/discharge. Random physical verification of medicines being issued from the pharmacy counter will also be performed on the day of the visit.

Note: All prescriptions and exit interviews will be selected systematically (every 5th prescription/register entry) from records and exiting patients during the 6-month reference period only.

For more details refer following tables:
Table 1: Sample Size from each facility level for prescription audit
Table 2: Sample states to be evaluated
Table 3: State wise, number of sample health institution for data collection on medicine availability

Table 1. Sample Size from each facility level for prescription audit

Facility Level	No. of Prescriptions to be Audited (Apr–Sep 2025 only)	Proportion OPD: IPD	No. of Exit Interviews (Patient Satisfaction) – OPD	No. of Exit Interviews (Patient Satisfaction) – IPD (on discharge)
DH	600	70: 30	60	40
SDH	600	80: 20	50	30
CHC	600	90: 10	50	20
AAM-PHC/UPHC	120 (or 10 % of total OPD registrations in the 6-month period, whichever is higher)	NA	30	0
AAM-SHC/USHC	60 (or 10 % of total OPD registrations in the 6-month period, whichever is higher)	NA	20	0

Note: -

a. At primary level if the case load is low,10% of total OPD (Outpatient Department) may be considered.
b. At AAM-SHC level, e-prescriptions and refill prescriptions may be considered.

Table 2. Sample states to be evaluated

Zone	Number of states to be selected	Names of the States/UT
North	1	Uttar Pradesh
East	1	Jharkhand
West	1	Maharashtra
South	1	Kerala
Centre	1	Gujarat
North-East	1	Nagaland
UT	1	Puducherry

Table 3. State wise, number of sample health institution for data collection on medicine availability

State	Total Number of Districts (a)	Number of Sample Districts (10% of the total number of districts {or at least two districts in each state) (b)	No. of Blocks (c)	Total number of DHs (d)	Total number of SDHs (e)	Total number of CHCs (Urban & Rural) (f)	Total number of AAM-PHCs (Urban & Rural) (g)	Total number of AAM-SHCs (Urban & Rural) (h)	Number of Sample Health Institutions for 3rd Party Evaluation					
									DH (One DH per sample districts) (i)	**SDH** (One SDH of sample districts) (j)	**CHC** (2 CHCs of each sample district) (k)	**AAM-PHC/UPHC** (1 PHC under each CHC) (l)	**AAM-SHC/USHC** (2 SHC under each PHC) (m)	Total no. of Sample Health Facilities to be Audited (DH, SDH, CHC, AAM-PHC & AAM-SHC/USHC
Uttar Pradesh	75	8	826	125	0	950	3653	25723	8	NA	16	16	32	72
Nagaland	12	2	74	12	0	23	136	465	2	NA	4	4	8	18
Jharkhand	24	2	264	21	13	195	385	3863	2	2	4	4	8	20
Maharashtra	36	4	351	22	95	481	2812	10740	4	4	8	8	16	40
Kerala	14	2	152	47	87	230	945	5412	2	2	4	4	8	20
Gujarat	33	3	250	20	56	370	1836	9149	3	3	6	6	12	30
Puducherry	4	4	6	4	0	4	45	84	2	NA	4	4	8	18
Total	196	23	1923	251	251	2253	9812	55436	23	11	46	46	92	218

2.2.2. Team composition

- Service provider shall designate teams as per the ToR. Each team to visit one site in a day. Each team will consist of two members, including domain experts or individuals with expertise in health logistics and supply chain management, or monitoring and evaluation or statistician.

2.2.3 Timeline for Data Collection and Reporting:

- Data Collection at health facilities: Completion of data collection and patient interviews within 90 days of time from the date of issuance of order or execution of MoU/Contract.
- Total Duration: The selected empaneled organization must submit the compiled facility wise and state wise analysis report, cleaned & raw data sheets along with supporting documents within 120 days from the date of issuance of order or execution of Contract.
- The service provider shall submit all raw data collected as part of this exercise/study to the client upon completion of the study.

2.2.4 Working Areas:

Assessment of medicine availability as per IPHS and State-notified Essential Drugs List (EDL) at various level of selected health facilities.

Quantitative data will be collected on stock availability, consumption, inventory and on medicines prescribed and dispensed at various levels of public health facilities. Additionally, qualitative data will be gathered through patient facility feedback, patient surveys, in-depth interviews, and focus group discussions with providers, managers, users, programme participants to understand their experience, perception & Satisfaction, and non-users. Furthermore, all the collected data will be submitted after analysis including working sheets and raw data.

2.2.5 Participants to be covered at the facility:

- Staff/Official (Pharmacist/Nursing/CHO/MOs) responsible for management of stock and store
- Patient (hospitalized & non-hospitalized)/relatives'/ attendants

2.2.6. Data Collection:

- Collection of information on medicine availability, inventory data, and consumption.
- Data Period: 1st April 2025 to 30th September 2025.
- Free quality medicines provided to patient.
- Prospective of service providers and patients towards free quality medicines.

Note:

- Any modifications to the NHSRC Evaluation toolkit shall be made only after obtaining NHSRCs written consent.
- The selected technical partner shall conduct data collection activities using the structural questionnaire provided in Annexure-VII series (NHSRC evaluation toolkit)
- Statistical Analysis: Use appropriate statistical methods to analyze quantitative data.

- To ensure quality of the audit, real time monitoring of the audit process may be carried out by officials of MoHFW, NHSRC, respective State and SHSRC.
- MoHFW, NHSRC and State reserves the right to validate the quality of the collected, data collected by the selected technical partner at any point of time across the audit process.

2.2.7 Reporting:

- Deployment of resources, development of schedule, trainings, and pretesting within thirty (30) days of time from the date of issuance of order or execution of Contract.
- Submit interim progress reports in each month.
- On completion of field level activities (data collection), data cleaning & data compilation, the successful party has to provide the compiled facility wise and state wise analysis report, submission of working sheets latest by 120 days of time from the date of issuance of order or execution of MoU/Contract.

2.2.8 Ethical Consideration:

- Participants' consent: Prior to conducting interviews with patients, relatives, or caregivers, a written informed consent must be obtained using the consent form outlined in Annexure-III, which must be translated into the local language as well as in English by the selected agency.
- Confidentiality: All collected data will be kept confidential and shared only with the NHSRC. Any data collected through IT platforms will be securely stored and accessed only by the NHSRC or authorized state officials.
- The service provider shall ensure that no identifiable patient or staff information is collected, stored or transmitted in violation of data protection norms. All data shall be anonymized before sharing.
- Ethical Clearance will be obtained by NHSRC prior to the start of the study.

2.2.9 Data Security and Management:

The Partner shall treat all data collected during the assignment as strictly confidential, store it in encrypted form with access restricted only to authorized personnel, and shall not disclose, transfer, or use the same for any purpose other than fulfilment of this contract without prior written approval of NHSRC/MoHFW; upon completion/termination of the contract, all raw data, backups, and copies shall be irrevocably destroyed or handed over to NHSRC within fifteen (15) days, as directed.

Any instance of data leakage, unauthorized disclosure, or breach of data security by the partner or its personnel shall constitute a material breach of this Contract, entitling NHSRC/MoHFW to forthwith terminate the Contract without notice or liability, forfeit the performance security, and pursue all available legal remedies including blacklisting and civil/criminal action.

Confidentiality: All collected data will be kept confidential and shared only with the NHSRC. Any data collected through IT platforms will be securely stored and accessed only by the NHSRC or authorized state officials.

The working papers, raw data and the data generated out of the process is the sole property of NHSRC, MoHFW. The selected partner cannot use the data for their own research purposes, nor license the data to be used by others, without the written consent and approval from NHSRC. No identifiable patient or staff information is collected, stored or transmitted in violation of data protection norms. All data shall be anonymized before sharing.

3. Deliverable:

The selected technical support partner has to complete field-level data collection, data cleaning, and submit the compiled facility wise and state wise analysis report along with cleaned dataset and all supporting documents within 120 days from the date of signing the contract (including a one-month grace period). The deliverables will be as follows:

The filled pre-approved checklist (accepted by the selected technical support partner) of each evaluated facility, each interviewed official, and patient has to be submitted:

- Availability of free quality medicines (Both IPHS EML and State EDL).
- Stock verification
- Number of medicines dispensed to the patient against prescriptions
- Prescription of medicines in generic names
- Transportation system in use to supply the medicines to the visited facility.
- Availability of locally procured medicines
- Indent verses supply of medicines
- Number and percentage of expired medicines
- Number and percentage of wastage medicines
- Patient satisfaction on availability of medicines
- Perspective of service provider and patient towards quality medicines

The signed consent form of each interviewed patient/ relative/ attendant has to be submitted.

4. Methodology for selection of the Technical Support Partner:

The prospective technical support partner would be required to submit a detailed proposal i.e. Technical and Financial proposals separately under sealed cover clearly indicating **"Technical bid for RFP, THIRD PARTY EVALUATION FOR AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" and **"Financial bid for RFP**, **THIRD PARTY AUDIT OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" on the right-hand upper corner of each envelope, placed in one covering envelope clearly mentioning on the top of it "**THIRD PARTY EVALUATION FOR AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" in the tender box, addressed to the Principal Administrative Officer, NHSRC, NIHFW Campus, Baba Gangnath Marg, Munirka, New Delhi-110067 by 21/12/2025 by 14:00 Hours.

Two separate envelopes must be submitted containing the technical bid and financial bid respectively within the covering envelope. Failure to observe this may lead to disqualification of the organization from further consideration. The Technical support Partner should clearly mention of any partnership deal struck with other agencies to carry out the project. It is required to submit a copy of the contract between the partners duly signed and attested by the authorized signatory for the bid. In the Technical bid, the response of the prospective technical partner on the format given below should be furnished on a separate sheet duly signed by authorized signatory.

The prospective technical partners are required to furnish the following details in their technical proposal, apart from that information, as mentioned in clause/point number 5 of this document:

1. *Brief Profile of Organization (not exceeding five pages)*
2. *Proposed Methodology- This section should describe your understanding of the Public Health System and the methodology, which will be followed by the organization in the execution of this assignment. The methodology should essentially include following sections -*

   Technical Approach, Methodology and Work plan (not exceeding ten pages) - In this section, we expect to understand your concept of the Public Health System in the country and other related issues, with reference to stated and implied objectives of the assignment. A brief write-up on following topics may please be included in the proposal:

   i. *Indian Public Health Standard (IPHS) EML and its rationalization.*
   ii. *Availability of medicines in public health facilities.*
   iii. *Out-of-pocket expenditure on medicines.*

3. Following documents should be attached as Annexures to the Technical Proposal

I. *Registration Certificate of the organization i.e. proprietary /partnership/ LLP/ Company/ society/ trust/ NGO/ educational institute/ etc.*

II. *Contact details of Head Office, Registered Office and Regional/Branch Offices (Please mention name of contact person, full address, telephone number, email details). Full Valid Business Registration Certificates, Lease Agreement or Property Ownership, Utility Bills (Recent – Within 3 Months) and Employee Records or EPFO/ESIC filings to be submitted as documentary proof.*

III. *Certified audited balance sheets justifying the annual turnover for the last three financial years, i.e. FY-2024-25, FY-2023-24 and FY-2022-23. For average annual turnover of last three years, submit a declaration duly certified by CA. Also submit the ITR filed.*

IV. *Positive Net worth (Avg. of preceding 3 years) declaration duly certified by CA.*

V. *Details of the years of experience of the organization in developing and implementing different projects with government/ PSU. List of all assignments undertaken by the organization during preceding years.*

VI. *Work order/ Contract/ MoU obtained/ executed with Government or PSU relating to third party Audit or baseline study or Evaluation on medicine accessibility/ availability or supply chain process evaluation or public health program evaluation or out of pocket*

expenditure or perception of doctors over generic medicines/ Standard treatment guidelines (STGs)/ FDSI or Perception of patients towards the available services in public health facilities or Perception of Community towards FDSI or various government health care schemes.

VII. *Strength of full time employees, (excluding secretarial and clerical staff) who have previous experience of working on third party Audit or baseline study or Evaluation on medicine accessibility/ availability or supply chain process evaluation or public health program evaluation, out of pocket expenditure or perception of doctors over generic medicines/ Standard treatment guidelines (STGs)/ FDSI or Perception of patients towards the available services in public health facilities or Perception of Community towards FDSI or various government health care schemes. (Please provide numbers for each category) - (i) pharmacy expert (ii) Healthcare / Hospital Management Specialist.*

VIII. *Technical proposal/proposed methodology with respect to the technical approach, methodology and work plan in reference to stated and implied objectives of the assignment.*

IX. *Documents/ Enclosures, supporting to the proposed objective and scope of work, if any.*

X. *Filled curriculum vitae as per Annexure-I (Along with supporting document).*

XI. *Filled Technical proposal.*

XII. *Presentation on assignment- The bidder will be required to make a presentation on their organization's experience, planning, approach, strategy, technology, timeline, and personnel to be engaged, with reference to the clauses of the RFP. The presentation will be held at NHSRC, NIHFW Campus, Baba Gangnath Marg, Munirka, New Delhi-110067 during the technical evaluation of bids for which bidders will be intimated in advance.*

XIII. *A certificate from the authorized signatory that the organization had not been blacklisted or debarred by Central Government / State Government*

XIV. *A signed statement, mentioning the number of different states which can be undertaken simultaneously by your organization.*

XV. *In case of any partnership deal struck with other agencies to carry out the project, copy of the MoU or contract between the partners duly signed and attested by the authorized signatory for the Bid.*

XVI. *The duly signed Integrity Pact (Annexure VII) must be submitted along with the complete set of documents.*

5. Evaluation of Technical Proposal:

Following evaluation criteria would be used to evaluate the technical proposal of organization. Hence the Technical Support Partner (TSP) may provide answers to Serial No 1 to 8.

Technical proposal format			
Sl. No.	**Information to be furnished by TSP**	**Total Score**	**Details**

1	**Pan-India presence. Please mention numbers of office in India (01 Mark for each state, where the organization has its office, up to 10 states)**	**10**		
2	**Average Annual turnover per year in preceding three years Less than Rs. 50 lakhs =0** **Rs. 50 – Rs. 100 lakhs = 5 More than Rs. 100 lakhs = 10 Note:** • **Annual Turnover for the last three financial years i.e. FY- 2024-25 FY-2023-24 and FY-2022-23 has to be considered.** • **For average annual turnover of last three years, submit a declaration duly certified by CA. Also submit the ITR filed.**	**10**	**Years (FY)** 	**Figures**
3	**Positive Net worth (Avg. of preceding 3 years)** **Less than Rs. 50 lakhs =0 More than Rs. 50 lakhs – Rs. 100 lakhs = 5** **More than Rs. 100 lakhs - Rs. 200 lakhs = 10** **More than Rs. 200 lakhs = 15**	**10**	**Years (FY)** 	**Figures**
4	**Details of the years of experience of the organization in developing and implementing different projects with government/ PSU.** **More than 15 years = 15** **>12 – 15 years = 12** **>10 – 12 years = 10** **>07 – 10 years = 07** **>05 – 07 years = 05** **>03 – 05 years = 03** **>01 – 03 years = 01** **01 year or less = 0**	**15**		
5	**Number of Government/ PSU projects pertaining to Third party Audit or baseline study or Evaluation on medicine accessibility/ availability or supply chain process evaluation or public health program evaluation or Out of pocket**	**20**		

	expenditure or perception of doctors over generic medicines/ Standard treatment guidelines (STGs)/ FDSI or Perception of patients towards the available services in public health facilities or Perception of Community towards FDSI or various government health care schemes, executed by the organization. • **1 mark for each project up to 15 projects** • **15 + = 20**		
6.	**Domain Experts must be full-time employees (excluding secretarial and clerical staff) who have prior experience in field surveys, third-party evaluations, baseline studies, or evaluations related to medicine accessibility/ availability, supply chain process assessments, public health programme evaluations, out-of-pocket expenditure, doctors' perceptions of generic medicines/Standard Treatment Guidelines (STGs)/FDSI, patients' perceptions of services in public health facilities, community perceptions toward FDSI, or various government healthcare schemes** **Up to 12 = 03** **13-20 = 06** **21-30 = 09** **31-50 = 12** **51 + = 20**	**20**	
Type of Experts (Full Time Employee with field experience)			**Number of employees for each category**
a	**Pharmacy expert**		
b	**Hospital management expert**		
c	**Public health experts**		
d	**Statistician**		

7	**Quality of Technical proposal with respect to the technical approach, methodology and work plan in reference to stated and implied objectives of the assignment (Max marks – 10)** **(As given in section 4-2. a)**	**10**	
8	**Presentation on assignment regarding organization experience, planning, approach, strategy, technology, timeline, & personnel to be engaged with reference to the clauses of RFP**	**5**	

Only those bidders who have fulfilled the eligibility criteria shall be evaluated. The cut off marks for short listing based on the technical evaluation is 60 out of 100 (total marks). Evaluation committee shall have the right to verify the claims made by the bidder; in whichever way it deems fit. Based on the Bid Evaluation, only technically qualified Bidders scoring more than cut off marks shall be short listed for financial bid evaluation.

6. Evaluation of Financial Proposal:

6.1 Evaluation Method: Quality and Cost Based Selection (QCBS) method will be followed during the overall selection process. Based on the evaluation of technical proposal, the technically qualified bidders shall be ranked highest to lowest Technical Score (ST) in accordance with the marks obtained during the technical evaluation stage. There shall be 70 % weightage to technical score and 30 % weightage to financial score.

6.2 Financial bid of only the short-listed Bidders shall be opened. The lowest evaluated financial bid (Fm) will be given the maximum financial score (Sf) of 100 (one hundred) points. The financial scores (Sf) of the other Financial Proposals will be computed as per the formula, **"Sf = 100 x Fm/F"** in which Sf is the financial score, Fm is the lowest financial quote and F is the financial quote under consideration.

6.3 Since geographical variation and state wise sample size are important factors in delivery of services, the prospective bidder has to quote the total rate for all the selected six states and one UT along with the individual rate for each state and UT separately in the financial bid format (Annexure-II).

7. Submission of Bids:

7.1 The prospective technical support partner would be required to submit a detailed proposal i.e. Technical and Financial proposals separately under sealed cover clearly indicating **"Technical bid for RFP, THIRD PARTY EVALUATION FOR AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" and **"Financial bid for RFP**, **THIRD**

PARTY AUDIT OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA" on the right-hand upper corner of each envelope, placed in one covering envelope clearly mentioning on the top of it "**THIRD PARTY EVALUATION FOR AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA**" in the tender box, addressed to the Principal Administrative Officer, NHSRC, NIHFW Campus, Baba Gangnath Marg, Munirka, New Delhi-110067 by 21/12/2025 by 14:00 Hours. The Technical support Partner should clearly mention of any partnership deal struck with other agencies to carry out the project. It is required to submit a copy of the MOU or contract between the partners duly signed by the authorized signatory for the bid. This will be considered as a part of technical bid.

8. *The conditions of the ToRs, if required, may be modified by the mutual consent of signatories of the agreement. (Annexure VI)*

9. Payment Schedule, Contract Period, Timelines and Deduction

9.1 Payment Schedule / Mechanism:

1. The total project cost is to be finalized on the basis of the final quoted amount in the financial bid and subsequent price negotiation, if any.
2. The agency has to quote the price in financial bid, which must include all expenses considering the cost of Human Resources, Logistics, Capex and Overhead Cost for completion of the assignment.
3. GST as applicable will be paid extra.
4. No advance will be paid.

The following is the tentative payment schedule to the agency on successful completion of the phase wise assignment. However, the payment schedule subject to change, if so, required at the time of signing contract for the assignment.

Phase	Up to Stage	% of Contract Fees
1st	Deployment of Resources, Development of action plan, questionnaires, trainings, and pretesting.	30%
2nd	On completion of field level activities (data collection), data cleaning & data compilation, the selected party has to provide the compiled facility wise and state wise analysis report, along with working sheets, raw data and supporting documents.	70%

9.2 The contract will be operationalized by: NHSRC, MoHFW, GoI

9.3. This project is for a period of 365 days {field level evaluation within ninety (90) days & work sheet submission along with supporting documents within one hundred twenty (120) days,

starting from the date of release of work order/ execution of MoU.

9.4. The Technical Support Partner and their interface personnel are required to show professional behavior in course of interaction with all stake holders.

9.5. The Technical Support Partner is expected to comply with the provisions of Term of Reference and timelines suggested therein. Failure to comply with the above may culminate in deduction from their bills of an amount commensurate with the impact of noncompliance or even termination of the contract to be decided by NHSRC.

10. The contract shall be finalized as per the process detailed below:

a) The technical bids shall be opened by Tender Evaluation Committee.
b) The minimum qualifying score of technical bid evaluation would be 60%. The financial bids of unsuccessful bidders would be dispatched on their address by registered post/ courier by NHSRC.
c) Those who score 60% or more shall be communicated by e-mail on their address, at least seven days before the scheduled date & time of opening of the financial bid, to be present on the date, time and venue of opening of Financial Bids.
d) The Financial Bids shall be opened before financial evaluation committee (FEC) and representatives of the invited bidders who turn up on the day of opening.
e) The technical support partner TSP will be finalized based on the highest QCBS score.

11. Future Use of Data: The working papers, raw data and the data generated out of the process is the sole property of NHSRC, MoHFW. The agency cannot use the data for their own research purposes, nor license the data to be used by others, without the written consent and approval from NHSRC.

N.B.: The selected agency has to commence and complete the assignment as per requirement of the NHSRC, MoHFW and submit the final work sheet in the prescribed format.

12. Other Terms and conditions:

12.1 Authority's Right to Vary Scope at Time of Award:
If any change in Scope of the Contract causes an increase or decrease in the cost of, or the time required for, the Bidder performance of any part of the work under the Contract, an equitable adjustment shall be made in the Contract Price or schedule of implementation, or both, and the Contract, shall, accordingly be amended. Any claims by the Bidder for adjustment under this Para must be asserted within thirty (30) days from the date of the Bidder receipt of the Authority changed order.

12.2. Authority's right to accept and to reject any/ all Bids:
Authority reserves the right to reject any / all bid partially or fully at any stage without assigning any reason thereof.

12.3. Notification of Award & Signing of Contract:

- Prior to expiry of the period of Bid validity, the Authority will notify the successful Bidders in writing that its Bid has been accepted and send the successful Bidders the filled Contract Form.
- Within 10 days of receipt of the Notification of Award, the successful Bidders shall sign the contract and return it to the Authority (by submitting the performance security amount). If the successful Bidder/s thus selected fails to sign the contract as stipulated, the Authority reserves the right to offer the contract to the next highest scoring Bidder. However, the authority reserves the right to award the work to more than one agency.

12.4. Penalty:

Authority will levy penalty in case the agency fails to provide the services specified by the Authority in the ToR of this RFP document. The amount of penalty shall be commensurate with the nature of the breach/ defect/ deviation/fault and as decided by Authority. Such an amount payable by the Service Provider shall be final and binding and shall not exceed 10% of the Total Accepted Contract Value of the agency for the Contract Period,

If there is repeated delay in submitting interim / final report as demanded by the Authority, then penalty shall be charged as deemed appropriate by the Authority subject to maximum of 10% upper limit.

12.5. Termination of The Contract:

The competent authority may, by a written notice of termination to the Bidder, suspend the Contract if the Bidder fails to perform any of its obligations under this Contract (including the carrying out of the services) provided that such notice of suspension.

- Shall specify the nature of the failure and
- Shall request the Bidder to make good such failure within a specified period from the date of receipt of such notice of suspension by the Bidder.

12.6. Proposal Validity:

Proposal must remain valid for 180 days after the submission date. During this period, Agencies shall maintain the availability of professional staff nominated in the Proposal and fully commit to their financial proposal, unchanged. The Client will make is best effort to complete negotiation within this period. The proposal validity may be mutually extended, if required.
Changes to the proposals shall not be permitted once they have been submitted to NHSRC, MoHFW. All applicants must retain a copy of the proposal and all enclosures which accompany their application for their own records. The proposal must accompany with detailed information on the organization's primary contact details.

12.7. Performance Security:

- Within 10 days of receipt of Notification of Award, the successful Bidders has to submit the performance security in the form of Account payee Demand Draft from any of the Commercial Banks in favor of the, National Health Systems Resource Centre (NHSRC),

Munirka, New Delhi- 110067, having validity not less than 365 days from the date of signing of the contract

- The Performance Security will be released by the Purchaser without any interest to the bidder upon satisfactory completion of the Contract obligations
- In the event of the Bidder's failure to fulfil their contractual obligations or perform satisfactorily, the Performance Security shall be forfeited.

13. Address for submission of Bids:

Principle Administrative Officer, NHSRC, NIHFW campus, Baba Gangnath Marg, Munirka, New Delhi-110067 by **21/12/2025 14:00 Hours**

Annexure-I

CURRICULUM VITAE

Sl. No	Particulars		Documents to be submitted	
1.	**Name of the Organization (as mentioned in the registration certificate/Deed.** Attach the copy of documentary evidence.			
2.	**Date of registration**			
3.	**Type of the organization: proprietary /partnership/ LLP/ Company/ society/ trust/ NGO/ educational institute/ etc.**			
4.	**Address of the Head office of the Organization:** **Telephone no.:** **E-mail ID:** **Name of the authorized person:**			
5.	**Correspondence address (if different from above)**			
6.	**GST Registration no.**			
7.	**Name of the authorized signatory: Designation:** **Telephone no.:** **E-mail ID:**			
8.	**Current Designation**			
9.	**Period of employment with the Organization (Years & Months)**		- -----Years	- ------- months
10.	**Academic qualification**			
11.	**Year of Establishment**			
12.	**Pan-India presence. Please mention numbers of office in India.**			
	Address of the offices in different States/UTs.	Type of the office (Head office/Regional	Name of the Contact person, telephone number and E-mail id details:	

	Full Valid Business Registration Certificates, Lease Agreement or Property Ownership, Utility Bills (Recent – Within 90 days) and Employee Records or EPFO/ESIC filings to be submitted as documentary proof	office/Branch office)		
12.i				
12.ii				
12.iii				
12.iv				
12.v				
13.	**Average Annual turnover per year in preceding three years** **Note:** • **Annual Turnover for the last three financial years i.e. FY-2024-25 FY-2023-24 and FY-2022-23 has to be considered.** • **For average annual turnover of last three financial years, submit a declaration duly certified by CA. Also submit the ITR filed.**		Year (FY)	Figures
14.	**Positive Net worth (Avg. of preceding 3 financial years) declaration duly certified by CA.**		Year (FY)	Figures

15.	**Details of the years of experience of the organization in developing and implementing different projects with government/ PSU. (Attach documentary evidence)**			
	Name of the client	**Type of the work/assignment performed**	**Project Cost**	**Year**
15.i				
15.ii				
15.iii				
15.iv				
15.v				

16	**Details of the Government/ PSU projects relating to third party Audit or baseline study or Evaluation on medicine accessibility/ availability or supply chain process evaluation or public health program evaluation or out of pocket expenditure or perception of doctors over generic medicines/ Standard treatment guidelines (STGs)/ FDSI or Perception of patients towards the available services in public health facilities or Perception of Community towards FDSI or various government health care schemes executed by the organization. Work order/ Contract/ MoU, obtained/ executed with Government or PSU has to be enclosed.**			
	Name of the client	**Type of the work/assignment performed**	**Project Cost**	**Year**
16.i				
16.ii				
16.iii				
16.iv				
16.v				

17	**Strength of full-time employees, (excluding secretarial and clerical staff) who have previous experience of working on third party Audit or baseline study or Evaluation on medicine accessibility/ availability or supply chain process evaluation or out of pocket expenditure or perception of doctors over generic medicines/ Standard treatment guidelines (STGs)/ FDSI or Perception of patients towards the available services in public health facilities or Perception of Community towards FDSI or various government health care schemes. (Please provide numbers for each category) - (i) pharmacy expert (ii) Healthcare / Hospital Management Specialist**			
	Name of the person	**Qualification**	**Designation**	**Total years of work experience**
17.i				
17.ii				
17.iii				
17.iv				
17.v				

Annexure-II

FINACIAL BID FORMAT

RFP Notice No. – NHSRC/25-26/QPS/DU/RFP/615 **Dated 30/11/2025**

To,

The Executive Director,

National Health Systems Resource Centre (NHSRC),
NIHFW campus, Baba Gangnath Marg,
Munirka, New Delhi-110067.

Sir,
I/we hereby bid for providing services for as per the "Terms and Reference given in this RFP document within the time specified and in accordance with the specification/T&C. The rates are quoted in prescribed format given below:

SI. No.	Particulars	Total Costs (in INR)	Applicable GST %, if any	Applicable GST amount	Total Cost including GST
1	Total Cost for Conducting Third party audit of availability of free drugs services under FDSI in selected primary and secondary care public health facilities in six states and one UT in India.				
	The state wise break-up is as follows				
	Uttar Pradesh				
	Nagaland				
	Jharkhand				
	Maharashtra				
	Kerala				
	Gujarat				
	Puducherry				

The rates indicated above are all inclusive for completion of assignments & submission of report to NHSRC, MoHFW and are valid for the total contract period.

Signature of the Bidder with Seal

Annexure- III

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India

Informed Consent Form for Patient Interview

Title: Medicine Availability Assessment at Public Health Facilities

Introduction:

We are conducting a third-party evaluation to assess the availability of medicines at public health facilities. As part of this audit, we would like to interview patients and their relatives to gather information about their experiences with medicine availability. Your participation in this interview will help us understand the challenges and strengths of the current medicine supply system.

Purpose of the Interview:

The purpose of this interview is to gather information about your experiences with medicine availability at this public health facility. Your responses will be used to identify areas for improvement for further strengthening the medicine supply system.

Confidentiality:

All information collected during this interview will be kept confidential and anonymous. Your name and any identifying information will not be shared with anyone. The data collected will be used for the purpose of this audit only.

Voluntary Participation:

Your participation in this interview is entirely voluntary. You have the right to refuse to answer any question or to stop the interview at any time. Your decision to participate or not will not affect the care you receive at this health facility.

Consent:

I, [Patient or their relative name], age-, residing at- po- Dist.- State- hereby consent to participate in this interview about medicine availability at public health facilities. I understand the purpose of the interview, what to expect, and the confidentiality measures in place. I voluntarily agree to participate in this interview.

Signature/ **Thumb Impression of the patient/ caretaker**: _____

Date: _____

Witness Signature (optional): _____

Date: _____

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India

AGREEMENT FORMAT

*(*On a Stamp Paper of Rs.100/-)*

This Contract Agreement (hereinafter referred to as the "Agreement") is made and entered into on this ____ day of _____, 2025 (hereinafter referred to as the "Contract signing date")

BETWEEN:

The National Health Systems Resource Centre (NHSRC), a technical support wing of the Ministry of Health & Family Welfare, Government of India, having its office at NIHFW Campus, Baba Gang Nath Marg, Munirka, New Delhi-110067 (hereinafter referred to as the "Client", which expression shall, unless repugnant to the context or meaning thereof, include its successors and assigns) of the First Part;

AND

_____ [Name of the Selected Bidder], a _____ [Type of Organization, e.g., research/academic organization/institution/consulting agency/Non-Govt. Organization] having its registered office at _____ [Address of the Selected Bidder] (hereinafter referred to as the "Service Provider", which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns) of the Second Part.

WHEREAS:

A. The Client issued a Request for Proposal (RFP) bearing No. _____ dated _____ (hereinafter referred to as the "RFP") for "THIRD PARTY EVALUATION FOR AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA".
B. The Service Provider submitted its proposal in response to the RFP (hereinafter referred to as the "Proposal").
C. The Client has evaluated the Proposals received and has selected the Service Provider to undertake the work as detailed in the RFP and the Proposal.
D. The Client and the Service Provider now desire to enter into this Agreement to set forth the terms and conditions under which the Service Provider shall provide the services.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the Parties agree as follows:

1. Definitions

Unless the context otherwise requires, the terms defined in the RFP shall have the same meaning when used in this Agreement.

2. Scope of Work

The Service Provider shall perform the "THIRD PARTY EVALUATION OF AVAILABILITY OF FREE DRUGS UNDER FDSI IN SELECTED PRIMARY AND SECONDARY PUBLIC HEALTH CARE FACILITIES IN SIX STATES AND ONE UT IN INDIA" as detailed in the RFP (including but not limited to Section 2, "Objectives & Scope of Work") and the Service Provider's Proposal, which are hereby incorporated by reference and form an integral part of this Agreement. This includes, but is not limited to:

- Conducting data collection on medicine availability in the selected states and Union Territory as per the sampling strategy outlined in the RFP.
- Assessing the availability of free quality medicines (IPHS EML and State EDL).
- Determining the number of medicines dispensed to patients against prescribed prescriptions.
- Evaluating the prescription of medicines in generic names.
- Transportation system in use to supply the medicines in the visited facility
- Availability of locally procured medicines.
- Indent versus supply of medicines.
- Collecting data through pre-approved questionnaires and patient interviews.

3. Deliverables

The Service Provider shall provide the deliverables as specified in Section 3 of the RFP, including but not limited to:

- Filled pre-approved checklists for each evaluated facility, interviewed official, and patient.
- Verification reports on stock.
- Data on the number of medicines dispensed.
- Reports on the transportation system for medicine supply.
- Information on locally procured medicines.
- Information on indent versus supply.
- Signed consent forms of interviewed participants in both local language and English.
- Cleaned data sheets – include raw data as stated above and supporting documents within the agreed timeline.
- Second party shall make every effort to deliver satisfactory work product to the first party including any alterations/corrections, as raised by first party. Any such alterations/corrections shall be made by second part within 10 days of receipt of the communication mail

4. Timeline

The Service Provider shall adhere to the timelines specified in Section 2.2.3 of the RFP, including:

- Deployment of resources, development of schedule, acceptance of questionnaires, trainings, and pretesting within thirty (30) days from the Contract signing date.
- Completion of data collection and patient interviews within ninety (90) days from the Contract signing date.
- Submission of cleaned data sheets and supporting documents within one hundred twenty (120) days from the Contract signing date.
- Submission of interim progress reports on a monthly basis.

5. Payment Terms

The Client shall pay the Service Provider the contract value of INR _____(Indian Rupees _____ only) as per the financial proposal submitted by the Service Provider and accepted by the Client. The payment schedule shall be as follows:

The following is the payment schedule to the agency on successful completion of the phase wise assignment.

Phase	Up to Stage	% of Contract Fees
1st	Deployment of Resources, Development of action plan, questionnaires, trainings, and pretesting.	30%
2nd	On completion of field level activities (data collection), data cleaning & data compilation, the selected party has to provide the compiled facility wise and state wise analysis report, along with working sheets, raw data and supporting documents.	70%

All payments shall be subject to satisfactory performance of the services and acceptance of the deliverables by the Client.

6. Performance Security

The Service Provider shall, within 10 (ten) days of receipt of Notification of Award, furnish a Performance Security in the form of a Account payee Demand Draft from any of the Commercial Banks bank acceptable to the Client for an amount equivalent to 3% (three percent) of the total contract value, having validity not less than three hundred sixty-five (365) days from the date of signing of the contract. The Performance Security shall be released after the satisfactory completion of the services and the expiry of the liability period, if any as per tender conditions.

7. Evaluation Team Composition

The Service Provider shall deploy audit teams as per the first party's requirement composed of members having expertise in public health, health logistics & supply chain, and monitoring &

evaluation, as outlined in Section 2.2.2 of the RFP and the Service Provider's Proposal.

8. Reporting

The Service Provider shall submit reports as specified in Section 2.2.7 of the RFP, including interim progress reports and a final comprehensive report along with the cleaned data and supporting documents.

9. Ethical Considerations

The Service Provider shall adhere to the ethical considerations outlined in Section 2.2.8 of the RFP, including written informed consent from all participants using the consent form provided in Annexure-III of the RFP, translated into the local language along with English.

10. INTELLECTUAL PROPERTY RIGHTS (IPR):

10.1 The Parties are committed to working in good faith to develop fair principles for dealing with intellectual property and technology transfer, including ownership, use, publication, and confidentiality. These principles shall be governed in accordance with the First Party's general policies and this Agreement, and shall be incorporated into Supplementary Agreements, if required. Except as expressly set forth herein by both the parties, each Party is and shall remain the owner of all intellectual property that it owns or controls as of the Effective Date or that it develops or acquires individually thereafter.

10.2 It is agreed between the Parties that all intellectual property developed by the Second Party during its association with the First Party under this MoU, including discoveries or inventions made in the performance of its duties related in any way to the work of the First Party, will remain the property of the First Party.

10.3 All software design documents, source code and other IT artefacts created by the Second Party in performing the Services under this MoU shall become and remain the Intellectual Property of the First Party, and the Second Party shall, not later than upon termination or expiration of this MoU, deliver all such documents, codes, software and artefacts to the First Party, together with a detailed inventory thereof.

10.4 The First Party holds absolute rights to all data and deliverables generated as part of meeting the performance requirements of this contract and the same cannot be used for any publications by the Second Party without prior written approval of the First Party.

10.5 The Parties recognize that all third-party Intellectual Property Rights are the exclusive property of their respective owners

10.6 **BRANDING AND PUBLICITY**

10.6.1 Communication materials related to the implementation of the activities under the project, studies and publications, if any, shall have co-branding in the communications documents. After taking prior express consent from the other Party, each Party can use the other Party's logo and name for regular communication materials such as brochures, mailers, etc. Such use of logo and brand/ identity shall be strictly limited to the context and scope of collaboration between the Parties as covered in this MOU.

10.6.2 Either of the Parties, without the prior written consent of the other, will not disclose or publicize either through press release, promotional activity, advertising material or otherwise through any mode, the existence of this MoU and the scope of work performed thereof."

11. CONFIDENTIALITY

11.1. Each Party shall undertake to observe confidentiality and secrecy of documents and information received from the other Party during the term of the MoU or any other agreements executed pursuant to this MoU. This obligation shall survive even after the termination of the agreement.

11.2. This is exclusive of those cases in which disclosure of such confidential documents or information is mandatory under prevailing laws. NHSRC may also inform Ministry of Health and Family welfare on explicit instruction.

11.3. It is agreed between the parties that all Confidential Information of the First Party shall remain the exclusive property of such Party, and no right, title or interest in or to any of the Confidential Information or any material developed therefrom is transferred to the any of the recipient Party or hereby or by its delivery to any of the recipient Party thereunder.

11.4. Use: The recipient Party shall use or cause the Confidential Information to be used only in a manner consistent with the terms and conditions of this agreement and at no time shall the recipient Party otherwise use the confidential information for the benefit of itself or any other person or entity or in any manner adverse to, or to the detriment of, the disclosing first or its affiliates."

11.5. The recipient part has to sign the Non-Disclosure Agreement (NDA) as eclosed in Annexure-V.

12. Indemnification

The Service Provider shall indemnify and hold harmless the Client, its officers, employees, and agents from and against any and all claims, losses, damages, liabilities, costs, and expenses (including legal fees) arising out of or in connection with any breach of this Agreement, negligence, or willful misconduct on the part of the Service Provider, its employees, or agents.

13. TERMINATION

13.1. Either Party shall have the right to terminate this MOU/Contract by giving written notice of 30 (Thirty) days to the other in the event that:

a) the other Party has committed a material breach of any of its obligations hereunder which cannot be remedied;

b) the other Party has committed a material or repeated breach of any of its obligations hereunder and has failed to remedy such breach (if the same is capable of remedy) within 15 (Fifteen) days of being required by written notice so to do.

13.2. Either Party's right to terminate this MOU shall be without prejudice to the other rights and remedies it may have under Applicable Law.

13.3. Nothing in this MOU/Contract shall prevent the Parties from terminating the

MOU/Contract for convenience by providing a written notice of 15 (Fifteen) working days to the other Party.

14. Notices

All notices and communications under this Agreement shall be in writing and shall be deemed to have been duly given if delivered personally or sent by registered post/courier/email to the addresses mentioned hereinabove.

15. Entire Agreement

This Agreement, along with the RFP document bearing number NHSRC/25-26/QPS/DU/RFP/615, amendments & clarifications to Pre-Bid queries and the Service Provider's Proposal, constitutes the entire agreement between the Parties with respect to the subject matter hereof.

16. Amendments

No amendment or modification of this Agreement shall be valid unless made in writing and signed by duly authorized representatives of both Parties.

17. Force Majeure

Neither Party shall be liable for any failure or delay in the performance of its obligations under this Agreement to the extent that such failure or delay is caused by a Force Majeure event, provided that the affected Party promptly notifies the other Party of the occurrence and nature of such event and uses its best efforts to mitigate the effects thereof.

18. RESOLUTION OF DISPUTES

18.1. Parties shall endeavor that any/all dispute(S), relating to this Agreement or claims arising out of or relating to this Agreement or breach, termination or the invalidity thereof or any matter directly or indirectly connected with this Agreement is resolved through mutual dialogue and discussion within 30 days.

18.2. Absent amicable settlement, all disputes arising out of or in connection with this agreement shall be put forward before an Arbitrator who will be appointed after consulting both parties. The Arbitrator is to be located in NCT Delhi.

18.3. Adjudication if any, and unavoidable will be of courts in NCT Delhi.

19. Governing Law and Jurisdiction

This Agreement shall be governed by and construed in accordance with the laws of India. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts in Delhi.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Contract signing date.

SIGNED FOR AND ON BEHALF OF
THE NATIONAL HEALTH SYSTEMS RESOURCE CENTRE (NHSRC)

By: _____
Name:
Title:
Date:

SIGNED FOR AND ON BEHALF OF
_____ (Name of Service Provider)

By: _____
Name:
Title:
Date:

Enclosures:

- Copy of the Request for Proposal (RFP) No. _____dated _____.
- Copy of the Service Provider's Proposal dated _____.
- All Annexures from the RFP.

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India

NON-DISCLOSURE AGREEMENT

This **Non-Disclosure Agreement (NDA)** is made and entered into on …….. by and among the following parties:

The National Health Systems Resource Centre (hereinafter referred to as "**NHSRC**"), an autonomous body registered under The Societies Act, 1860 and having its registered office at National Institute of Health & Family Welfare Campus, Baba Gang Nath Marg, Block F, Munirka, New Delhi, Delhi – 110067, hereinafter referred to as the "First Party" and represented through its authorized representative NHSRC, whose expression shall unless repugnant to the context or meaning thereof, includes the consultants, successors and assigns of the **First Party;**

AND …….., as the **Second Party**.

1. BACKGROUND

1.1 WHEREAS the First Party has been set up under the National Health Mission (NHM) of the Government of India to serve as an apex body for technical assistance. The First Party is entrusted with the responsibility to undertake evidence-based policy research and health systems strengthening by nurturing collaboration between decision-makers, health programme managers and the public health research community. The First Party supports research related activities under health systems research platforms and Implementations research for health systems strengthening platform to enable systems to generate evidence from the field and thus informing policy level decisions.

1.2 AND WHEREAS the Second Party is ……..

1.3 AND WHEREAS the purpose of this NDA is to lay down the terms on which confidential information shall be disclosed/exchanged among the parties during and after the implementation of the Exercise.

NOW, THEREFORE, the Parties agree as follows:

a. **'Exercise'** refers to ……..

b. **"Confidential Information"** means all non-public information or material disclosed or

provided by one Party to another, either orally or in writing, or obtained by the recipient Party from a third party or any other source, concerning any aspect of the business or affairs of one of the other Parties or its affiliates, including without limitation, any information or material pertaining to products, formulae, specifications, designs, processes, plans, policies, procedures, employees, work conditions, legal and regulatory affairs, assets, inventory, discoveries, trademarks, patents, manufacturing, packaging, distribution, sales, marketing, expenses, financial statements and data, customer and supplier lists, raw materials, costs of goods and relationships with third parties, marked as "confidential." Confidential Information, if in tangible or readable form, shall be marked as such at the time of disclosure and if disclosed orally, shall be reduced to writing and marked confidential within ten (10) days after disclosure. Confidential Information also includes any notes, analyses, compilations, studies or other material or documents prepared by the recipient Party which contain, reflect or are based, in whole or in part, on the Confidential Information.

Notwithstanding the foregoing, Confidential Information shall not include information or material that:

i. is publicly available or becomes publicly available through no action or fault of the recipient Party;
ii. was already in the recipient Party's possession or known to the recipient Party prior to being disclosed or provided to the recipient Party by or on behalf of the other Party, *provided*, that, the source of such information or material was not bound by a contractual, legal or fiduciary obligation of confidentiality to the non-disclosing Party or any other Party with respect thereto,
iii. was or is obtained by the recipient Party from a third Party, *provided*, that, such third Party was not bound by a contractual, legal or fiduciary obligation of confidentiality to the non-disclosing Party or any other Party with respect to such information or material, or
iv. is independently developed by the recipient Party without reference to the Confidential Information.

c. Confidential Information need not be novel, unique, patentable, copyrightable or constitute a trade secret in order to be designated Confidential Information. The Parties acknowledge that the Confidential Information is proprietary to the other Party, has been developed and obtained through great efforts by the Party and that Parties regard all of their Confidential Information as trade secrets.
d. The Parties shall use the Confidential Information solely for and in connection with the Purpose.
e. As among the Parties, all Confidential Information disclosed to the Receiving Party by the Disclosing Party shall remain the sole and exclusive property of the Disclosing Party. The Parties expressly acknowledge and agree that no right or license with respect to the Confidential Information is granted hereby to the Receiving Party, and none may be inferred from the provisions of this Agreement.
f. The Second Party may be given access to confidential information, data or any other

business-related property/information by the First Party for effective implementation of this Agreement and the same must be protected and used only in the interests of the assigning Party.

g. All Confidential Information of each Party shall remain the exclusive property of such Party, and no right, title or interest in or to any of the Confidential Information or any material developed therefrom is transferred to the any of the recipient Party or hereby or by its delivery to any of the recipient Party hereunder.
h. All data generated by the Second Party during execution of the Exercise or as a result of the same, shall be the sole and exclusive property of the First Party, and the Second Party shall not disclose or publish the same without the written consent of the First Party, which consent shall not be unreasonably withheld.
i. First Party shall have the right to initiate internal enquiry and/or legal action against the Second Party in accordance with terms of this Agreement and the applicable law.

j. **NON-DISCLOSURE**

i. The Parties shall use the Confidential Information only for the Purpose and not disclose any or part or summary or extract of the Confidential Information to any third party, including third parties affiliated with the other Party, without that Party's prior written consent, which prior consent the Party may refuse to give without assigning any reasons.
ii. The Parties shall hold and keep in strictest confidence any and all Confidential Information and shall treat the Confidential Information with at least the same degree of care and protection as it would treat its own Confidential Information.
iii. Either Party shall not copy or reproduce in any way (including without limitation, store in any computer or electronic system) any Confidential Information or any documents containing Confidential Information without the Party's prior written consent. The Receiving Party shall not remove, overprint or deface any notice of copyright, trademark, service mark, logo or other labels or indicia of ownership (whether of the Disclosing Party or any of its licensors, vendors or suppliers).
iv. Either Party shall not commercially/non-commercially use or disclose any Confidential Information or any materials derived therefrom to any other person or entity other than persons in the direct employment of the other Party who have a need to have access to and knowledge of the Confidential Information solely for the Purpose as defined above, and such persons are under similar obligation of confidentiality and non-disclosure as these presents. In the event that any employees, agents or affiliates of either Party disclose or cause to be disclosed the Confidential Information, that Party shall be liable for such disclosure.
v. Advise each such employee, representatives, associates and researchers, before he or she receives access to the Confidential Information, with written consent from Disclosing Party, of the obligations of Receiving Party under this Agreement, and require each such employee, representatives, associates and researchers to agree to maintain those obligations.
vi. The Parties may not disclose Confidential Information to any third party under any circumstances regardless of whether the third party has executed a Non-Disclosure

Agreement with the Party.

vii. The obligation to ensure confidentiality and non-disclosure shall survive even after the termination of this agreement.

viii. Both Parties agrees to notify the other Party immediately if it learns of any use or disclosure of the Party's Confidential Information in violation of the terms of this Agreement. The Receiving Party shall cooperate with the Disclosing Party to regain possession or prevent further unauthorized use of the Confidential Information.

ix. The Parties further acknowledge and agree that no representation or warranty, express or implied, is or will be made, and no responsibility or liability is or will be accepted by either Party, or by any of its respective directors, officers, employees, agents or advisers, as to, or in relation to, the accuracy of completeness of any Confidential Information made available to the other Party or its advisers; it is responsible for making its own evaluation of such Confidential Information.

x. Within fifteen (15) days of notice furnished by the Disclosing Party, the Receiving Party shall return to the other Party all documentation, copies, notes, diagrams, computer memory media and other materials containing any portion of the Confidential Information together with all copies and reproductions thereof, or confirm to the other Party, in writing, the destruction of such Confidential Information.

xi. If Confidential Information is required to be disclosed by the Receiving Party by law, regulation, governmental or regulatory authority, such Confidential Information may be disclosed pursuant to such requirement so long as the Receiving Party provides the Disclosing Party with prior written notice of the disclosure, to the extent such notice is permitted by law, within a reasonable time after receipt of notice of the required disclosure and, upon request of the Disclosing Party, shall seek to obtain confidential treatment of such information. The Receiving Party may, in addition to the foregoing, use or disclose Confidential Information if and to the extent necessary to establish and enforce its rights under this Agreement.

2. PUBLICATIONS

2.1. The Second Party shall not, without the prior consent of the First party in writing, disclose to any other person the fact that Confidential Information of First Party has been and/or disclosed under this Agreement, that discussions or negotiations are taking place among the parties, or any of the terms, conditions, status or other facts with respect thereto, except as required by law and then only with prior notice as soon as possible to the other party.

2.2. All findings and Report(s) submitted by the Second Party during the implementation of this Exercise shall remain the sole and exclusive ownership of the First Party and shall not be published by the Second Party without the written consent of the First Party.

2.3. The Second Party shall not publish, circulate, distribute or disseminate any data related to the Exercise in any form, i.e., written or verbal, without the prior consent of the First Party in writing.

2.4. Any data or Report(s) prepared during the course of implementation of this Exercise, if approved for publication by the First Party, shall be so published, on any platform, in a manner that the said data or Report(s) shall acknowledge the First Party.

2.5. No party shall make any public disclosure or press release regarding this agreement or the Purpose, nor use the name or trademarks of the other party without the prior written consent of the other party at issue.

3. ROLES AND RESPONSIBILITIES OF THE PARTIES

3.1. No principal-agent or employer-employee relationship is being created by either Party in favour of the other under or in pursuance of this Agreement and it is distinctly and clearly understood, agreed and declared by/ between the Parties hereto that:

a) Neither Party shall claim ownership of any material or claim interest thereon, which has been solely created or published by the other Party.

b) The rights, which a Party shall have over the material, are only those set out in this Agreement.

3.2. The relationship between the Parties under and/or in pursuance of this Agreement is as between Principal and Principal. Consequently, neither party shall be entitled to represent the other and/or make any commitment on behalf of and/or with a third party. Furthermore, no relationship in the nature of Partnership or Association of persons is hereby being created or intended to be created among the Parties.

4. INTELLECTUAL PROPERTY RIGHTS

4.1. "Intellectual Property Rights" mean all rights, including but not limited to copyrights, patents, trademarks, trade secret rights and/or other intellectual property rights associated with any ideas, concepts, techniques, inventions, processes, works of authorship, confidential information developed or created by the Parties, solely or jointly, during the execution of this Agreement.

4.2. The Parties are committed to working in good faith to develop fair principles for dealing with intellectual property and technology transfer, including ownership, use, publication, and confidentiality. These principles shall be governed in accordance with the First Party's general policies and the applicable laws and this Agreement and shall be incorporated into Supplementary Agreements, if required. Except as expressly set forth herein by the First Party, all Parties shall remain the owner of their respective intellectual property, owned or controlled by them, as of the Effective Date.

4.3. It is agreed among the Parties that all intellectual property developed by the Second Party as a result of its collaboration with the First Party on the Exercise, including discoveries or inventions made in the performance of their duties related in any way to the work of the First Party in connection with the Exercise, will be the property of the First Party.

4.4. All software design documents, source code and other IT artefacts created by the Second Party in connection with the Exercise shall become and remain the Intellectual Property of the First Party, and the Second Party shall, not later than upon termination or expiration

of this Agreement, deliver all such documents, codes, software and artefacts to the First Party, together with a detailed inventory thereof.

4.5. The First Party holds absolute rights to all data and deliverables generated as part of implementation of the Exercise and the same cannot be used for any publications by the Second Party without prior written approval of the First Party, which approval shall not be unreasonably withheld.

5. TERMINATION

5.1. The term of this Agreement shall be for a period of five (5) year(s) and the obligations of confidentiality shall continue perpetually after the termination of this Agreement or until such Confidential Information becomes public.

5.2. Upon termination of this Agreement and the receipt of a written request from the First Party or the Second Party shall, at the sole option of the First Party, either:

a) promptly return all confidential data shared by the First Party, or
b) destroy in a manner reasonably acceptable to the First Party, all confidential data, including all copies thereof, that contain or evidence Confidential Information protected hereunder.

5.3. The First Party may request a certification of the return or destruction of all Confidential Information by the Second.

5.4. Upon the termination of this Agreement, the confidentiality obligations set forth hereunder shall continue in effect for so long as the information remains a confidential, and the provisions set forth in this NDA, regarding ownership shall continue in effect for so long as necessary to give full effect thereto.

6. NO RIGHTS GRANTED

Nothing in this Agreement shall be construed as granting any rights under any patent, copyright or other intellectual property right of Disclosing Party, nor shall this Agreement grant Recipient any rights in or to Disclosing Party's Confidential Information other than the limited right to review such Confidential Information solely for the purpose stated under Clause 1.

7. REMEDIES

The Receiving Party acknowledges that any breach of this Agreement may give rise to irreparable harm to the Disclosing Party for which monetary damages alone would not be an adequate remedy. The Receiving Party agrees that, in addition to the Disclosing Party's other remedies, all of which are expressly reserved, the Disclosing Party shall be entitled to enforce the provisions of this Agreement by injunction and seek other equitable relief as per Applicable Law.

8. WAIVER

No waiver of any provision of this Agreement, nor any consent to or approval of any departure here from, shall be effective unless it is in writing and signed by the party against whom

enforcement of any such waiver, consent or approval is sought. Any such waiver, consent or approval shall be effective only in the specific instance and for the purpose for which given. Neither the failure of a party to enforce, nor the delay of a party in enforcing, any condition, provision or part of this Agreement at any time shall be construed as a waiver of that condition, provision or part or forfeit any rights to future enforcement thereof.

9. SEVERABILITY

If any provision of this Agreement, or the application thereof, shall, for any reason and to any extent, be found invalid or unenforceable, the remainder of this Agreement and the application of such provision to other persons or circumstances shall not be affected thereby, but rather shall be enforced to the maximum extent permissible under applicable law, so long as, and to the extent that, such enforceability does not materially adversely affect the mutual rights and obligations of the parties hereunder.

10. INDEMNITY AND INSURANCE

10.1. No Party shall be liable for or in respect to any damages or compensation payable to any employee, associate, agent or contractor or sub-contractor of another Party in connection with this Agreement or the Exercise. Each Party shall indemnify and keep indemnified the other Parties against all such damages and compensation, all claims, proceedings, damages, costs, charges and expenses whatsoever in respect thereof or in relation thereto.

10.2. The Second Party shall indemnify and keep indemnified the First Party for any losses or penalties as may be levied upon the Second Party, by any judicial, statutory, or administrative authorities, or Courts of law, on account of violation of any law, rule, regulation, condition, etc. attributable to the Second Party, its agents, or any other person in its employment of or any of its contractors/sub-contractors.

11. REPRESENTATIONS AND WARRANTIES

Each Party represents and warrants to each other that:

a) It is duly organized, validly existing and in good standing under the laws of its land;
b) It has full power and authority to execute, deliver and perform its obligations under this Agreement and to carry out the obligations contemplated hereby;
c) There are no actions, suits, proceedings, or investigations pending or to their knowledge threatened against them at law or in equity before any court or before any other judicial, quasi-judicial or other authority, the outcome of which may constitute the inability of either party to perform their obligations as per this Agreement;
d) The obligation to notify change: In the event that any of the representations or warranties made/given by either party ceases to be true or stands changed, it shall promptly notify each other of the same.

12. AMENDMENTS AND ASSIGNMENT

This Agreement may not be amended in any respect whatsoever except by a further agreement, in writing, fully executed by each of the Parties. This Agreement shall be binding upon the Parties and their successors and permitted assigns. The provisions of this Agreement are personal to the Receiving Party and may not be assigned, sold, or otherwise transferred, in whole or in part, without the prior written consent of the Disclosing Party.

13. CONFLICT OF INTEREST

All Parties warrant that this Agreement is not likely to have any conflict of interest with any of their organizational, financial, contractual, or other interests relating to the activities under this Agreement. All parties also agree that this Agreement will not be treated as a deterrent to allow similar activities or collaboration with other organizations.

14. GOVERNING LAW AND DISPUTE RESOLUTION

14.1. The Parties shall endeavour that any/all dispute(s), relating to this Agreement or claims arising out of or relating to this Agreement or breach, termination, or the invalidity thereof or any matter directly or indirectly connected with this Agreement is resolved through mutual dialogue and discussion.

14.2. Any dispute arising from or in connection with this Agreement shall be referred to conciliation according to Part-III of the Arbitration and Conciliation Act, 1996. Any dispute not referred for conciliation or a dispute which exists after termination of the conciliation procedure shall be decided by Arbitration. The Conciliator shall be appointed by mutual consent of all Parties.

14.3. If the Parties fail to resolve the Dispute, the Dispute shall be resolved by Arbitration in accordance with the Arbitration and Conciliation Act, 1996, India.

14.4. The Arbitration Tribunal shall consist of 1 (one) Arbitrator which shall be appointed by the mutual consent of all Parties.

14.5. The seat and place of Arbitration shall be New Delhi, India. The language of the Arbitration will be English.

14.6. Each Party shall bear its own legal fees and expenses incurred in connection with the Arbitration.

14.7. The Award shall be enforceable in any Court having jurisdiction as per the applicable Law of India.

14.8. The Parties submit that Courts of New Delhi alone shall have exclusive jurisdiction to settle any dispute arising out of or in connection with this Agreement.

14.9. The provisions of this clause will survive the Termination of this Agreement for any reason whatsoever.

15. MISCELLANEOUS

15.1. All communications between the Parties shall be in writing only.

15.2. This Agreement supersedes all prior negotiations, understandings, commitments, representations, and proposals (written and oral) among the Parties, and the rights and obligations of the Parties with respect to the matter of this Agreement shall henceforth be governed solely by the provisions of this Agreement, as may be amended from time to time by a written agreement signed by each Party, unless so specified herein this Agreement.

15.3. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which collectively shall be deemed one and the same instrument.

15.4. This Agreement has been written and executed in the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control. The words "include" and "including" and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words "without limitation". The wording of this Agreement shall be deemed to be the wording mutually chosen by the parties and no rule of strict construction shall be applied against either party. This Agreement represents the entire agreement and understanding of the parties regarding the subject matter hereof.

In witness thereof, the duly authorized representatives of the collaborating parties sign this Agreement on …….. at ……..

Agreed and accepted for the **First Party**
Name: _____
Signature: _____

Agreed and accepted for the **Second Party**
Name: _____
Signature: _____

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India

Terms of Reference (ToR) for Technical Staff to be Engaged by the Recipient Party

1. Deployment of Technical Staff

- The Recipient Party shall deploy **two (02) technical staff members at each evaluation site** to conduct the study. Sufficient teams must be engaged to ensure completion of **all field data collection activities within 90 days** from the date of issuance of the Work Order or execution of the MoU/Contract.
- The engaged staffs will collect the information in the provided as per the questioners.
- The Recipient Party shall engage an adequate number of **data analysts** to compile and submit facility-wise and state-wise analytical reports, along with cleaned and raw datasets and all supporting documents, **within 120 days** from the date of issuance of the Work Order or execution of the Contract.

2. Qualification and Experience Requirements

- The study requires professionals such as **Pharmacy Experts**, **Healthcare/Hospital Management Experts**, **Data Analysts**, or **Statisticians**. Graduates in relevant disciplines shall be engaged for this assignment.
- **Technical staff should possess expertise in one or more of the following areas:**
  - Health logistics and supply chain management
  - Monitoring and evaluation
  - Statistics and data analysis
  - Public health systems
- **The engaged personnel should have prior experience in conducting:**
  - Field surveys
  - Third-party audits
  - Baseline or evaluation studies related to medicine accessibility/availability

- Supply chain assessments
- Public health program evaluations
- Studies on out-of-pocket expenditure
- Perception studies related to doctors' or patients' viewpoints on generic medicines, Standard Treatment Guidelines (STGs), FDSI, or public health facility services.

3. Conduct and Professionalism

- The Technical Support Partner and all deployed personnel shall maintain **professional behaviour, integrity, and ethical conduct** while interacting with beneficiaries, healthcare staff, state officials, and all other stakeholders.

- Any misconduct, manipulation of data, or non-compliance with prescribed protocols may lead to termination of the contract.

National Health Systems Resource Centre,
Ministry of Health & Family Welfare, Government of India

Integrity Pact Format

National Health Systems Resource Centre (NHSRC) and _____

1. It is hereby agreed between NHSRC and _____ that both parties will adhere to the following guidelines of this Integrity Pact: -

   a) As the Principal (NHSRC/ its representative) will promise not to seek or accept any benefit, which is not legally available.
   b) The bidder will promise not to offer any benefit to the employees of the principal (NHSRC) not available legally.
   c) NHSRC (Principal) will treat all bidders with equity and reason.
   d) Bidders will not enter into any undisclosed agreement or understanding with other bidders with respect to prices, specifications, certifications, subsidiary contract etc.
   e) Bidders will not pass any information provided by NHSRC (Principal) as part of business relationships to others and will not commit any offence under PC/ IPC Acts.
   f) Foreign bidders will disclose the name and address of agents and representatives in India and Indian bidders to disclose their foreign principals or associates.
   g) Bidders will disclose the payments to be made by them to agents/ brokers or any other intermediary.
   h) Bidders will disclose any transgressions with any other public/ govt organization that may impinge on the anti-corruption principle. The date of such transgression, for the purpose of disclosure by the bidders in this regard, would be the date on which cognizance of the said transgression was taken by the competent authority. The period for which such transgression(s) is/ are to be reported by the bidders shall be the last three years to be reckoned from date of bid submission. The transgression(s) for which cognizance was taken even before the said period of three years, but are pending conclusion, shall also be reported by the bidders.

2. Any violation of the Integrity Pact would entail disqualification of the bidders and exclusion from future business dealings, as per the existing provisions of GFR 2017, PC Act 1998 and other Financial Rules/ Guidelines etc. as may be applicable to the organization concerned.
3. A person/ bidder signing the Integrity Pact shall not approach the Courts while representing the matters to Independent External Monitors and he/ she will await their decision on the matter.

Signature of the Bidder Name **Authorised Signatory**

(Name & Adress of Agency) **NHSRC**

Annexure-VIII

Questionnaire- Medicine Availability at all level of Public Health Facility

Name of Facility:	
Name with Designation of Facility I/c	
Name with Designation of Official Responsible for Stock & Store Management:	
Name of the Supplying Institution (From where the facility receives medicines)	
Name of District	
Name of State	

Sl No.	Component		Question	Means of Verification	Answer
1	FDSI	1.a	Wide publicity of free essential medicine provision in health facilities (check for any such notification from states & facts)	Notification of State/Distrcit authority and posters, wall writing and hoardings etc. in all public health facilities and at other vantage points, also through different media	
		1.b	Availability Grievance redressal mechanism monitored by Rogi Kalyan Samiti (RKS) for DH/SDH/CHC and by Jan Arogya Samiti (JAS) on medicine availability	SOP/Proceedings/others documents	
		1.c	If grievance redressal mechanisim available, then number of grievances received during the (April 2025- September 2025)	Mentioned the number	
		1.d	Whether a system of Prescription audit is put in place(Y/N) Applicable for DH/SDH/CHC/AAM-PHC	Document/Interaction	
		1.e	If any prescription audit done, then record the total number of prescriptions vs numbers of prescription audited (April 2025- September 2025)	Enclose the finding from Prescription audit if done	
2	Product Selection(EML)	2.a	Whether Notified EML available for the facility	Notified EDL/ Availability of EDL with the Facility	
		2.b	Whether the notified EDL is adequate to fulfill the demand based on the disease burden on your facility If not adequate,then which additional medicines the facility needed to fulfill the patient's requirement (List of additional medicines suggested)	Interaction with Facility I/c / Pharmacist/Nursing	
3	Demand Forecasting	3.a	Details of Annual demand forecasting method: (Annual indent preparation & finalization mechanism- Consumption based or disease prevalence pattern)	Ask the facility I/c & Store personnel, verify documents (April 2025-September 2025), enclose the Annual indent copy	
		3.b	Facility specific challenges to prepare annual indent	Interaction with facility I/c & Store personnel,	
		4.a	Medicine allocation to the facility (Allocation based on monthly Indent or Allocation based on Annual Indent/Consumption)	Interaction with Store personnel/ SOP	
		4.b	Frequency of Medicine allocation to the facility (Monthly allocation/ Bi-monthly/Qtrly/ Specify Others)	Record/Document	

4	Transportation & Storage	4.c	Medicine Transportation Mechanisim (Transportation by supplying store to the facility / Facility is collecting the medicine by arrangement of vehicle from supplying store)	Record/Document/Interaction	
		4.d	Actual timeline of receipt of medicine at the facility (12 month) , Questionnaire-Va	Record/Challan	
		4.e	Updation of Stock Ledger/BIN Card by Store personnel (Daily Updation/ weekly Updation/ Monthly Updation/etc.	Record	
		4.f	Physical verification of stock (Monthly/ Bi-monthly/Quaterly/Yearly/ others)	Verification from stock ledger/ BIN Card/Stock count record	
		4.g	Availability of dedicated cold chain equipment to store temperature sensitive medicines (Non-RI vaccine like Insulin/Rabies vaccine/ etc), If available, then list the name of equipment-Domestic Freeze/ILR	Cold chain equipment for non-RI vaccines, do not consider cold chain equipment for Routine immunization vaccines)	
		4.h	Medicine Storage Mechanisim (Store on the Rack in organized manner/ Cabinet /store directly on Floor/Un-organized storage	Record the actual practice with photograph	
		4.i	If Not of Standard Quality (NSQ) reported, then mechanism to dispose (Return to District-Warehouse/ Dispose off the medicine in the facility/ Handing over the NSQ medicines to approved waste-disposal contractor	Record	
		4.j	Psychotropic and Narcotic medicines are kept at secure place as per NDPS Act and Rules (Lock & Key)	Record/ Physical inspectiont/Preserve photographic evidence	
		4.k	Expiry Medicine Storage (Stored in a designted place with labeled as Expired- Not To Be Used/ Stored in a separate cabinet or room/If other then specify)	Record/ Physical inspectiont	
		4.l	Disposal of Expired Medicines Mechanism (When to dispose / whether approval required from authority, mention designation of authority/ any committee approval required with composition/	Record/ Physical inspectiont	
		4.m	For expired medicines: Mechanism to dispose (Return to District-Warehouse/ Dispose off the medicine in the facility/ Handing over the expired medicines to approved waste-disposal contractor/Others	SOP/Proceedings/others documents	
5	Inventory	5.a	Collect information as per Questionnaire-Vb	Stock ledger/BIN card/ LMIS	
		5.b	Maximum Stock Level of medicines fixed for the facility, If yes then what is the maxium stock level- 2 month's stock/3 month's stock/6 month's stock/ other. Record No, if it is not fixed	Record/SOP	
		5.c	Minimum Stock Level of medicines fixed for the facility, If yes then what is the minimum stock level- 2 month's stock/ 3 month's stock/6 month's stock/ other. Record No, if it is not fixed	Record/SOP	
6	IT Enable Supply Chain Management of Medicines	6.a	Type of IT sysyem available(DVDMS/ any specific LMIS) for stock management		
		6.b	Frequency of stock updation in IT software(daily updation/ weekly/monthly/ others)	Verification of LMIS/Interaction/collect screenshots	
		6.c	Specfic challenges for using the IT software & its updation (Like not trained/ IT software not user friendly/ Network issues/ work load/ etc.)	Interaction	
7	Dispensing of NCD Medicine	7.a	Dispensing mechanism of Hypertension & Diabetic medicines (Quanity dispensed to patients like dispensing for one month's requirement/ 2 month's requirement/ others)		

	Dispensing of NCD Medicine	7.b	Replenishment mechanism of Hypertension & Diabetic medicines	Ask how they are making replensihment of medicines to Diabetic & Hypertensive Patients , verify it/ Notification	
8	Local Procurement Mechanism	8.a	Whether there is Local Procurement provision at your facility (Y/N)		
		8.b	If Yes, Brief description about local procurement policy encompassing - (predefined limit approved for local procurement- 10% or 20% budget or need based)		
		8.c	Local procurement mechanisim- Local procurement of non-notified medicines/ Local procurement when there is stock outs or non-supply/ Local procurement if intimated specifically from District/State/ If others then specify		
9	Perception of Patients on Free Medicines	9.a	Collect Information as per Annexure-Vc	Patients on attendance (If inpatiens are available -include 50% inpatient & 50% out-patient)	
10	Others	10.a	No. of batches collected by the Drug Inspector from the facility for testing (during Apr-24 to Mar-25)	List the name of drugs whose sample is picked up for testing	
		10.b	If sample picked up by Drug Inspector, Result thereof; (NSQ & SQ)	Number of NSQ & SQ (Collect Test Report copy)	
		10.c	Is the Health Facility Medical Officers / Physicians know which medicines are available so that he can prescribe (Fully Aware/Partially Aware/ Not Aware)	Interaction	
		10.d	Adverse Drug Reactions (ADR) Reporting & Management Mechanism (No defined mechanisim/ Defined mechanism for reporting but no mechanism for management/ others, pls specify)	Record/SOP/Notification	
		10.e	No. of ADR reported during April 2025- September 2025	Record/Interaction	
11	Training & Capacity Building	11.a	Whether store personnel is trained on Inventory management during April 2025- September 2025, If yes then date of training. Record No if no training conducted		
		11.b	If store personnel not trained during last year, then the date of his/her last training		
12	Supportive Supervision	12.a	Number of supportive supervision visits during April 2025- September 2025 by Medical Officers/ Store manager/Program Managers from District/State/ Block/Others- regarding Medicine availability /stock & stores	Check the visit register/ signature in ledger or records/other documents	

(Annexure-VIIIa)

Questionnaire-Stock Receipt Status (During 1st Apr-25 to 30th Sep.-25)

Sl No.		Means of Verification	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25
1	Pre-defined timeline fixed for allocation/receipt of stock to health facility (like 1st week /2nd week of month or any particular timeline)	Document/ Interaction with Store personnel						
2	Pre-defined timeline to raise indent (monthly/weekly/ specify others)	Document/ Interaction with Store personnel						
3	Actual date of Indent by the facility	Indent book or copy/ other document						
4	Actual Stock Receipt Date (At the Health facility)	Challan/Invoices/Stock ledger						

Annexure-VIIIb_DH

District Hospital (DH) : Stock Availability Data Period-Year -April 2025- September 2025

S.No.	Drug Name	IPHS medicine Notified in State EML for the facility	Currently Medicine Available (On the date of site visit) Current Quantity		Medicine Available	Stock out events	Number of stock out events	Date of stock out	Date of stock made available after stock out	Period of Stock Out/Replenishment time (In days)	Eexpired medicines (if yes then quantity)	Time taken to Dispose the expired medicines (Date of Expiry - Date of Disposal)	NSQ medicines reported (if yes then quantity/otherwise record No)	Time taken to dispose NSQ medicine (Date of NSQ reported & Date of disposal)	Annual Indent Quantity (in numbers-Tab/cap/ampoule/vial/bottle/tube)	Total quantity indented during monthly indent (Sum monthly/daily/weekly indent quantity)	Total quantity Receipt	Actual current stock (Physical count)	Quantity as per Stock ledger	Quantity as per DVDMS/ State LMIS	Locally Procured Quantity	Locally Procured Value in Rs.
	Means of verification	State notified EML	Stock ledger /Bin card/ Challan	Stock ledger	Stock ledger	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card		Stock ledger/ Physical verification at site	Stock ledger /Proceeding/ Handover document	Record, also enclose NSQ report	Stock ledger /Proceeding/ Handover document	Records	Records/LMIS	Stock ledger /LMIS	Sample drugs: (Telmisartan,Amlodipine Glimepride, Metformin, paracetamol, RL,NS,Diclofenac/Acceclofenac/Cetrizine or Levo-				
	District Hospital (DH)	Y/N	Unit(Pack size)	Quantity (Quantity in numbers like number of Tablets/Capsules/Injections/tubes/bottles/ etc)	Y/N	Y/N																
Anesthetic Agent																						
1	Halothane Gas for Inhalation	Y	100 ml			Y	3	03.04.25	07.04.25	4												
								27.05.25	8.06.25	12												
								05.7.25	12.07.25	5												
2	Isoflurane Gas for Inhalation	N				N	__	__	__	__												
3	Ketamine Injection 10 mg/ml Ketamine Injection 50 mg/ml		2 ml vial																			
4	Nitrous Oxide Gas for Inhalation																					
5	Oxygen Gas for Inhalation																					
6	Propofal Injection 10 mg/ml																					
7	Sevoflurane Injection																					
8	Promethazine Injection 25 mg/ml, 50 mg/ml																					
9	Pentazocine Injection 30mg/ml																					
10	Thiopentane Injection 0.5 gm/1 gm																					
11	Bupivacaine Injection 0.5 mg/ml (sensorcain)																					
12	Lignocaine Injection 2% Lignocaine Injection 4%w/v, 5%w/v Lignocaine Jelly Lignocaine Ointment 2%-5% Lignocaine Spray 10%																					
13	Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) Injection 2% (A) + 1:200000 (5 mcg/ml) (B)																					
14	Atropine Injection 0.6 mg/ml, 1 mg/ml																					
15	Glycopyrolate Injection 0.2 mg/ml																					
16	Midazolam Injection 1 mg/ml Midazolam Tablet 250 mg Midazolam Tablet 500 mg																					
Non opioid Analgesic, Anti-Pyretic and Non steroidal Anti Inflammatory Medicines																						

17	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Injection 25 mg/3ml																					
18	Ibuprofen Tablet 200 mg Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg/5 ml																					
19	Paracetamol (Acetaminophen) Tablet 500 mg, 600mg Paracetamol (Acetaminophen) Injection 150 mg/ml Paracetamol (Acetaminophen) Syrup 125 mg/5ml Paracetamol (Acetaminophen) Syrup 120 mg/5ml, 60 ml Paracetamol Suppository 80 mg																					
20	Colchicine Tablet 0.5 mg																					
21	Azathioprine Tablet 50 mg																					
22	Hydroxychloroquine Tablet 200 mg Hydroxychloroquine Tablet 400 mg																					
23	Methotrexate* Tablet 2.5 mg Methotrexate Tablet 7.5 mg Methotrexate Injection 50 mg/ml																					
24	Sulfasalazine Tablet 500 mg																					
25	Naproxen Tablet 250 mg Naproxen Tablet 500 mg																					
26	Duloxetine Tablet 10 mg, 30 mg, 60 mg																					
27	Tapentadol Tablet 25 mg, 100 mg																					
28	Gabapentin Tablet 100 mg, 400 mg																					
29	Pregabalin Tablet 25 mg,150 mg Pregabalin syrup 50 mg/ml																					
30	Nortriptyline Tablet 10 mg, 50 mg																					
Anti allergics and medicines used in Anaphylaxis																						
31	Adrenaline Injection 1 mg/ml (1:1000)																					
32	Cetirizine Tablet 5 mg Cetirizine Tablet 10 mg Cetirizine Oral Liquid 5 mg/5 ml																					
33	Chlorpheniramine Tablet 4 mg, 5mg, 10mg, 20mg, 40mg Chlorpheniramine Oral liquid 2 mg/5 ml, 5 mg/5 ml																					
34	Dexamethasone Tablet 0.5 mg Dexamethasone Injection 4 mg/ml																					
35	Hydroxyzine Syrup 10 mg/5 ml Hydroxyzine Tablet 25 mg																					
36	Hydrocortisone Powder for Injection 100 mg Hydrocortisone Injection 200 mg Hydrocortisone Cream/Gel/Ointment 0.5%/1%																					

37	Pheniramine Maleate Injection 22.75 mg/ml																				
Antidote and other Substances used in Poisioning																					
38	Activated Charcoal																				
39	Calcium Gluconate Injection 100 mg/ml Calcium Gluconate Injection 1 gm, IV-10 ml amp																				
40	Desferrioxamine Injection 500 mg																				
41	N-acetylcysteine Injection 200 mg/ml N-acetylcysteine Sachet 200 mg N-acetylcysteine Tablet 600 mg/Dispersible																				
42	Naloxone Injection 0.4 mg/ml																				
43	Neostigmine Injection 0.5 mg/m																				
44	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																				
45	Deferiprone capsule 250mg & 500mg																				
46	Deferasirox Tablet 250mg & 500mg																				
Anti Convulsant/Anti Epileptic Medicines																					
47	Carbamazepine Tablet 100 mg, 200 mg Carbamazepine Oral Liquid 100 mg/5 ml, 200mg/5ml Carbamazepine CR Tablet 200 mg, 400 mg																				
48	Levetiracetam Tablet 250 mg, 500 mg																				
49	Lorazepam Tablet 1 mg Lorazepam Injection 1 mg/ml Lorazepam Injection 2 mg/ml																				
50	Magnesium Sulphate Injection 500 mg/ml Magnesium Sulphate Injection IP 50% w/v																				
51	Phenytoin Tablet 50 mg/100 mg, 300 mg Phenytoin Oral Liquid 30 mg/5 ml Phenytoin Oral Liquid 125 mg/5 ml Phenytoin Injection 25 mg/ml, 50 mg/ml Phenytoin ER Tablet 300 mg																				
52	Sodium Valproate Tablet 100 mg, 200mg, 300mg, 500mg Sodium Valproate Tablet 500 mg Sodium Valproate Oral Liquid 200 mg/5 ml																				
Anti Infective Medicines																					
53	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml																				
54	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml																				

55	Ivermectin Tablet 600 mg																				
56	Amoxicillin Capsule 250 mg Amoxicillin Tablet 500 mg Amoxicillin Suspension 125 mg/5 ml Amoxicillin Oral Liquid 250 mg/5 ml																				
57	Ampicillin Capsule 500 mg Ampicillin Injection 500 mg/ml																				
58	Amoxicillin (500 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (875 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (500 mg) + Clavulanic Acid (100 mg) Injection Amoxicillin (1 gm) + Clavulanic Acid (200 mg) Injection Amoxicillin (125 mg) + Clavulanic Acid (31.25 mg/5 ml) Dry Syrup																				
59	Tablet Penicillin V (Phenoxymethyl Penicillin) 250 mg																				
60	Benzylpenicillin Injection 10 lakh unit Benzathine Benzylpenicillin Injection 12 lakh unit																				
61	Cefazolin Powder for Injection 500 mg Cefazolin Powder for Injection 1 gm																				
62	Cefixime Tablet 200 mg, 400mg Cefixime Oral Liquid 50 mg/5 ml																				
63	Cefotaxime Injection 1 g/vial Powder for Injection 250 mg																				
64	Ceftazidime Powder for Injection 250 mg Ceftazidime Powder for Injection 1g																				
65	Ceftriaxone Powder for Injection 250 mg Ceftriaxone Powder for Injection 500 mg Ceftriaxone Powder for Injection 1 g																				
66	Cloxacillin Capsule 250 mg Cloxacillin Oral Liquid 125 mg/5 ml Cloxacillin Injection 500 mg/vial																				
67	Piperacillin (A) + Tazobactam (B) Powder for Injection 1 g (A) + 125 mg (B) Powder for Injection 2 g (A) + 250 mg (B) Powder for Injection 4 g (A) + 500 mg (B)																				

68	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral Liquid 200 mg/5 ml																					
69	Norfloxacin Dispersible Tablet 100 mg Norfloxacin Tablet 400 mg/Oral liquid																					
70	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral Liquid 250 mg/5 ml Ciprofloxacin I.V 200 mg/100 m																					
71	Clarithromycin Tablet 250 mg Clarithromycin Tablet 500 mg Clarithromycin Oral Liquid 125 mg/5 ml																					
72	Co-trimoxazole [Sulphamethoxazol e (A) +Trimethoprim (B)] Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 ml																					
73	Doxycycline Capsule 100 mg Doxycycline Dry Syrup 50 mg/5 ml																					
74	Metronidazole Tablet 200 mg, 400 mg Metronidazole Injection 5 mg/ml, 500 mg/100 ml Metronidazole Oral Liquid 200 mg/5 ml																					
75	Nitrofurantoin Tablet 100 mg Nitrofurantoin Oral Liquid 25 mg/5 ml																					
76	Vancomycin Powder for Injection 250 mg Vancomycin Powder for Injection 500 mg Vancomycin Powder for Injection 1 g																					
77	Amikacin Injection 100 mg Amikacin Injection 500 mg																					
78	Clofazimine Tablet 50 mg Clofazimine Capsule 100 mg Clofazimine Capsule 200 mg																					
79	Delamanid Tablet 50 mg																					
80	Dapsone Tablet 25 mg Dapsone Tablet 100 mg																					
81	Rifampicin Tablet 75 mg Rifampicin Capsule 150 mg Rifampicin Capsule 300 mg Rifampicin Capsule 450 mg Rifampicin Oral Liquid 100 mg/5 ml																					
82	Capreomycin Injection 1 gm Capreomycin Injection 750 mg Capreomycin Injection 500 mg																					
83	Cycloserine Capsule 125 mg Cycloserine Capsule 250 mg																					

84	Ethambutol Tablet 100 mg Ethambutol Tablet 200 mg Ethambutol Tablet 400 mg Ethambutol Tablet 600 mg Ethambutol Tablet 800 mg																					
85	Ethionamide Tablet 125 mg Ethionamide Tablet 250 mg																					
86	Isoniazid Tablet 50 mg Isoniazid Tablet 75 mg Isoniazid Tablet 100 mg Isoniazid Tablet 300 mg Isoniazid Oral Liquid 100 mg/5 ml																					
87	Kanamycin Powder for Injection 500 mg Kanamycin Powder for Injection 750 mg Kanamycin Powder for Injection 1 g																					
88	Levofloxacin Tablet 250 mg Levofloxacin Tablet 500 mg, Levofloxacin Tablet 750 mg																					
89	Linezolid Tablet 600 mg																					
90	Moxifloxacin Tablet 500 mg Moxifloxacin Tablet 400 mg																					
91	Sodium Aminosalicylate Granules 10 gm Sodium Aminosalicylate Granules 9.2 gm																					
92	Pyrazinamide Tablet 150 mg Pyrazinamide Tablet 400 mg Pyrazinamide Tablet 500 mg Pyrazinamide Tablet 750 mg Pyrazinamide Oral Liquid 250 mg/5 ml																					
93	Rifabutin Capsule 150 mg Rifabutin Injection 500 mg																					
94	Streptomycin Powder for Injection 750 mg Streptomycin Powder for Injection 1 gm Streptomycin Powder for Injection 500 gm																					
95	Bedaquiline Tablet 100 mg																					
96	Amphotericin B Injection 50 mg a) Amphotericin B (conventional) b) Amphotericin B (Lipid)																					
97	Clotrimazole Tablet 100 mg Clotrimazole Pessary 100 mg																					
98	Fluconazole Tablet 150 mg																					
99	Itraconazole Tablet/Capsule 100 mg																					
100	Acyclovir Tablet 200 mg																					
101	Ganciclovir Capsule 200 mg																					
102	Abacavir Tablet 300 mg																					
103	Lamivudine (A) + Zidovudine (B) Tablet 150 mg (A) + 300 mg (B)																					
104	Tenofovir (A) + Lamivudine (B) + Efavirenz (C) Tablet 300 mg (A) + 300 mg (B) + 600 mg (C)																					

105	Zidovudine Tablet 300 mg Zidovudine Oral liquid 50 mg/5 ml																					
106	Zidovudine (A) + Lamivudine (B) + Nevirapine(C) Tablet 300 mg (A) + 150 mg (B) + 200 mg (C)																					
107	Efavirenz Tablet 50 mg Efavirenz Tablet 200 mg Efavirenz Tablet 600 mg																					
108	Nevirapine Dispersible Tablet 50 mg Nevirapine Dispersible Tablet 200 mg																					
109	Lopinavir (A) + Ritonavir (B) Capsule Lopinavir 133 mg + Ritiovir 33 mg Tablet Lopinavir 200 mg +Ritinovir 50 mg																					
110	Ritonavir Tablet 100 mg																					
111	Entecavir Tablet 0.5 mg Entecavir Tablet 1 mg																					
112	Sofosbuvir Tablet 400 mg																					
113	Tenofovir Tablet 300 mg Tenovir Aalafenamide Fumarate Tablet 25 mg Tenofovir Disoproxil* Fumarate Tablet 300 mg																					
114	Sofosbuvir 400 mg + Velpatasvir 400 mg Tablet																					
115	Diloxanide Furoate Tablet 500 mg																					
116	Tinidazole Tablet 300 mg, 500 mg																					
117	Miltefosine Capsule 10 mg Miltefosine Capsule 50 mg																					
118	Tablet Artemether (A) + Lumefantrine (B) Tablet 20 mg (A) + 120 mg (B) Tablet 80 mg (A) + 480 mg (B) Oral liquid 80 mg (A) + 480 mg (B)/5 ml																					
119	Artesunate Powder for Injection 60 mg Artesunate Powder for Injection 120 mg																					
120	Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Combi pack (A+B) 1 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg) (B) 1 Tablet 50 mg (A) + 1 Tablet 500 mg + 25 mg) (B) 1 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) (B) 1 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) (B) 1 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B)																					
121	Chloroquine Tablet 150 mg Chloroquine Oral Liquid 50 mg/5 ml																					
122	Clindamycin Capsule 150 mg Clindamycin Capsule 300 mg																					

123	Primaquine Tablet 2.5 mg Primaquine Tablet 7.5 mg Primaquine Tablet 15 mg																				
124	Quinine Tablet 300 mg, Quinine Injection 300 mg/ml (Protected from light)																				
Anti Covid Medicines																					
125	Favipiravir Tablet 200 mg, 400 mg																				
126	Remdesivir Injection 100 mg/20 ml																				
Anti Migraine Medicines																					
127	Sumatriptan Tablet 25 mg																				
128	Flunarizine Tablet 5 mg Flunarizine Tablet 10 mg																				
129	Propranolol Tablet 5 mg, 10 mg, 40 mg																				
Anti- Neoplastic Medicines																					
130	5-Fluorouracil Injection 250 mg/5 ml																				
131	Actinomycin D Injection 0.5 mg (5 mcg)																				
132	All-Trans Retinoic Acid Capsule 10 mg																				
133	Arsenic Trioxide Injection 1 mg/ml																				
134	Bleomycin Powder for Injection 15 units																				
135	Calcium Folinate Tablet 15 mg Calcium Folinate Injection 3 mg/ml																				
136	Capecitabine Tablet 500 mg																				
137	Carboplatin Injection 10 mg/ml																				
138	Chlorambucil Tablet 2 mg/5 mg Chlorambucil Powder for Injection 500 mg																				
139	Cyclophosphamide Powder for Injection 500 mg																				
140	Docetaxel Powder for Injection 20 mg																				
141	Etoposide Capsule 50 mg Etoposide Capsule 100 mg																				
142	Imatinib Tablet 100 mg Imatinib Tablet 400 mg																				
143	Paclitaxel Injection 30 mg/5 ml Paclitaxel Injection 100 mg/16.7 ml																				
144	Trastuzumab Injection 440 mg/50 ml																				
Hormones and Anti Hormonal Medicines used in Cancer Therapy																					
145	Bicalutamide Tablet 50 mg																				
146	Prednisolone Tablet 5 mg Prednisolone Tablet 10 mg Prednisolone Oral Liquid 5 mg/5 ml Prednisolone Oral Liquid 15 mg/5 ml																				
147	Letrozole Tablet 2.5 mg																				
148	Tamoxifen Tablet 10 mg Tamoxifen Tablet 20 mg																				
Immunosuppressive Medicines																					

149	Mycophenolate Mofetil Tablet 250 mg																					
150	Cyclosporine Capsule 10 mg, 25 mg, 50 mg, 100 mg, Oral Liquid 100 mg/ml Injection 50 mg/ml																					
151	TacrolimusCapsule 0.5 mg, 1 mg, 2 mg																					
Pain and Palliative Care Medicine																						
152	Allopurinol Tablet 100 mg, 300 mg																					
153	Acetylsalicylic Acid (Aspirin) Tablet 25 mg Acetylsalicylic Acid Tablet 50 mg Acetylsalicylic Acid Tablet 75 mg Acetylsalicylic Acid Tablet 150 mg, 300 mg																					
154	Amitriptyline Tablet 10 mg/25 mg																					
155	Diazepam Injection 5 mg/ml Diazepam Oral Liquid 2 mg/5 ml Diazepam Suppository 5 m Diazepam Tablet 5 mg, Diazepam Injection 10 mg/2 ml																					
156	Filgrastim Injection 300mcg																					
157	Fluoxetine Capsule 20 mg																					
158	Haloperidol Tablet 1.5 mg Haloperidol Tablet 5 mg Haloperidol Injection 5 mg/ml																					
159	Loperamide Tablet 2 mg																					
160	Metoclopramide Tablet 10 mg, Metoclopramide Oral Liquid 5 mg/5 ml Metoclopramide Injection 5 mg/ml																					
161	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml																					
162	Buprenorphine Tablet (sub-lingual) 0.4 mg																					
163	Disulfiram Tablet 250 mg																					
164	Naltrexone Tablet 50 mg																					
165	Tramadol Capsule 50 mg Tramadol Capsule100 mg Tramadol Injection 50mg/ml																					
166	Zoledronic Acid Powder for Injection 4 mg																					
167	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml																					
Opioid Analgesic Medicines																						
168	Morphine Injection 10 mg/ml Morphine Injection 15 mg/ml Morphine Tablet 10 mg Morphine Injection 10 mg/ml Morphine Tablet 10 mg Morphine Tablet 20 mg Morphine Tablet SR/30 mg																					

169	Codeine Tablet 15 mg Codeine Oral Solution 15 mg/5 ml																				
170	Fentanyl Injection 50mcg/ml																				
171	Methadone Tablet 5 mg, 40 mg Methadone Oral solution 5 mg/ml Methadone Injection 10 mg/ml																				
Anti- Parkinsonism Medicines																					
172	Levodopa (A) + Carbidopa (B) Tablet 100 mg (A) + 10 mg (B) CR Tablet 100 mg (A) + 25 mg (B) CR Tablet 200 mg (A) + 50 mg (B) Tablet 250 mg (A) + 25 mg (B)																				
173	Trihexyphenidyl (Benzhexol) Tablet 2 mg																				
Medicines Affecting Blood																					
174	Clonidine Tablet 100mcg																				
175	Erythropoietin Injection 2000 IU/ml Erythropoietin Injection 10000 IU/ml																				
176	Ferrous Salts equivalent to 60 mg of Elemental Iron Ferrous Salts Oral Liquid equivalent to 25 mg of Elemental Iron/ml																				
177	Ferrous Salt (A) + Folic Acid (B) Tablet 45 mg Elemental Iron (A) + 400 mcg (B) Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) Oral Liqiud 20 mg Elemental Iron(A) + 100 mcg (B)/ml Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) as Enteric Coated																				
178	Folic Acid Tablet 5 mg Folic Acid Tablet 0.4 mg Folic Acid 5 mg Injection 1 mg/ml																				
179	Hydroxyurea Capsule 500 mg																				
180	Iron Sucrose Injection 20 mg/ml																				
181	Phytomenadione (Vitamin K1) Tablet 10 mg Phytomenadione (Vitamin K1) Inj 10 mg/ml																				
182	Menadione Injection (Vitamin K3) 10 mg/ml																				
183	Heparin Sodium Injection 1000 IU																				
184	Tranexamic Acid Tablet 500 mg																				
185	Warfarin Tablet 1 mg Warfarin Tablet 2 mg Warfarin Tablet 3 mg Warfarin Tablet 5 mg																				
186	Coagulation factor VII																				
187	Coagulation factor VIII																				
188	Coagulation factor IX																				

189	APCC (Activated Prothrombin Complex Concentrate) Inhibitor																					
Cardiovascular Medicines																						
190	Clopidogrel Tablet 75 mg																					
191	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg Diltiazem Injection5 mg/ml																					
192	Glyceryl Trinitrate Sublingual Tablet 0.5 mg Glyceryl trinitrate Injection 125 mg/5 ml																					
193	Isosorbide-5- mononitrate Tablet 10 mg, Isosorbide-5- mononitrate SR Tablet 30 mg																					
194	Isosorbide Dinitrate Tablet 5 mg Isosorbide Dinitrate Tablet 10 mg																					
195	Atenolol Tablet 50 mg, 100 mg																					
196	Metoprolol Tablet 25 mg Metoprolol Tablet 50 mg Metoprolol Tablet 100 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg																					
197	Amiodarone Tablet 100 mg Amiodarone Injection 50 mg/ml																					
198	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg Amlodipine Tablet 10 mg																					
199	Hydrochlorothiazid Tablet 12.5 mg Hydrochlorothiazid Tablet 25 mg Hydrochlorothiazide Tablet 50 mg																					
200	Labetalol Injection 5 mg/ml Labetalol Tablet 100 mg Labetalol Injection 20 mg/2 ml																					
201	Methyldopa Tablet 250 mg Methyldopa Tablet 500 mg																					
202	Enalapril Tablet 2.5 mg Enalapril Tablet 5 mg Enalapril Tablet 10 mg																					
203	Captopril Tablet 25 mg																					
204	Lisinopril Tablet 5 mg																					
205	Verapamil Tablet 40 mg, 120 mg Verapamil Injection 5 mg/2 ml																					
206	Ramipril Tablet 2.5 mg/5 mg																					
207	Telmisartan Tablet 40 mg																					
208	Digoxin Tablet 0.25 mg Digoxin Tablet 250 mg																					
209	Dobutamine Injection 50 mg/ml																					
210	Dopamine Injection 40 mg/ml																					
211	Protamine Injection 50 mg/5 ml																					
212	Noradrenaline Injection 2 mg/ml																					
213	Enoxaparin LMWH Injection																					
214	Clofibrate Tablet 500 mg																					

215	Streptokinase Injection 15 lac/Vial Sterptokinase Injection 7.5 lac/Vial																					
216	Fenofibrate Tablet 40 mg, 160 mg																					
217	Atorvastatin Tablet 10 mg Atorvastatin Tablet 40 mg																					
218	Esmolol Injection 10 mg/ml																					
219	Sodium nitroprusside Injection 10 mg/ml																					
220	Alteplase Powder for Injection 20 mg Alteplase Powder for Injection 50																					
Medicines used in Dementia																						
221	Donepezil Tablet 5 mg																					
Dermatological Medicines (Topical)																						
222	Clotrimazole cream 1% Clotrimazole Oral Lotion or Mouth Paint: 15 ml																					
223	Framycetin cream 0.5%																					
224	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg preparation																					
225	Silver Sulphadiazine 2 to 4%																					
226	Miconazole Ointment or Cream 2% 15 gm preparation																					
227	Betamethasone Cream 0.05% Betamethasone Cream 0.1% Betamethasone Injection 12 mg Betamethasone Injection 4 mg/ml																					
228	Calamine Lotion																					
229	Benzoyl Peroxide Gel 2.5% Benzoyl Peroxide Gel 5%																					
230	Coal Tar Solution 5%																					
231	Salicylic Acid Ointment 6%																					
232	Gamma Benzene Hexachloride Lotion 100 ml																					
233	Permethrin Lotion 1% Permethrin Cream 5%																					
234	Glycerin Oral Liquid																					
235	Petroleum Jelly 100%																					
Diagnostic Agents																						
236	Lignocaine Eye Drops 4%																					
237	Tropicamide Eye Drops 1%																					
Dialysis Solution																						
238	Haemodialysis Fluid																					
239	Intraperitoneal Dialysis Solution																					
Disinfectants and Antiseptics																						
240	Cetrimide Solution 20%																					
241	Chlorhexidine Solution 5%																					
242	Ethyl Alcohol																					
243	Hydrogen Peroxide Solution 6%																					
244	Povidone Iodine Solution 4% to 10% Povidone Iodine Solution 10% (equivalent to 1% available iodine)																					

245	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P)																				
Diuretics Medicines																					
246	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml																				
247	Indapamide Tablet 1.5 mg																				
248	Chlorthalidone Tablet 12.5 mg																				
249	Mephentermine Injection 15 mg/ml																				
250	Mannitol Injection 10% Mannitol Injection 20%																				
251	Spironolactone Tablet 25 mg Spironolactone Tablet 50 mg																				
252	Methyl Cellulose Tablet, Powder																				
Dental Restorative Material and Medicines																					
253	Zinc Oxide Eugenol																				
254	Silver Amalgam																				
255	Glass Ionomer Cement (GIC)																				
256	Calcium Hydroxide																				
257	Sodium Hypochlorite																				
258	Gutta Percha (GP)																				
259	Light Cure Composite																				
260	Ketorolac 10 mg tablet																				
261	Gum Paint (Tannic Acid)																				
262	Povidine-iodine Germicide Gargle 20% w/v																				
263	Tooth Paste (Potassium Nitrate)																				
Ear, Nose and Throat (ENT) Medicines																					
264	Ciprofloxacin Drops 0.3% Ciprofloxacin Eye/Ear Drops																				
265	Clotrimazole Drops 1%																				
266	Xylometazoline Nasal Drops 0.05 %, 0.1% Xylometazoline Nasal Drops: Paediatric (0.05), Adult (0.1%)																				
267	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg																				
268	Normal Saline nasal drop: sodium chloride drops 0.05% w/v																				
269	Wax Solvent Ear Drops: Benzocaine, Paradichlorobenzene, Turpentine Oil																				
270	Boro-Spirit Ear Drops-0.183 gm Boric Acid in 2.08 ml of Alcohol																				
271	Combo Ear Drops-Chloramphenicol 5% w/v + Clotrimazole 1% +Lignocaine Hydrochloride 2%																				
272	Liquid Paraffin-Menthol Drops: Menthol 10 gm +Eucalyptus 2 ml+ Camphor 10 mg+ liquid paraffin to 100 ml																				
Gastrointestinal Medicines																					
273	Omeprazole Capsule 20 mg																				
274	Ranitidine Tablet 150 mg Ranitidine Injection 25 mg/m																				

275	Sucralfate Tablet 10 mg Sucralfate Oral Liquid 1 mg/ml																					
276	Metoclopramide Injection 5 mg/ml																					
277	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml																					
278	Dicyclomine Tablet 10 mg Dicyclomine Injection 10 mg/ml Dicyclomine Tablet 500 mg																					
279	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml																					
280	Drotaverine Tablet 500 mg																					
281	Bisacodyl Tablet 5 mg Bisacodyl Suppository 5 mg																					
282	Zinc Sulphate Tablet 10 mg Zinc Sulphate Dispersible Tablet USP eq. to Elemental Zinc 20 mg																					
283	Lactulose Oral Liquid 10g/15 ml																					
284	Ispaghula- Granules, Husk, Powder																					
285	Senna Tablet, Granules, Powder																					
Hormones, other Endocrine Medicines and Contraceptives																						
286	Human Chorionic Gonadotropin Injection 1000 IU Human Chorionic Gonadotropin Injection 5000 IU																					
287	Methylprednisolone Tablet 8 mg, 32 mg Methylprednisolone Injection 40 mg/ml Methylprednisolone Injection 500 mg																					
288	Ethinylestradiol (A) + Levonorgestrel (B) Tablet 0.03 mg (A) + 0.15 mg (B) Tablet 0.03 mg (A) + 0.15 mg (B) with Ferrous Fumarate																					
289	IUCD 380A IUCD 375																					
290	Male Condom																					
291	Tubal Ring																					
292	Ormeloxifene Tablet 30 mg																					
293	Ethinylestradiol Tablet 0.01 mg Ethinylestradiol Tablet 0.05 mg																					
294	Levonorgestrel Tablet 1.5 mg Levonorgestrel Tablet 0.75 mg																					
295	Glimepiride Tablet 1 mg Glimepiride Tablet 2 mg																					
296	Gliclazide Tablet 40 mg																					

297	Insulin (Soluble) Injection 40 IU/ml Insulin Lente Basal Injection Insulin Rapid Injection Insulin Mixtard																					
298	Metformin Tablet 500 mg Metformin Controlled released 750 mg																					
299	Premix Insulin 30:70 Injection (Regular: NPH) Premix Insulin 30:70 Injection 40 IU/ml																					
300	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg																					
301	Medroxyprogesterone Tablet 5 mg, 10 mg Medroxyprogesterone acetate Injection 150 mg																					
302	Carbimazole Tablet 5 mg Carbimazole Tablet 10 mg																					
303	Levothyroxine Tablet 50 mcg,100mcg																					
Immunological/Vaccines																						
304	Anti-Rabies Immunoglobulin																					
305	Anti-Tetanus Immunoglobulin																					
306	Anti-D Immunoglobulin																					
307	Diphtheria Antitoxin																					
308	Hepatitis B Immunoglobulin																					
309	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																					
310	Rabies Vaccine																					
311	Immunological/Vaccines, As per Current Immunization Programme Guidelines																					
Muscle Relaxant and Cholinesterase Inhibitors																						
312	Atracurium Injection 10 mg/ml																					
313	Succinylcholine Injection 50 mg/ml																					
314	Vecuronium Powder for Injection 4 mg Vecuronium Powder for Injection 10 mg																					
Medicines for Neonatal Care																						
315	Caffeine Oral Liquid 20 mg/ml Caffeine Injection 20 mg/ml																					
Ophthalmological Medicines																						
316	Acyclovir Ointment 3%																					
317	Ciprofloxacin Drops 0.3%																					
318	Gentamicin Drops 0.3% Gentamicin Injection 40 mg/ml																					
319	Povidone iodine Drops 0.6% Povidone iodine Drops 5%																					
320	Prednisolone Drops 0.1% Prednisolone Drops 1%																					
321	Acetazolamide Tablet 250 mg																					
322	Pilocarpine Drops 2% Pilocarpine Drops 4%																					
323	Timolol Drop 0.5%																					
324	Atropine Ointment 1%																					
325	Homatropine Drops 2%																					
326	Tropicamide Drops 1%																					

327	Carboxymethylcellulose Drops 0.5%																				
Oxytocic and Anti-Oxytocic Medicines																					
328	Methylergometrine 0.125 mg Tablet Methylergometrine 0.2 mg/ml Injection																				
329	Mifepristone Tablet 200 mg																				
330	Misoprostol Tablet 100mcg Misoprostol Tablet 200mcg (oral/vaginal)																				
331	Combi-pack with Mifepristone + Misoprostol (1 tablet of Mifepristone 200 mg and 4 tablets of Misoprostol 200mcg)																				
332	Oxytocin Injection 5 IU/ml Oxytocin Injection 10 IU/ml																				
333	Nifedipine Tablet 10 mg Nifedipine Soft Gelatin Capsule 5 mg																				
Psychotherapeutic Medicines																					
334	Chlorpromazine Tablet 100 mg																				
335	Clozapine Tablet 25 mg Clozapine Tablet 100 mg																				
336	Diphenylhydantoin Tablet 100 mg																				
337	Fluphenazine Depot Injection 25 mg/ml																				
338	Risperidone Tablet 2 mg Risperidone Injection																				
339	Phenobarbitone Tablet 30 mg Phenobarbitone Tablet 60 mg Phenobarbitone Oral Liquid 20 mg/5 ml																				
340	Olanzapine Tablet 5 mg Olanzapine Injection 10 mg																				
341	Escitalopram Tablet 10 mg Escitalopram Tab 5 mg																				
342	Imipramine Tablet 25 mg Imipramine Tablet 75 mg																				
343	Lithium Tablet 300 mg																				
344	Clonazepam Tablet 0.5 mg Clonazepam Tablet 0.25 mg																				
345	Zolpidem Tablet 10 mg																				
Medicines Acting on Respiratory Tract																					
346	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Inhalation (MDI/DPI) 200 mcg/dose Budesonide Respirator solution for use in nebuliser 0.5 mg/ml Budesonide Respirator solution for use in nebuliser 1 mg/ml																				
347	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone) MDI, DPI																				
348	Budesonide Nebulisation Solution																				

349	Ipravent/Levoline Nebulisation Solution (Levosalbutamol/Ipratopium)																				
350	Budesonide (A)+ Formoterol (B) Inhalation (MDI/DPI) 100 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 200 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg (A)+ 6 mcg (B)																				
351	Etofyllin B Plus (A), Anhydrous Theophylline IP (B) combination injection 84.7 mg/ml (A) + 25.3 mg/ml (B)																				
352	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebuliszer 250 mcg/ml																				
353	Levosalbutamol 50mcg/dose																				
354	Salbutamol Tablet 2 mg Salbutamol Tablet 4 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Inhalation (MDI/DPI) 100 mcg/dose, Salbutamol Respirator solution for use in nebuliser 5 mg/m																				
355	Formoterol Inhaled Bronchodilator																				
356	Salmeterol Inhaled Bronchodilator																				
357	Theophylline Tablet																				
358	Tiotropium Inhalation (MDI) 9 mcg/dose Tiotropium Inhalation (DPI) 18 mcg/dose																				
359	Deriphyllin Tablet SR																				
360	Montelukast Tablet 5 mg Montelukast Tablet 10 mg Montelukast syrup																				
Solutions Correcting Water, Electrolyte Distribution and Acid-Base Distribution																					
361	Dextrose IV Injection 5% w/v, 500 ml																				
362	Glucose Injection 5% Glucose Injection 10% Glucose Injection 25% Glucose Injection 50%																				
363	Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B)																				
364	Hydroxyethyl Starch 6%IP (6% Saline solution for infusion)																				
365	Oral Rehydration Salts Oral Rehydration Powder 27.5 gm WHO Formula																				
366	Potassium Chloride Injection 150 mg/ml Potassium Chloride Oral Liquid 500 mg/5 ml																				
367	Ringer Lactate Injection (as per IP)																				

368	Sodium Bicarbonate Injection (as per IP)																					
369	Sodium Chloride Injection 0.9%																					
370	Sterile Water for Injection IP-05 ml																					
Vitamins and Minerals																						
371	Ascorbic Acid (Vitamin C) Tablet 100 mg Ascorbic Acid (Vitamin C) Tablet 500 mg																					
372	Calcium Carbonate Tablet 250 mg Calcium Carbonate Tablet 500 mg																					
373	Calcium with Vitamin D Tablets USP Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125 mg																					
374	Cholecalciferol Tablet 1000 IU Cholecalciferol Tablet 60,000 IU Cholecalciferol Oral Liquid 400 IU/ml Cholecalciferol Granules 60,000 IU in Sachet Cholecalciferol Injection of 6,00,000 IU Vitamin D3 60,000 Granules in 1 gm Sachet																					
375	Nicotinamide Tablet 50 mg																					
376	Multivitamin Tab/Cap																					
377	Pyridoxine Tablet 25 mg Pyridoxine Tablet 40 mg Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg																					
378	Riboflavin Tablet 5 mg																					
379	Thiamine Tablet 100 mg Thiamine Injection 100 mg/ml																					
380	Vitamin A Oral liquid 100000 IU/ml																					
Dressing																						
381	Dressing Bandage and Gauze with Band-Aid																					
Data Collected from State Essential Drugs List (EDL)																						
Sl. No	**List of medicines not Part of IPHS but available in State Notified EDL**																					
Sl. No	**List of Medicines Found at Health Facility but not part of IPHS EML & State Notified EDL**																					

Sub-District Hospital (SDH) : Stock Availability Data Period-Year - April 2025- September 2025

S.No.	Drug Name	IPHS medicine Notified in State EML for the facility	Currently Medicine Available (On the date of site visit) Current Quantity		Medicine Available	Stock out events	Number of stock out events	Date of stock out	Date of stock made available after stock out	Period of Stock Out/Replenishment time (In days)	Eexpired medicines (if yes then quantity)	Time taken to Dispose the expired medicines (Date of Expiry - Date of Disposal)	NSQ medicines reported (if yes then quantity/otherwise record No)	Time taken to dispose NSQ medicine (Date of NSQ reported & Date of disposal)	Annual Indent Quantity (in numbers-Tab/cap/ampoule/vial/bottle/tube)	Total quantity indented during monthly indent (Sum monthly/daily/weekly indent quantity)	Total quantity Receipt	Actual current stock (Physical count)	Quantity as per Stock ledger	Quantity as per DVDMS/ State LMIS	Locally Procured Quantity	Locally Procured Value in Rs.
	Means of verification	State notified EML	Stock ledger /Bin card/ Challan	Stock ledger	Stock ledger	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card		Stock ledger/ Physical verification at site	Stock ledger /Proceeding/ Handover document	Record, also enclose NSQ report	Stock ledger /Proceeding/ Handover document	Records	Records/LMIS	Stock ledger /LMIS	(Telmisartan,Amlodipine Glimepride, Metformin, paracetamol, RL,NS,Diclofenac/Acceclofenac/Cetrizine or Levo-cetrizine/ Amoxicillin				
	CHC (FRU/ Non-FRU)	Y/N	Unit(Pack size)	Quantity (Quantity in numbers like number of Tablets/Capsules/Injections/tubes/bottles/ etc)	Y/N	Y/N																
Anesthetic Agent																						
1	Halothane Gas for Inhalation		100ml			Y	3	03.04.25	07.04.25	4												
								27.05.25	8.06.25	12												
								05.7.25	12.07.25	5												
2	Isoflurane Gas for Inhalation					N	__	__	__	__												
3	Ketamine Injection 10 mg/ml Ketamine Injection 50 mg/ml		2 ml vial																			
4	Nitrous Oxide Gas for Inhalation																					
5	Oxygen Gas for Inhalation																					
6	Propofal Injection 10 mg/ml																					
7	Sevoflurane Injection																					
8	Promethazine Injection 25 mg/ml, 50 mg/ml																					
9	Pentazocine Injection 30mg/ml																					
10	Thiopentane Injection 0.5 gm/1 gm																					
11	Bupivacaine Injection 0.5 mg/ml (sensorcain)																					
12	Lignocaine Injection 2% Lignocaine Injection 4%w/v, 5%w/v Lignocaine Jelly Lignocaine Ointment 2%-5% Lignocaine Spray 10%																					
13	Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) Injection 2% (A) + 1:200000 (5 mcg/ml) (B)																					
14	Atropine Injection 0.6 mg/ml, 1 mg/ml																					
15	Glycopyrolate Injection 0.2 mg/ml																					
16	Midazolam Injection 1 mg/ml Midazolam Tablet 250 mg Midazolam Tablet 500 mg																					
Non opioid Analgesic, Anti-Pyretic and Non steroidal Anti Inflammatory Medicines																						

17	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Injection 25 mg/3ml																				
18	Ibuprofen Tablet 200 mg Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg/5 ml																				
19	Paracetamol (Acetaminophen) Tablet 500 mg, 600mg Paracetamol (Acetaminophen) Injection 150 mg/ml Paracetamol (Acetaminophen) Syrup 125 mg/5ml Paracetamol (Acetaminophen) Syrup 120 mg/5ml, 60 ml Paracetamol Suppository 80 mg																				
20	Naproxen Tablet 250 mg Naproxen Tablet 500 mg																				
21	Duloxetine Tablet 10 mg, 30 mg, 60 mg																				
22	Tapentadol Tablet 25 mg, 100 mg																				
23	Gabapentin Tablet 100 mg, 400 mg																				
24	Pregabalin Tablet 25 mg,150 mg Pregabalin syrup 50 mg/ml																				
25	Nortriptyline Tablet 10 mg, 50 mg																				
Anti allergics and medicines used in Anaphylaxis																					
26	Adrenaline Injection 1 mg/ml (1:1000)																				
27	Cetirizine Tablet 5 mg Cetirizine Tablet 10 mg Cetirizine Oral Liquid 5 mg/5 ml																				
28	Chlorpheniramine Tablet 4 mg, 5mg, 10mg, 20mg, 40mg Chlorpheniramine Oral liquid 2 mg/5 ml, 5 mg/5 ml																				
29	Dexamethasone Tablet 0.5 mg Dexamethasone Injection 4 mg/ml																				
30	Hydroxyzine Syrup 10 mg/5 ml Hydroxyzine Tablet 25 mg																				
31	Hydrocortisone Powder for Injection 100 mg Hydrocortisone Injection 200 mg Hydrocortisone Cream/Gel/Ointment 0.5%/1%																				
32	Pheniramine Maleate Injection 22.75 mg/ml																				
Antidote and other Substances used in Poisioning																					
33	Activated Charcoal																				
34	Calcium Gluconate Injection 100 mg/ml Calcium Gluconate Injection 1 gm, IV-10 ml amp																				

35	Desferrioxamine Injection 500 mg																				
36	N-acetylcysteine Injection 200 mg/ml N-acetylcysteine Sachet 200 mg N-acetylcysteine Tablet 600 mg/Dispersible																				
37	Neostigmine Injection 0.5 mg/m																				
38	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																				
39	Deferiprone capsule 250mg & 500mg																				
40	Deferasirox Tablet 250mg & 500mg																				
Anti Convulsant/Anti Epileptic Medicines																					
41	Carbamazepine Tablet 100 mg, 200 mg Carbamazepine Oral Liquid 100 mg/5 ml, 200mg/5ml Carbamazepine CR Tablet 200 mg, 400 mg																				
42	Levetiracetam Tablet 250 mg, 500 mg																				
43	Lorazepam Tablet 1 mg Lorazepam Injection 1 mg/ml Lorazepam Injection 2 mg/ml																				
44	Magnesium Sulphate Injection 500 mg/ml Magnesium Sulphate Injection IP 50% w/v																				
45	Phenytoin Tablet 50 mg/100 mg, 300 mg Phenytoin Oral Liquid 30 mg/5 ml Phenytoin Oral Liquid 125 mg/5 ml Phenytoin Injection 25 mg/ml, 50 mg/ml Phenytoin ER Tablet 300 mg																				
46	Sodium Valproate Tablet 100 mg, 200mg, 300mg, 500mg Sodium Valproate Tablet 500 mg Sodium Valproate Oral Liquid 200 mg/5 ml																				
Anti Infective Medicines																					
47	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml																				
48	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml																				
49	Ivermectin Tablet 600 mg																				
50	Amoxicillin Capsule 250 mg Amoxicillin Tablet 500 mg Amoxicillin Suspension 125 mg/5 ml Amoxicillin Oral Liquid 250 mg/5 ml																				
51	Ampicillin Capsule 500 mg Ampicillin Injection 500 mg/ml																				

52	Amoxicillin (500 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (875 mg) + Clavulanic Acid (125 mg) Tablet Amoxicillin (500 mg) + Clavulanic Acid (100 mg) Injection Amoxicillin (1 gm) + Clavulanic Acid (200 mg) Injection Amoxicillin (125 mg) + Clavulanic Acid (31.25 mg/5 ml) Dry Syrup																					
53	Tablet Penicillin V (Phenoxymethyl Penicillin) 250 mg																					
54	Benzylpenicillin Injection 10 lakh unit Benzathine Benzylpenicillin Injection 12 lakh unit																					
55	Cefazolin Powder for Injection 500 mg Cefazolin Powder for Injection 1 gm																					
56	Cefixime Tablet 200 mg, 400mg Cefixime Oral Liquid 50 mg/5 ml																					
57	Cefotaxime Injection 1 g/vial Powder for Injection 250 mg																					
58	Ceftazidime Powder for Injection 250 mg Ceftazidime Powder for Injection 1g																					
59	Ceftriaxone Powder for Injection 250 mg Ceftriaxone Powder for Injection 500 mg Ceftriaxone Powder for Injection 1 g																					
60	Cloxacillin Capsule 250 mg Cloxacillin Oral Liquid 125 mg/5 ml Cloxacillin Injection 500 mg/vial																					
61	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral Liquid 200 mg/5 ml																					
62	Norfloxacin Dispersible Tablet 100 mg Norfloxacin Tablet 400 mg/Oral liquid																					
63	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral Liquid 250 mg/5 ml Ciprofloxacin I.V 200 mg/100 m																					
64	Clarithromycin Tablet 250 mg Clarithromycin Tablet 500 mg Clarithromycin Oral Liquid 125 mg/5 ml																					

65	Co-trimoxazole [Sulphamethoxazol e (A) +Trimethoprim (B)] Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 ml																					
66	Doxycycline Capsule 100 mg Doxycycline Dry Syrup 50 mg/5 ml																					
67	Metronidazole Tablet 200 mg, 400 mg Metronidazole Injection 5 mg/ml, 500 mg/100 ml Metronidazole Oral Liquid 200 mg/5 ml																					
68	Nitrofurantoin Tablet 100 mg Nitrofurantoin Oral Liquid 25 mg/5 ml																					
69	Amikacin Injection 100 mg Amikacin Injection 500 mg																					
70	Clofazimine Tablet 50 mg Clofazimine Capsule 100 mg Clofazimine Capsule 200 mg																					
71	Delamanid Tablet 50 mg																					
72	Dapsone Tablet 25 mg Dapsone Tablet 100 mg																					
73	Rifampicin Tablet 75 mg Rifampicin Capsule 150 mg Rifampicin Capsule 300 mg Rifampicin Capsule 450 mg Rifampicin Oral Liquid 100 mg/5 ml																					
74	Capreomycin Injection 1 gm Capreomycin Injection 750 mg Capreomycin Injection 500 mg																					
75	Cycloserine Capsule 125 mg Cycloserine Capsule 250 mg																					
76	Ethambutol Tablet 100 mg Ethambutol Tablet 200 mg Ethambutol Tablet 400 mg Ethambutol Tablet 600 mg Ethambutol Tablet 800 mg																					
77	Ethionamide Tablet 125 mg Ethionamide Tablet 250 mg																					
78	Isoniazid Tablet 50 mg Isoniazid Tablet 75 mg Isoniazid Tablet 100 mg Isoniazid Tablet 300 mg Isoniazid Oral Liquid 100 mg/5 ml																					
79	Levofloxacin Tablet 250 mg Levofloxacin Tablet 500 mg, Levofloxacin Tablet 750 mg																					
80	Linezolid Tablet 600 mg																					
81	Moxifloxacin Tablet 500 mg Moxifloxacin Tablet 400 mg																					
82	Pyrazinamide Tablet 150 mg Pyrazinamide Tablet 400 mg Pyrazinamide Tablet 500 mg Pyrazinamide Tablet 750 mg Pyrazinamide Oral Liquid 250 mg/5 ml																					
83	Rifabutin Capsule 150 mg Rifabutin Injection 500 mg																					

84	Streptomycin Powder for Injection 750 mg Streptomycin Powder for Injection 1 gm Streptomycin Powder for Injection 500 gm																				
85	Bedaquiline Tablet 100 mg																				
86	Clotrimazole Tablet 100 mg Clotrimazole Pessary 100 mg																				
87	Fluconazole Tablet 150 mg																				
88	Itraconazole Tablet/Capsule 100 mg																				
89	Acyclovir Tablet 200 mg																				
90	Entecavir Tablet 0.5 mg Entecavir Tablet 1 mg																				
91	Diloxanide Furoate Tablet 500 mg																				
92	Tinidazole Tablet 300 mg, 500 mg																				
93	Miltefosine Capsule 10 mg Miltefosine Capsule 50 mg																				
94	Chloroquine Tablet 150 mg Chloroquine Oral Liquid 50 mg/5 ml																				
95	Primaquine Tablet 2.5 mg Primaquine Tablet 7.5 mg Primaquine Tablet 15 mg																				
96	Quinine Tablet 300 mg, Quinine Injection 300 mg/ml (Protected from light)																				
Anti Covid Medicines																					
97	Favipiravir Tablet 200 mg, 400 mg																				
98	Remdesivir Injection 100 mg/20 ml																				
Anti Migraine Medicines																					
99	Flunarizine Tablet 5 mg Flunarizine Tablet 10 mg																				
100	Propranolol Tablet 5 mg, 10 mg, 40 mg																				
Anti- Neoplastic Medicines																					
101	All-Trans Retinoic Acid Capsule 10 mg																				
102	Arsenic Trioxide Injection 1 mg/ml																				
103	Calcium Folinate Tablet 15 mg Calcium Folinate Injection 3 mg/ml																				
104	Capecitabine Tablet 500 mg																				
105	Carboplatin Injection 10 mg/ml																				
106	Chlorambucil Tablet 2 mg/5 mg Chlorambucil Powder for Injection 500 mg																				
Hormones and Anti Hormonal Medicines used in Cancer Therapy																					
107	Prednisolone Tablet 5 mg Prednisolone Tablet 10 mg Prednisolone Oral Liquid 5 mg/5 ml Prednisolone Oral Liquid 15 mg/5 ml																				
Pain and Palliative Care Medicine																					
108	Allopurinol Tablet 100 mg, 300 mg																				

109	Acetylsalicylic Acid (Aspirin) Tablet 25 mg Acetylsalicylic Acid Tablet 50 mg Acetylsalicylic Acid Tablet 75 mg Acetylsalicylic Acid Tablet 150 mg, 300 mg																				
110	Diazepam Injection 5 mg/ml Diazepam Oral Liquid 2 mg/5 ml Diazepam Suppository 5 m Diazepam Tablet 5 mg, Diazepam Injection 10 mg/2 ml																				
111	Fluoxetine Capsule 20 mg																				
112	Haloperidol Tablet 1.5 mg Haloperidol Tablet 5 mg Haloperidol Injection 5 mg/ml																				
113	Loperamide Tablet 2 mg																				
114	Metoclopramide Tablet 10 mg, Metoclopramide Oral Liquid 5 mg/5 ml Metoclopramide Injection 5 mg/ml																				
115	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml																				
116	Tramadol Capsule 50 mg Tramadol Capsule100 mg Tramadol Injection 50mg/ml																				
117	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml																				
Opioid Analgesic Medicines																					
118	Morphine Tablet 10 mg																				
119	Codeine Tablet 15 mg Codeine Oral Solution 15 mg/5 ml																				
120	Fentanyl Injection 50mcg/ml																				
121	Methadone Tablet 5 mg, 40 mg Methadone Oral solution 5 mg/ml Methadone Injection 10 mg/ml																				
Anti- Parkinsonism Medicines																					
122	Levodopa (A) + Carbidopa (B) Tablet 100 mg (A) + 10 mg (B) CR Tablet 100 mg (A) + 25 mg (B) CR Tablet 200 mg (A) + 50 mg (B) Tablet 250 mg (A) + 25 mg (B)																				
123	Trihexyphenidyl (Benzhexol) Tablet 2 mg																				
Medicines Affecting Blood																					
124	Clonidine Tablet 100mcg																				

125	Ferrous Salts equivalent to 60 mg of Elemental Iron Ferrous Salts Oral Liquid equivalent to 25 mg of Elemental Iron/ml																					
126	Ferrous Salt (A) + Folic Acid (B) Tablet 45 mg Elemental Iron (A) + 400 mcg (B) Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) Oral Liqiud 20 mg Elemental Iron(A) + 100 mcg (B)/ml Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) as Enteric Coated																					
127	Folic Acid Tablet 5 mg Folic Acid Tablet 0.4 mg Folic Acid 5 mg Injection 1 mg/ml																					
128	Iron Sucrose Injection 20 mg/ml																					
129	Phytomenadione (Vitamin K1) Tablet 10 mg Phytomenadione (Vitamin K1) Inj 10 mg/ml																					
130	Menadione Injection (Vitamin K3) 10 mg/ml																					
131	Heparin Sodium Injection 1000 IU																					
132	Tranexamic Acid Tablet 500 mg																					
133	Hydroxyurea Capsule 500 mg																					
134	Coagulation factor VII																					
135	Coagulation factor VIII																					
136	Coagulation factor IX																					
137	APCC (Activated Prothrombin Complex Concentrate) Inhibitor																					
138	Warfarin Tablet 1 mg Warfarin Tablet 2 mg Warfarin Tablet 3 mg Warfarin Tablet 5 mg																					
Cardiovascular Medicines																						
139	Clopidogrel Tablet 75 mg																					
140	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg Diltiazem Injection5 mg/ml																					
141	Glyceryl Trinitrate Sublingual Tablet 0.5 mg Glyceryl trinitrate Injection 125 mg/5 ml																					
142	Isosorbide-5- mononitrate Tablet 10 mg, Isosorbide-5- mononitrate SR Tablet 30 mg																					
143	Isosorbide Dinitrate Tablet 5 mg Isosorbide Dinitrate Tablet 10 mg																					
144	Atenolol Tablet 50 mg, 100 mg																					
145	Metoprolol Tablet 25 mg Metoprolol Tablet 50 mg Metoprolol Tablet 100 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg																					
146	Amiodarone Tablet 100 mg Amiodarone Injection 50 mg/ml																					

147	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg Amlodipine Tablet 10 mg																				
148	Hydrochlorothiazid Tablet 12.5 mg Hydrochlorothiazid Tablet 25 mg Hydrochlorothiazide Tablet 50 mg																				
149	Labetalol Injection 5 mg/ml Labetalol Tablet 100 mg Labetalol Injection 20 mg/2 ml																				
150	Methyldopa Tablet 250 mg Methyldopa Tablet 500 mg																				
151	Enalapril Tablet 2.5 mg Enalapril Tablet 5 mg Enalapril Tablet 10 mg																				
152	Captopril Tablet 25 mg																				
153	Lisinopril Tablet 5 mg																				
154	Verapamil Tablet 40 mg, 120 mg Verapamil Injection 5 mg/2 ml																				
155	Ramipril Tablet 2.5 mg/5 mg																				
156	Telmisartan Tablet 40 mg																				
157	Digoxin Tablet 0.25 mg Digoxin Tablet 250 mg																				
158	Dobutamine Injection 50 mg/ml																				
159	Dopamine Injection 40 mg/ml																				
160	Protamine Injection 50 mg/5 ml																				
161	Noradrenaline Injection 2 mg/ml																				
162	Enoxaparin LMWH Injection																				
163	Clofibrate Tablet 500 mg																				
164	Streptokinase Injection 15 lac/Vial Sterptokinase Injection 7.5 lac/Vial																				
165	Finofibrate Tablet 40 mg, 160 mg																				
166	Atorvastatin Tablet 10 mg Atorvastatin Tablet 40 mg																				
Medicines used in Dementia																					
167	Donepezil Tablet 5 mg																				
Dermatological Medicines (Topical)																					
168	Clotrimazole cream 1% Clotrimazole Oral Lotion or Mouth Paint: 15 ml																				
169	Framycetin cream 0.5%																				
170	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg preparation																				
171	Silver Sulphadiazine 2 to 4%																				
172	Miconazole Ointment or Cream 2% 15 gm preparation																				
173	Betamethasone Cream 0.05% Betamethasone Cream 0.1% Betamethasone Injection 12 mg Betamethasone Injection 4 mg/ml																				
174	Calamine Lotion																				
175	Benzoyl Peroxide Gel 2.5% Benzoyl Peroxide Gel 5%																				

176	Coal Tar Solution 5%																				
177	Salicylic Acid Ointment 6%																				
178	Gamma Benzene Hexachloride Lotion 100 ml																				
179	Permethrin Lotion 1% Permethrin Cream 5%																				
180	Glycerin Oral Liquid																				
181	Petroleum Jelly 100%																				
Diagnostic Agents																					
182	Lignocaine Eye Drops 4%																				
183	Tropicamide Eye Drops 1%																				
Dialysis Solution																					
184	Haemodialysis Fluid																				
Disinfectants and Antiseptics																					
185	Cetrimide Solution 20%																				
186	Chlorhexidine Solution 5%																				
187	Ethyl Alcohol																				
188	Hydrogen Peroxide Solution 6%																				
189	Povidone Iodine Solution 4% to 10% Povidone Iodine Solution 10% (equivalent to 1% available iodine)																				
190	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P)																				
Diuretics Medicines																					
191	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml																				
192	Indapamide Tablet 1.5 mg																				
193	Chlorthalidone Tablet 12.5 mg																				
194	Mephentermine Injection 15 mg/ml																				
195	Mannitol Injection 10% Mannitol Injection 20%																				
196	Spironolactone Tablet 25 mg Spironolactone Tablet 50 mg																				
197	Methyl Cellulose Tablet, Powder																				
Dental Restorative Material and Medicines																					
198	Zinc Oxide Eugenol																				
199	Silver Amalgam																				
200	Glass Ionomer Cement (GIC)																				
201	Calcium Hydroxide																				
202	Sodium Hypochlorite																				
203	Gutta Percha (GP)																				
204	Light Cure Composite																				
205	Ketorolac 10 mg tablet																				
206	Gum Paint (Tannic Acid)																				
207	Povidine-iodine Germicide Gargle 20% w/v																				
208	Tooth Paste (Potassium Nitrate)																				
Ear, Nose and Throat (ENT) Medicines																					
209	Ciprofloxacin Drops 0.3% Ciprofloxacin Eye/Ear Drops																				
210	Clotrimazole Drops 1%																				
211	Xylometazoline Nasal Drops 0.05 %, 0.1% Xylometazoline Nasal Drops: Paediatric (0.05), Adult (0.1%)																				
212	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg																				

213	Normal Saline nasal drop: sodium chloride drops 0.05% w/v																				
214	Wax Solvent Ear Drops: Benzocaine, Paradichlorobenzene, Turpentine Oil																				
215	Boro-Spirit Ear Drops-0.183 gm Boric Acid in 2.08 ml of Alcohol																				
216	Combo Ear Drops- Chloramphenicol 5% w/v + Clotrimazole 1% +Lignocaine Hydrochloride 2%																				
217	Liquid Paraffin-Menthol Drops: Menthol 10 gm +Eucalyptus 2 ml+ Camphor 10 mg+ liquid paraffin to 100 ml																				
Gastrointestinal Medicines																					
218	Omeprazole Capsule 20 mg																				
219	Ranitidine Tablet 150 mg Ranitidine Injection 25 mg/m																				
220	Sucralfate Tablet 10 mg Sucralfate Oral Liquid 1 mg/ml																				
221	Metoclopramide Injection 5 mg/ml																				
222	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml																				
223	Dicyclomine Tablet 10 mg Dicyclomine Injection 10 mg/ml Dicyclomine Tablet 500 mg																				
224	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml																				
225	Drotaverine Tablet 500 mg																				
226	Bisacodyl Tablet 5 mg Bisacodyl Suppository 5 mg																				
227	Zinc Sulphate Tablet 10 mg Zinc Sulphate Dispersible Tablet USP eq. to Elemental Zinc 20 mg																				
228	Lactulose Oral Liquid 10g/15 ml																				
229	Ispaghula- Granules, Husk, Powder																				
230	Senna Tablet, Granules, Powder																				
Hormones, other Endocrine Medicines and Contraceptives																					
231	Human Chorionic Gonadotropin Injection 1000 IU Human Chorionic Gonadotropin Injection 5000 IU																				
232	Methylprednisolone Tablet 4mg, 8 mg, 32 mg Methylprednisolone Injection 40 mg/ml Methylprednisolone Injection 500 mg																				

233	Ethinylestradiol (A) + Levonorgestrel (B) Tablet 0.03 mg (A) + 0.15 mg (B) Tablet 0.03 mg (A) + 0.15 mg (B) with Ferrous Fumarate																					
234	IUCD 380A IUCD 375																					
235	Male Condom																					
236	Tubal Ring																					
237	Ormeloxifene Tablet 30 mg																					
238	Ethinylestradiol Tablet 0.01 mg Ethinylestradiol Tablet 0.05 mg																					
239	Levonorgestrel Tablet 1.5 mg Levonorgestrel Tablet 0.75 mg																					
240	Glimepiride Tablet 1 mg Glimepiride Tablet 2 mg																					
241	Gliclazide Tablet 40 mg																					
242	Insulin (Soluble) Injection 40 IU/ml Insulin Lente Basal Injection Insulin Rapid Injection Insulin Mixtard																					
243	Metformin Tablet 500 mg Metformin Controlled released 750 mg																					
244	Premix Insulin 30:70 Injection (Regular: NPH) Premix Insulin 30:70 Injection 40 IU/ml																					
245	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg																					
246	Medroxyprogesterone Tablet 5 mg, 10 mg Medroxyprogesterone acetate Injection 150 mg																					
247	Carbimazole Tablet 5 mg Carbimazole Tablet 10 mg																					
248	Levothyroxine Tablet 50 mcg,100mcg																					
Immunological/Vaccines																						
249	Anti-Rabies Immunoglobulin																					
250	Anti-Tetanus Immunoglobulin																					
251	Diphtheria Antitoxin																					
252	Hepatitis B Immunoglobulin																					
253	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																					
254	Rabies Vaccine																					
255	Immunological/Vaccines, As per Current Immunization Programme Guidelines																					
Muscle Relaxant and Cholinesterase Inhibitors																						
256	Vecuronium Powder for Injection 4 mg Vecuronium Powder for Injection 10 mg																					
Ophthalmological Medicines																						
257	Acyclovir Ointment 3%																					
258	Ciprofloxacin Drops 0.3%																					
259	Gentamicin Drops 0.3% Gentamicin Injection 40 mg/ml																					
260	Povidone iodine Drops 0.6% Povidone iodine Drops 5%																					

261	Prednisolone Drops 0.1% Prednisolone Drops 1%																					
262	Acetazolamide Tablet 250 mg																					
263	Pilocarpine Drops 2% Pilocarpine Drops 4%																					
264	Timolol Drop 0.5%																					
265	Atropine Ointment 1%																					
266	Homatropine Drops 2%																					
267	Tropicamide Drops 1%																					
268	Carboxymethylcellulose Drops 0.5%																					
Oxytocic and Anti-Oxytocic Medicines																						
269	Methylergometrine 0.2 mg/ml Injection																					
270	Mifepristone Tablet 200 mg																					
271	Misoprostol Tablet 100mcg Misoprostol Tablet 200mcg (oral/vaginal)																					
272	Combi-pack with Mifepristone + Misoprostol (1 tablet of Mifepristone 200 mg and 4 tablets of Misoprostol 200mcg)																					
273	Oxytocin Injection 5 IU/ml Oxytocin Injection 10 IU/ml																					
274	Nifedipine Tablet 10 mg Nifedipine Soft Gelatin Capsule 5 mg																					
Psychotherapeutic Medicines																						
275	Chlorpromazine Tablet 100 mg																					
276	Diphenylhydantoin Tablet 100 mg																					
277	Fluphenazine Depot Injection 25 mg/ml																					
278	Risperidone Tablet 2 mg Risperidone Injection																					
279	Phenobarbitone Tablet 30 mg Phenobarbitone Tablet 60 mg Phenobarbitone Oral Liquid 20 mg/5 ml																					
280	Olanzapine Tablet 5 mg Olanzapine Injection 10 mg																					
281	Escitalopram Tablet 10 mg Escitalopram Tab 5 mg																					
282	Imipramine Tablet 25 mg Imipramine Tablet 75 mg																					
283	Lithium Tablet 300 mg																					
284	Clonazepam Tablet 0.5 mg Clonazepam Tablet 0.25 mg																					
Medicines Acting on Respiratory Tract																						
285	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Inhalation (MDI/DPI) 200 mcg/dose Budesonide Respirator solution for use in nebuliser 0.5 mg/ml Budesonide Respirator solution for use in nebuliser 1 mg/ml																					
286	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone) MDI, DPI																					
287	Budesonide Nebulisation Solution																					

288	Ipravent/Levoline Nebulisation Solution																				
289	Budesonide (A)+ Formoterol (B) Inhalation (MDI/DPI) 100 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 200 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg (A)+ 6 mcg (B)																				
290	Etofyllin B Plus (A), Anhydrous Theophylline IP (B) combination injection 84.7 mg/ml (A) + 25.3 mg/ml (B)																				
291	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebuliszer 250 mcg/ml																				
292	Levosalbutamol 50mcg/dose																				
293	Salbutamol Tablet 2 mg Salbutamol Tablet 4 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Inhalation (MDI/DPI) 100 mcg/dose, Salbutamol Respirator solution for use in nebuliser 5 mg/m																				
294	Formoterol Inhaled Bronchodilator																				
295	Salmeterol Inhaled Bronchodilator																				
296	Theophylline Tablet																				
297	Deriphyllin Tablet SR																				
298	Montelukast Tablet 5 mg Montelukast Tablet 10 mg Montelukast syrup																				
Solutions Correcting Water, Electrolyte Distribution and Acid-Base Distribution																					
299	Dextrose IV Injection 5% w/v, 500 ml																				
300	Glucose Injection 5% Glucose Injection 10% Glucose Injection 25% Glucose Injection 50%																				
301	Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B)																				
302	Hydroxyethyl Starch 6%IP (6% Saline solution for infusion)																				
303	Oral Rehydration Salts Oral Rehydration Powder 27.5 gm WHO Formula																				
304	Ringer Lactate Injection (as per IP)																				
305	Sodium Bicarbonate Injection (as per IP)																				
306	Sodium Chloride Injection 0.9%																				
307	Sterile Water for Injection IP-05 ml																				
Vitamins and Minerals																					
308	Ascorbic Acid (Vitamin C) Tablet 100 mg Ascorbic Acid (Vitamin C) Tablet 500 mg																				

309	Calcium Carbonate Tablet 250 mg Calcium Carbonate Tablet 500 mg																					
310	Calcium with Vitamin D Tablets USP Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125 mg																					
311	Cholecalciferol Tablet 1000 IU Cholecalciferol Tablet 60,000 IU Cholecalciferol Oral Liquid 400 IU/ml Cholecalciferol Granules 60,000 IU in Sachet Cholecalciferol Injection of 6,00,000 IU Vitamin D3 60,000 Granules in 1 gm Sachet																					
312	Nicotinamide Tablet 50 mg																					
313	Multivitamin Tab/Cap																					
314	Pyridoxine Tablet 25 mg Pyridoxine Tablet 40 mg Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg																					
315	Riboflavin Tablet 5 mg																					
316	Thiamine Tablet 100 mg Thiamine Injection 100 mg/ml																					
317	Vitamin A Oral liquid 100000 IU/ml																					
Dressing																						

Data Collected from State Essential Drugs List (EDL)																						
Sl. No.	**List of medicines not Part of IPHS but available in State Notified EDL**																					
Sl. No.	**List of Medicines Found at Health Facility but not part of IPHS EML & State Notified EDL**																					

Community Health Centre (CHC): Stock Availability Data Period-Year -April 2025- September 2025

S.No.	Drug Name	IPHS medicine Notified in State EML for the facility	Currently Medicine Available (On the date of site visit) Current Quantity		Medicine Available	Stock out events	Number of stock out events	Date of stock out	Date of stock made available after stock out	Period of Stock Out/Replenishment time	Exepired medicines (if yes then quantity)	Time taken to Dispose the expired medicines (Date of Expiry - Date of Disposal)	NSQ medicines reported (if yes then quantity/otherwise record No)	Time taken to dispose NSQ medicine (Date of NSQ reported & Date of disposal)	Annual Indent Quantity (in numbers-Tab/cap/ampoule/vial/bottle/tube)	Total quantity indented during monthly indent (Sum monthly/daily/weekly indent quantity)	Total quantity Receipt	Actual current stock (Physical count)	Quantity as per Stock ledger	Quantity as per DVDMS/ State LMIS	Locally Procured Quantity	Locally Procured Value in Rs.
	Means of verification	State notified EML	Stock ledger /Bin card/ Challan	Stock ledger	Stock ledger	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card		Stock ledger/ Physical verification at site	Stock ledger /Proceeding/ Handover document	Record, also enclose NSQ report	Stock ledger /Proceeding/ Handover document	Records	Records/LMIS	Stock ledger /LMIS	(Telmisartan,Amlodipine Glimepride, Metformin, paracetamol, RL,NS,Diclofenac/Acceclofenac/Cetrizine or Levo-cetrizine/ Amoxicillin				
	CHC (FRU/ Non-FRU)	Y/N	Unit(Pack size)	Quantity (Quantity in numbers like number of Tablets/Capsules/Injections/tubes/bottles/ etc)	Y/N	Y/N																
Anesthetic Agent																						
1	Halothane Gas for Inhalation		100ml			Y	3	03.04.25	07.04.25	4												
								27.05.25	8.06.25	12												
								05.7.25	12.07.25	5												
2	Isoflurane Gas for Inhalation					N	__	__	__	__												
3	Ketamine Injection 10 mg/ml Ketamine Injection 50 mg/ml		2 ml vial																			
4	Nitrous Oxide Gas for Inhalation																					
5	Oxygen Gas for Inhalation																					
6	Propofal Injection 10 mg/ml																					
7	Promethazine Injection 25 mg/ml, 50 mg/ml																					
8	Pentazocine Injection 30mg/ml																					
9	Thiopentane Injection 0.5 gm/1 gm																					
10	Bupivacaine Injection 0.5 mg/ml (sensorcain)																					
11	Sevoflurane Inhalation (Only in DH)																					
12	Lignocaine Injection 2% Lignocaine Injection 4%w/v, 5%w/v Lignocaine Jelly Lignocaine Ointment 2%-5% Lignocaine Spray 10%																					
13	Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) Injection 2% (A) + 1:200000 (5 mcg/ml) (B)																					
14	Atropine Injection 0.6 mg/ml, 1 mg/ml																					
15	Midazolam Injection 1 mg/ml Midazolam Tablet 250 mg Midazolam Tablet 500 mg																					
Non opioid Analgesic, Anti-Pyretic and Non steroidal Anti Inflammatory Medicines																						
16	Acetylsalicylic Acid (Aspirin) Tablet 25 mg Acetylsalicylic Acid Tablet 50 mg Acetylsalicylic Acid Tablet 75 mg Acetylsalicylic Acid Tablet 150 mg, 300 mg																					

17	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml Diclofenac Injection 25 mg/3ml																					
18	Ibuprofen Tablet 200 mg Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg/5 ml																					
19	Paracetamol (Acetaminophen) Tablet 500 mg, 600mg Paracetamol (Acetaminophen) Injection 150 mg/ml Paracetamol (Acetaminophen) Syrup 125 mg/5ml Paracetamol (Acetaminophen) Syrup 120 mg/5ml, 60 ml Paracetamol Suppository 80 mg																					
20	Mefenamic acid capsule 250mg, 500mg																					
21	Naproxen Tablet 500 mg																					
22	Tramadol Capsule 50 mg Tramadol Capsule100 mg Tramadol Injection 50mg/ml																					
23	Allopurinol Tablet 100 mg, 300 mg																					
Opioid Analgesic Medicines																						
24	Morphine Tablet 10 mg Morphine Injection 10 mg/ml																					
25	Codeine Tablet 15 mg Codeine Oral Solution 15 mg/5 ml																					
26	Fentanyl Injection 50mcg/ml (Only in DH)																					
27	Methadone Injection 10mg/ml (Only in DH)																					
Anti allergics and medicines used in Anaphylaxis																						
28	Adrenaline Injection 1 mg/ml (1:1000)																					
29	Cetirizine Tablet 5 mg Cetirizine Tablet 10 mg Cetirizine Oral Liquid 5 mg/5 ml																					
30	Hydrocortisone Powder for Injection 100 mg Hydrocortisone Injection 200 mg Hydrocortisone Cream/Gel/Ointment 0.5%/1%																					
31	Hydroxyzine Syrup 10 mg/5 ml Hydroxyzine Tablet 25 mg																					
32	Pheniramine Maleate Injection 22.75 mg/ml																					
33	Chlorpheniramine Tablet 4 mg, 5mg, 10mg, 20mg, 40mg Chlorpheniramine Oral liquid 2 mg/5 ml, 5 mg/5 ml																					
Antidote and other Substances used in Poisioning																						
34	Activated Charcoal																					
35	Calcium gluconate injection 100mg/ml Calcium gluconate injection 1gm, IV-10ml amp																					

36	Desferrioxamine Injection 500 mg (Only in DH)																					
37	Naloxone Injection 0.4 mg/ml																					
38	Pralidoxime Chloride (2-PAM) 25mg/ml Injection																					
39	Neostigmine Injection 0.5 mg/m																					
Anti Convulsant/Anti Epileptic Medicines																						
40	Carbamazepine Tablet 100 mg, 200 mg Carbamazepine Oral Liquid 100 mg/5 ml, 200mg/5ml Carbamazepine CR Tablet 200 mg, 400 mg																					
41	Levetiracetam Tablet 250 mg, 500 mg																					
42	Lorazepam Tablet 1 mg Lorazepam Injection 1 mg/ml Lorazepam Injection 2 mg/ml																					
43	Magnesium Sulphate Injection 500 mg/ml																					
44	Phenytoin Tablet 50 mg/100 mg, 300 mg Phenytoin Oral Liquid 30 mg/5 ml Phenytoin Oral Liquid 125 mg/5 ml Phenytoin Injection 25 mg/ml, 50 mg/ml Phenytoin ER Tablet 300 mg																					
45	Sodium Valproate Tablet 100 mg, 200mg, 300mg, 500mg Sodium Valproate Tablet 500 mg Sodium Valproate Oral Liquid 200 mg/5 ml																					
Intestinal Anti -helminthics medicines																						
46	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml																					
47	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml																					
48	Ivermectin Tablet 600 mg																					
Anti-Fungal medicines																						
49	Clotrimazole Tablet 100 mg Clotrimazole Pessary 100 mg																					
50	Fluconazole Tablet 150 mg																					
51	Griseofulvin Tablet 125mg, 250mg																					
Anti Bacterial and other anti-infective medicines																						
52	Ampicillin Capsule 500 mg Ampicillin Injection 500 mg/ml																					
53	Amoxicillin Capsule 250 mg Amoxicillin Tablet 500 mg Amoxicillin Suspension 125 mg/5 ml Amoxicillin Oral Liquid 250 mg/5 ml																					

54	Amoxicillin (A) + Clavulanic acid (B) Tablet 500 mg (A) + 125 mg (B) Tablet 875 mg (A) + 125 mg (B) Powder for Injection 500 mg (A) + 100 mg (B) Powder for Injection 1 g (A) + 200 mg (B)																					
55	Tablet Penicillin V (Phenoxymethyl Penicillin) 250 mg																					
56	Benzathine benzylpenicillin Injection 12 lacs unit																					
57	Benzyl penicillin Powder for Injection 10 lac units																					
58	Cefazolin Powder for Injection 500 mg Cefazolin Powder for Injection 1 gm																					
59	Cefixime Tablet 200 mg, 400mg Cefixime Oral Liquid 50 mg/5 ml																					
60	Cefotaxime Injection 1 g/vial Powder for Injection 250 mg																					
61	Ceftazidime Powder for Injection 250 mg Ceftazidime Powder for Injection 1g																					
62	Cloxacillin Capsule 250 mg Cloxacillin Oral Liquid 125 mg/5 ml Cloxacillin Injection 500 mg/vial																					
63	Cefuroxime 250mg tablet Cefuroxime 1g Injection																					
64	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral Liquid 200 mg/5 ml																					
65	Norfloxacin Dispersible Tablet 100 mg Norfloxacin Tablet 400 mg/Oral liquid																					
66	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral Liquid 250 mg/5 ml Ciprofloxacin I.V 200 mg/100 m																					
67	Clarithromycin Tablet 500 mg																					
68	Co-trimoxazole [Sulphamethoxazole (A) +Trimethoprim (B)] Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 ml																					
69	Doxycycline Tablet 100 mg Doxycycline Syrup 50 mg/5 ml																					
70	Metronidazole Tablet 200 mg, 400 mg																					
71	Nitrofurantoin Tablet 100 mg Nitrofurantoin Oral Liquid 25 mg/5 ml																					

72	Amikacin Injection 100 mg Amikacin Injection 500 mg																					
73	Clofazimine Tablet 50 mg Clofazimine Capsule 100 mg Clofazimine Capsule 200 mg																					
74	Delamanid Tablet 50 mg																					
75	Dapsone Tablet 25 mg Dapsone Tablet 100 mg																					
76	Capreomycin Injection 1 gm Capreomycin Injection 750 mg Capreomycin Injection 500 mg																					
77	Cycloserine Capsule 125 mg Cycloserine Capsule 250 mg																					
78	Ethambutol Tablet 100 mg Ethambutol Tablet 200 mg Ethambutol Tablet 400 mg Ethambutol Tablet 600 mg Ethambutol Tablet 800 mg																					
79	Ethionamide Tablet 125 mg Ethionamide Tablet 250 mg																					
80	Isoniazid Tablet 50 mg Isoniazid Tablet 75 mg Isoniazid Tablet 100 mg Isoniazid Tablet 300 mg Isoniazid Oral Liquid 100 mg/5 ml																					
81	Kanamycin Powder for Injection 500 mg Kanamycin Powder for Injection 750 mg Kanamycin Powder for Injection 1 g																					
82	Levofloxacin Tablet 250 mg Levofloxacin Tablet 500 mg, Levofloxacin Tablet 750 mg																					
83	Linezolid Tablet 600 mg																					
84	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg																					
85	Moxifloxacin Tablet 500 mg Moxifloxacin Tablet 400 mg																					
86	Sodium Amino salicylate granules 10 gm/9.2 gms 4 Para- amino salicylic acid Tablet 500 mg																					
87	Pyrazinamide Tablet 150 mg Pyrazinamide Tablet 400 mg Pyrazinamide Tablet 500 mg Pyrazinamide Tablet 750 mg Pyrazinamide Oral Liquid 250 mg/5 ml																					
88	Rifabutin Capsule 150 mg																					
89	Rifampicin Tablet 75 mg Rifampicin Capsule 150 mg Rifampicin Capsule 300 mg Rifampicin Capsule 450 mg Rifampicin Oral Liquid 100 mg/5 ml																					
90	Streptomycin Powder for Injection 750 mg Streptomycin Powder for Injection 1 gm Streptomycin Powder for Injection 500 gm																					
91	Bedaquiline Tablet 100 mg																					
92	Diloxanide Furoate Tablet 500 mg																					
Anti- Viral medicines																						
93	Acyclovir Tablet 200 mg																					

Anti-Malarial medicines																						
94	Tab Artemether (A) + Lumefantrine (B) Tablet 20 mg (A) + 120 mg (B) Tablet 40 mg (A) + 240 mg (B) Tablet 80 mg (A) + 480 mg (B) Oral liquid 80 mg (A) + 480 mg (B)/5 ml																					
95	Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Combi pack (A+B) 1 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg) (B) 1 Tablet 50 mg (A) + 1 Tablet 500 mg + 25 mg) (B) 1 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) (B) 1 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) (B) 1 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B)																					
96	Chloroquine Tablet 150 mg Chloroquine Oral Liquid 50 mg/5 ml																					
97	Hydroxychloroquine Tablet 200 mg Hydroxychloroquine Tablet 400 mg																					
98	Artesunate Powder for injection 120 mg																					
99	Primaquine Tablet 2.5 mg Primaquine Tablet 7.5 mg Primaquine Tablet 15 mg																					
100	Quinine Tablet 300 mg																					
Anti Covid Medicines																						
101	Favipiravir Tablet 200 mg, 400 mg																					
102	Remdesivir Injection 100 mg/20 ml																					
Palliative Care Medicine																						
103	Diazepam Injection 5 mg/ml Diazepam Oral Liquid 2 mg/5 ml Diazepam Suppository 5 m Diazepam Tablet 5 mg, Diazepam Injection 10 mg/2 ml																					
Anti- Parkinsonism Medicines																						
104	Levodopa (A) + Carbidopa (B) Tablet 100 mg (A) + 10 mg (B) CR Tablet 100 mg (A) + 25 mg (B) CR Tablet 200 mg (A) + 50 mg (B) Tablet 250 mg (A) + 25 mg (B)																					
105	Trihexyphenidyl (Benzhexol) Tablet 2 mg																					
Medicines Affecting Blood																						

106	Ferrous Salts equivalent to 60 mg of Elemental Iron Ferrous Salts Oral Liquid equivalent to 25 mg of Elemental Iron/ml																				
107	Ferrous Salt (A) + Folic Acid (B) Tablet 45 mg Elemental Iron (A) + 400 mcg (B) Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) Oral Liqiud 20 mg Elemental Iron(A) + 100 mcg (B)/ml Tablet 100 mg Elemental Iron (A)+ 500 mcg (B) as Enteric Coated																				
108	Folic acid Tablet 5 mg																				
109	IFA Syrup																				
110	Hydroxyurea Capsule 500 mg																				
111	Iron Sucrose Injection 20 mg/ml																				
112	Phytomenadione (Vitamin K1) Tablet 10 mg Phytomenadione (Vitamin K1) Inj 10 mg/ml																				
113	Menadione Injection (Vitamin K3) 10 mg/ml																				
114	Tranexamic Acid Tablet 500 mg																				
115	Streptokinase Injection 15 lac/Vial Sterptokinase Injection 7.5 lac/Vial																				
116	Heparin Sodium Injection 1000 IU																				
117	Warfarin Tablet 1 mg Warfarin Tablet 2 mg Warfarin Tablet 3 mg Warfarin Tablet 5 mg																				
Cardiovascular Medicines																					
118	Clopidogrel Tablet 75 mg																				
119	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg																				
120	Glyceryl Trinitrate Sublingual Tablet 0.5 mg Glyceryl trinitrate Injection 125 mg/5 ml																				
121	Isosorbide Dinitrate Tablet 5 mg Isosorbide Dinitrate Tablet 10 mg																				
122	Isosorbide-5- mononitrate Tablet 10 mg, Isosorbide-5- mononitrate SR Tablet 30 mg																				
123	Atenolol Tablet 50 mg, 100 mg																				
124	Metoprolol Tablet 25 mg Metoprolol Tablet 50 mg Metoprolol Tablet 100 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg																				
125	Propranolol Tablet 40 mg																				
126	Amiodarone Tablet 100 mg																				
127	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg Amlodipine Tablet 10 mg																				
128	Indapamide Tablet 1.5 mg																				
129	Chlorthalidone Tablet 12.5 mg																				

130	Mannitol Injection 10% Mannitol Injection 20%																					
131	Labetalol Injection 5 mg/ml Labetalol Tablet 100 mg Labetalol Injection 20 mg/2 ml																					
132	Methyldopa Tablet 250 mg Methyldopa Tablet 500 mg																					
133	Enalapril Tablet 2.5 mg Enalapril Tablet 5 mg Enalapril Tablet 10 mg																					
134	Captopril Tablet 25 mg																					
135	Lisinopril Tablet 5 mg																					
136	Telmisartan Tablet 40 mg																					
137	Digoxin Tablet 0.25 mg Digoxin Tablet 250 mg																					
138	Dopamine Injection 40 mg/ml																					
139	Noradrenaline Injection 2 mg/ml																					
140	Enoxaparin LMWH Injection																					
141	Atorvastatin Tablet 10 mg Atorvastatin Tablet 40 mg																					
Medicines used in Dementia																						
142	Donepezil Tablet 5 mg																					
Dermatological Medicines (Topical)																						
143	Clotrimazole cream 1% Clotrimazole Oral Lotion or Mouth Paint: 15 ml																					
144	Framycetin cream 0.5%																					
145	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg preparation																					
146	Silver Sulphadiazine 2 to 4%																					
147	Miconazole Ointment or Cream 2% 15 gm preparation																					
148	Betamethasone Cream 0.05% Betamethasone Cream 0.1%																					
149	Calamine Lotion																					
150	Benzoyl Peroxide Gel 2.5% Benzoyl Peroxide Gel 5%																					
151	Coal Tar Solution 5%																					
152	Salicylic Acid Ointment 6%																					
153	Gamma Benzene Hexachloride Lotion 100 ml																					
154	Permethrin Lotion 1% Permethrin Cream 5%																					
155	Glycerin Oral Liquid																					
156	Petroleum Jelly 100%																					
Diagnostic Agents																						
157	Lignocaine Eye Drops 4%																					
158	Tropicamide Eye Drops 1%																					
Disinfectants and Antiseptics																						
159	Cetrimide Solution 20% (concentrate for dilution)																					
160	Chlorhexidine Solution 5% (concentrate for dilution)																					
161	Ethyl Alcohol (denatured)																					
162	Hydrogen Peroxide Solution 6%																					
163	Sodium Hypochlorite																					
164	Povidone Iodine Solution 4% to 10% Povidone Iodine Solution 10% (equivalent to 1% available iodine)																					

165	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P)																				
166	Potassium permanganate Crystals for topical solution																				
Diuretics Medicines																					
167	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml																				
168	Hydrochlorothiazid Tablet 12.5 mg Hydrochlorothiazid Tablet 25 mg Hydrochlorothiazide Tablet 50 mg																				
169	Spironolactone Tablet 25 mg Spironolactone Tablet 50 mg																				
170	Methyl Cellulose Tablet, Powder																				
Ear, Nose and Throat (ENT) Medicines																					
171	Ciprofloxacin Drops 0.3% Ciprofloxacin Eye/Ear Drops																				
172	Normal Saline nasal drop: sodium chloride drops 0.05% w/v																				
173	Xylometazoline Nasal Drops 0.05 %, 0.1% Xylometazoline Nasal Drops: Paediatric (0.05), Adult (0.1%)																				
174	Wax Solvent Ear Drops: Benzocaine, Paradichlorobenzene, Turpentine Oil																				
175	Boro-Spirit Ear Drops-0.183 gm Boric Acid in 2.08 ml of Alcohol																				
176	Combo Ear Drops-Chloramphenicol 5% w/v + Clotrimazole 1% +Lignocaine Hydrochloride 2%																				
177	Liquid Paraffin-Menthol Drops: Menthol 10 gm +Eucalyptus 2 ml+ Camphor 10 mg+ liquid paraffin to 100 ml																				
Gastrointestinal Medicines																					
178	Omeprazole Capsule 20 mg																				
179	Ranitidine Tablet 150 mg Ranitidine Injection 25 mg/m																				
180	Pantoprazole 40 mg Injection																				
181	Sucralfate Tablet 10 mg Sucralfate Oral Liquid 1 mg/ml																				
182	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml																				
183	Metoclopramide Tablet 10 mg, Metoclopramide Oral Liquid 5 mg/5 ml Metoclopramide Injection 5 mg/ml																				
184	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml																				

185	Dicyclomine Tablet 10 mg Dicyclomine Injection 10 mg/ml Dicyclomine Tablet 500 mg																					
186	Hyoscine Butyl- Bromide Tablet 500 mg Hyoscine Butyl- Bromide Injection 20 mg/ml																					
187	Bisacodyl Tablet 5 mg Bisacodyl Suppository 5 mg																					
188	Zinc Sulphate Tablet 10 mg Zinc Sulphate Dispersible Tablet USP eq. to Elemental Zinc 20 mg																					
189	Lactulose Oral Liquid 10g/15 ml																					
190	Ispaghula- Granules, Husk, Powder																					
191	Senna Tablet, Granules, Powder																					
Hormones, other Endocrine Medicines and Contraceptives																						
192	Dexamethasone Tablet 0.5 mg Dexamethasone Injection 4 mg/ml																					
193	Methylprednisolone Tablet 4 mg Methylprednisolone Tablet 8 mg																					
194	Prednisolone Tablet 5 mg Prednisolone Tablet 10 mg																					
195	Ethinylestradiol Tablet 0.01 mg Ethinylestradiol Tablet 0.05 mg																					
196	Levonorgestrel Tablet 1.5 mg Levonorgestrel Tablet 0.75 mg																					
197	Gliclazide Tablet 40 mg																					
198	Medroxyprogesterone Tablet 5 mg, 10 mg Medroxyprogesterone acetate Injection 150 mg																					
199	Family Planning medicines and commodities																					
Thyroid and Antithyroid medicines																						
200	Carbimazole Tablet 5 mg Carbimazole Tablet 10 mg																					
201	Levothyroxine Tablet 50 mcg,100mcg																					
Antidiabetic medicines																						
202	Glimepiride Tablet 1 mg Glimepiride Tablet 2 mg																					
203	Insulin (Soluble) Injection 40 IU/ml																					
204	Metformin Tablet 500 mg Metformin Controlled released 750 mg																					
205	Premix Insulin 30:70 Injection (Regular: NPH) Premix Insulin 30:70 Injection 40 IU/ml																					
206	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg																					
207	Norethisterone 5mg Tablet																					
Immunological/Vaccines																						
208	Diphtheria Antitoxin																					
209	Hepatitis B Immunoglobulin																					
210	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																					

211	BCG vaccine																					
212	DPT + Hib + Hep B vaccine																					
213	DPT vaccine																					
214	Hepatitis B vaccine																					
215	Japanese encephalitis vaccine																					
216	Measles vaccine																					
217	Oral poliomyelitis vaccine																					
218	Tetanus toxoid																					
219	Inactivated Polio Vaccine (IPV)																					
220	Pneumococcal Conjugated Vaccine (PCV)																					
221	Measles Rubella vaccine																					
222	Rabies vaccine Anti- Rabies Immunoglobulin																					
223	Immunological/Vaccines, As per Current Immunization Programme Guidelines																					
Muscle Relaxant and Cholinesterase Inhibitors																						
224	Vecuronium Powder for Injection 4 mg																					
Ophthalmological Medicines																						
225	Acyclovir Ointment 3%																					
226	Atropine 1% Drops																					
227	Gentamicin Drops 0.3% Gentamicin Injection 40 mg/ml																					
228	Povidone iodine Drops 0.6% Povidone iodine Drops 5%																					
229	Prednisolone Drops 0.1% Prednisolone Drops 1%																					
230	Acetazolamide Tablet 250 mg																					
231	Pilocarpine Drops 2% Pilocarpine Drops 4%																					
232	Timolol Drop 0.5%																					
233	Atropine Ointment 1%																					
234	Homatropine Drops 2%																					
235	Tropicamide Drops 1%																					
236	Carboxymethylcellulose Drops 0.5%																					
237	Erythromycin 0.5% ointment																					
Oxytocic and Anti-Oxytocic Medicines																						
238	Mifepristone Tablet 200 mg																					
239	Misoprostol Tablet 100mcg Misoprostol Tablet 200mcg (oral/vaginal)																					
240	Oxytocin Injection 5 IU/ml Oxytocin Injection 10 IU/ml																					
241	Methylergometrine 0.125 mg Tablet Methylergometrine 0.2 mg/ml Injection																					
242	Nifedipine Tablet 10 mg Nifedipine Soft Gelatin Capsule 5 mg																					
Psychotherapeutic Medicines																						
243	Chlorpromazine Tablet 100 mg																					
244	Diphenylhydantoin Tablet 100 mg																					
245	Fluphenazine Depot Injection 25 mg/ml																					
246	Haloperidol Tablet 5 mg Haloperidol Injection 5 mg/ml																					

247	Phenobarbitone Tablet 30 mg Phenobarbitone Tablet 60 mg Phenobarbitone Oral Liquid 20 mg/5 ml																					
248	Risperidone Tablet 2 mg																					
249	Olanzapine Tablet 5 mg																					
250	Amitriptyline Tablet 10 mg/25 mg																					
251	Escitalopram Tablet 10 mg Escitalopram Tab 5 mg																					
252	Fluoxetine Capsule 20 mg																					
253	Imipramine Tablet 25 mg Imipramine Tablet 75 mg																					
254	Lithium Tablet 300 mg																					
255	Clonazepam Tablet 0.5 mg Clonazepam Tablet 0.25 mg																					
Medicines Acting on Respiratory Tract																						
256	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Respirator solution for use in nebuliser 0.5 mg/ml																					
257	Budesonide (A)+ Formoterol (B) Inhalation (MDI/DPI) 100 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 200 mcg (A)+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg (A)+ 6 mcg (B)																					
258	Combination of LABA+ICS (Formoterol, Salmeterolol/Fluticasone) MDI, DPI																					
259	Etofyllin B Plus (A), Anhydrous Theophylline IP (B) combination injection 84.7 mg/ml (A) + 25.3 mg/ml (B)																					
260	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebuliszer 250 mcg/ml																					
261	Levosalbutamol 50mcg/dose																					
262	Salbutamol Tablet 2 mg Salbutamol Tablet 4 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Inhalation (MDI/DPI) 100 mcg/dose, Salbutamol Respirator solution for use in nebuliser 5 mg/m																					
263	Theophylline Tablet																					
264	Syrup Salbutamol Salbutamol Nebulizing solution																					
265	Tiotropium Inhalation (MDI) 9 mcg/dose Tiotropium Inhalation (DPI) 18 mcg/dose																					
266	Deriphyllin Tablet SR																					
267	Montelukast Tablet 5 mg Montelukast Tablet 10 mg Montelukast syrup																					
268	N Acetyl Cystine Tablet 600 mg/Dispersible																					

269	Betamethasone Injection 12 mg Betamethasone Injection 4 mg/ml																				
Solutions Correcting Water, Electrolyte Distribution and Acid-Base Distribution																					
270	Dextrose IV Injection 5% w/v, 500 ml																				
271	Glucose Injection 5% Glucose Injection 10% Glucose Injection 25% Glucose Injection 50%																				
272	Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B)																				
273	Hydroxyethyl Starch 6%IP (6% Saline solution for infusion)																				
274	Oral Rehydration Salts Oral Rehydration Powder 27.5 gm WHO Formula																				
275	Potassium Chloride Injection 150 mg/ml Potassium Chloride Oral Liquid 500 mg/5 ml																				
276	Ringer Lactate Injection (as per IP)																				
277	Sodium Bicarbonate Injection (as per IP)																				
278	Sodium Chloride Injection 0.9%																				
279	Water for Injection																				
Vitamins and Minerals																					
280	Ascorbic Acid (Vitamin C) Tablet 100 mg Ascorbic Acid (Vitamin C) Tablet 500 mg																				
281	Calcium Carbonate Tablet 250 mg Calcium Carbonate Tablet 500 mg																				
282	Calcium with Vitamin D Tablets USP Syrup Calcium with Phosphate in the ratio 2:1 with Vitamin D Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125 mg																				
283	Cholecalciferol Granules 60,000 IU in Sachet Cholecalciferol Injection of 6,00,000 IU Vitamin D3 60,000 granules in 1gm sachet																				
284	Nicotinamide Tablet 50 mg																				
285	Multivitamin Tab/Cap																				
286	Pyridoxine Tablet 25 mg Pyridoxine Tablet 40 mg Pyridoxine Tablet 50 mg Pyridoxine Tablet 100 mg																				
287	Riboflavin Tablet 5 mg																				
288	Thiamine Tablet 100 mg Thiamine Injection 100 mg/ml																				
289	Vitamin A Oral liquid 100000 IU/ml																				
Dental Restorative Material and Medicines																					
290	Zinc Oxide Eugenol																				

291	Silver Amalgam																					
292	Glass Ionomer Cement (GIC)																					
293	Calcium Hydroxide																					
294	Sodium Hypochlorite																					
295	Gutta Percha (GP)																					
296	Light Cure Composite																					
297	Ketorolac 10 mg tablet																					
298	Gum Paint (Tannic Acid)																					
299	Povidine-iodine Germicide Gargle 20% w/v																					
300	Tooth Paste (Potassium Nitrate)																					
Data Collected from State Essential Drugs List (EDL)																						
Sl. No.	**List of medicines not Part of IPHS but available in State Notified EDL**																					
Sl. No.	**List of Medicines Found at Health Facility but not part of IPHS EML & State Notified EDL**																					

Ayushman Arogya Mandir-Primary Health Centre (AAM-PHC) Stock Availability Data Period-Year - April 2025- September 2025

S.No.	Drug Name	IPHS medicine Notified in State EML for the facility	Currently Medicine Available (On the date of site visit) Current Quantity		Medicine Available	Stock out events	Number of stock out events	Date of stock out	Date of stock made available after stock out	Period of Stock Out/Replenishment time (In days)	Eexpired medicines (if yes then quantity)	Time taken to Dispose the expired medicines (Date of Expiry - Date of Disposal)	NSQ medicines reported (if yes then quantity/otherwise record No)	Time taken to dispose NSQ medicine (Date of NSQ reported & Date of disposal)	Annual Indent Quantity (in numbers-Tab/cap/ampoule/vial/bottle/tube)	Total quantity indented during monthly indent (Sum monthly/daily/weekly indent quantity)	Total quantity Receipt	Actual current stock (Physical count)	Quantity as per Stock ledger	Quantity as per DVDMS/ State LMIS	Locally Procured Quantity	Locally Procured Value in Rs.
	Means of verification	State notified EML	Stock ledger /Bin card/ Challan	Stock ledger	Stock ledger	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card		Stock ledger/ Physical verification at site	Stock ledger /Proceeding/ Handover document	Record, also enclose NSQ report	Stock ledger /Proceeding/ Handover document	Records	Records/LMIS	Stock ledger /LMIS	Sample drugs: (Telmisartan,Amlodipine Glimepride, Metformin, paracetamol, RL,NS,Diclofenac/Acceclofenac/Cetrizine or Levo-				
	PHC/ UPHC AAM	Y/N	Unit(Pack size)	Quantity (Quantity in numbers like number of Tablets/Capsules/Injections/tubes/bottles/ etc)	Y/N	Y/N																
Anesthetic Agent																						
1	Oxygen Gas for Inhalation		5 L water capacity/ 10 L water capacity/ 20–25 L water capacity/ ~ 46.7 L water capacity (D / jumbo)			Y	3	03.04.25	07.04.25	4												
								27.05.25	8.06.25	12												
								05.7.25	12.07.25	5												
2	Lignocaine Injection 2% Lignocaine Topical form 2%					N	—	—	—	—												
3	Lignocaine Injection 2% + Adrenaline Injection 1:200000 (5 mcg/ml)		2 ml vial																			
4	Atropine Injection 0.6 mg/ml, 1 mg/ml																					
5	Midazolam Injection 1 mg/ml																					
6	Ketamine Injection10 mg/ml																					
7	Injection Thiopentane 500 mg																					
8	Bupivacaine Injection 0.5 mg/ml (sensorcain)																					
9	Neostigmine Injection 0.5 mg/ml																					
10	Vecuronium Powder for Injection 4 mg																					
11	Pentazocine Injection 30mg/ml																					
Non opioid Analgesic, Anti-Pyretic and Non steroidal Anti Inflammatory Medicines																						
12	Aspirin (Acetylsalicylic acid) Tablet 150 mg Aspirin (Acetylsalicylic acid) Tablet 75 mg																					
13	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml																					
14	Ibuprofen Tablet 200 mg																					
15	Ibuprofen Oral Liquid 100 mg/5 ml, 50 ml bottle																					
16	Paracetamol Tablet 500 mg, Paracetamol Tablet 100 mg Paracetamol Syrup 125 mg/5 ml Paracetamol Suppository 100 mg																					
Anti allergics and medicines used in Anaphylaxis																						

17	Levocetirizine Tablet 5mg Levocetrizine Oral liquid 2.5 mg/5 ml (Paediatric Use)																				
18	Chlorpheniramine Tablet 4 mg																				
19	Dexamethasone Tablet 0.5 mg Dexamethasone Injection 4 mg/ml																				
20	Hydrocortisone Succinate Injection 100 mg																				
21	Pheniramine Maleate Injection 22.75 mg/ml																				
22	Prednisolone Tablet 5 mg Prednisolone Oral liquid 5 mg/5 ml																				
23	Hydroxyzine oral syrup																				
24	Betamethasone Injection 4 mg/ml																				
Antidote and other Substances used in Poisioning																					
25	Activated Charcoal																				
26	Calcium gluconate Injection 100 mg/ml																				
27	Snake Venom Antiserum a) Soluble/Liquid Polyvalent b) Lyophilised Polyvalent																				
Anti Convulsant/Anti Epileptic Medicines																					
28	Magnesium Sulfate Injection (50% solution), 2 ml ampoule																				
29	Diazepam Oral liquid 2 mg/5 ml Diazepam Injection 5 mg/ml Diazepam Tablet 5 mg																				
30	Phenobarbitone Tablet 30 mg Phenobarbitone oral liquid 20 mg/5 ml																				
31	Phenytoin Tablet 50 mg Phenytoin Tablet 300 mg Phenytoin ER Tablet 300 mg Phenytoin Injection 25 mg/ml																				
32	Sodium valproate Tablet 250 mg Sodium valproate Tablet 500 mg Sodium valproate Syrup each 5 ml contains 200 mg																				
33	Midazolam Nasal Spray																				
34	Carbamazepine Tablet 100 mg Carbamazepine Tablet 200 mg																				
35	Diphenylhydantoin Tablet 100 mg																				
Anti Infective Medicines																					
36	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml																				
37	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml																				
38	Amoxicillin Capsule 250 mg Amoxicillin Capsule 500 mg Amoxicillin Oral liquid 250 mg/5 ml																				
39	Amoxicillin 500 mg + Clavulanic acid 125 mg Tablet																				
40	Azithromycin Tablet 250 mg Azithromycin Tablet 500 mg Azithromycin Oral Liquid 200 mg/5 ml																				
41	Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg Ciprofloxacin Oral liquid 250 mg/5m																				

42	Cefixime Tablet 200 mg Cefixime Oral liquid 50 mg/5 ml Cefixime Oral liquid 100 mg/5 ml																				
43	Tab Co-trimoxazole [Sulphamethoxazol 80 mg +Trimethoprim 400 mg] Tab.20 mg trimethoprim + 100 mg sulphamethoxazole Co-trimoxazole Oral Liquid [Sulphamethoxazole 200 mg + Trimethoprim 40 mg/5 ml]																				
44	Gentamicin Injection 10 mg/ml Gentamicin Injection 80 mg/ml																				
45	Doxycycline Capsule 100 mg Doxycycline Dry Syrup 50 mg/5 ml																				
46	Norfloxacin tab/oral liquid																				
47	Tablet Penicillin V (Phenoxymethyl Penicillin) 250 mg																				
48	Benzyl penicillin Powder for Injection 10 lac units																				
49	Cefazolin Powder for Injection 500 mg Cefazolin Powder for Injection 1 gm																				
50	Cefotaxime Injection 250 Cefotaxime Injection 500 mg Cefotaxime Injection 1 g																				
51	Ceftriaxone Powder for Injection 250 mg Ceftriaxone Powder for Injection 500 mg Ceftriaxone Powder for Injection 1 g																				
Anti leprosy Medicines																					
52	Anti-leprosy medicines, As per current program guidelines (Adults and Pediatrics)																				
Anti- Tuberculosis Medicines																					
53	Anti-tuberculosis medicines, As per current program guidelines (Adults and Pediatrics)																				
Anti-Fungal Medicines																					
54	Clotrimazole Pessary 100 mg Clotrimazole Vaginal Tablet Clotrimazole Drops 1% Clotrimazole Cream 1%																				
55	Fluconazole Tablet 150 mg																				
56	Miconazole ointment Miconazole Tablet																				
Anti-Protozoal Medicines																					
57	Metronidazole Tablet 200 mg Metronidazole Tablet 400 mg Metronidazole Oral liquid 200 mg/5 ml																				
Anti-Malarial Medicines																					
58	Anti-malarial medicines, As per program guidelines(Adults and Pediatrics)																				
Pain and Palliative Care Medicine																					
59	Amitriptyline Tablet 10 mg/25 mg																				
60	Lactulose Oral Liquid 10g/15 ml																				
61	Tramadol capsule 50 mg																				

62	Povidone Iodine Lotion and Ointment																				
63	Ethamsylate Tablet																				
64	Deriphyllin Tablet SR																				
Anti- Parkinsonism Medicines																					
65	Levodopa (A) + Carbidopa (B) 100 mg (A) + 10 mg (B)																				
Medicines Affecting Blood																					
66	Ferrous salt 100 mg + Folic acid 500 mcg Tablet Ferrous salt 60mg + Folic acid 500 mcg Tablet Ferrous salt 45 mg + Folic acid 100 mcg Tablet Ferrous salt 20 mg + Folic acid 100 mcg Tablet																				
67	Folic acid Tablet 5 mg Folic acid Tablet 400 mcg																				
68	IFA Syrup																				
69	Phytomenadione Injection 10 mg/ml																				
Cardiovascular Medicines																					
70	Clopidogrel Tablet 75 mg																				
71	Diltiazem Tablet 60 mg Diltiazem SR Tablet 90 mg																				
72	Isosorbide-5- mononitrate Tablet 5 mg																				
73	Metoprolol Tablet 25 mg Metoprolol SR Tablet 25 mg Metoprolol SR Tablet 50 mg																				
74	Isosorbide dinitrate Tablet 5 mg (sublingual)																				
75	Dopamine Injection 40 mg/ml																				
76	Hydroxyurea capsule 100mg, 300mg, 500mg																				
Anti hypertensive medicines																					
77	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg																				
78	Enalapril Tablet 5 mg																				
79	Hydrochlorothiazide Tablet 12.5 mg Hydrochlorothiazide Tablet 25mg																				
80	Labetalol Tablet 100 mg Labetalol Injection 5 mg/ml																				
81	Methyldopa Tablet 250																				
82	Telmisartan Tablet 40 mg																				
Medicines used in shock and heart failure																					
83	Adrenaline injection 1mg/ml																				
Hypolipidemic medicines																					
84	Atorvastatin Tablet 10 mg																				
Dermatological Medicines (Topical)																					
85	Framycetin cream 0.5%																				
86	Silver sulphadiazine Cream 1%																				
87	Calamine Lotion																				
88	Betamethasone Cream 0.1%																				
89	Benzoyl peroxide Gel 2.5%																				
90	Benzyl Benzoate ointment/lotion																				
91	Mupirocin Ointment																				
92	Potassium Permanganate 0.1%																				
93	Zinc Oxide cream 10%																				
94	Fusidic Acid Cream 5 mg/10 gm preparation 2% or 20 mg per gram Fusidic Acid Cream 2%: 5 mg/10 mg preparation																				
95	Permethrin Cream 5%																				

Disinfectants and Antiseptics																					
96	Cetrimide Solution 20% (concentrate for dilution)																				
97	Chlorhexidine Solution 5% (concentrate for dilution)																				
98	Ethyl Alcohol (denatured)																				
99	Hydrogen Peroxide Solution 6%																				
100	Methylrosanilinium chloride (Gentian Violet)																				
101	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P)																				
102	Gamma Benzene Hexachloride Lotion 100 ml																				
Diuretics Medicines																					
103	Furosemide Tablet 40 mg Furosemide Injection 10 mg/ml																				
104	Mannitol Injection 10% Mannitol Injection 20%																				
Ear, Nose and Throat (ENT) Medicines																					
105	Xylometazoline Nasal drops 0.05 % Xylometazoline Nasal drops 0.1 %																				
106	Wax Solvent Ear Drops: Benzocaine, Paradichlorobenzene, Turpentine Oil																				
107	Combo Ear Drops- Chloramphenicol 5% w/v + Clotrimazole 1% +Lignocaine Hydrochloride 2%																				
108	Normal Saline nasal drop: sodium chloride drops 0.05% w/v																				
109	Boro spirit ear drop																				
110	Ofloxacin Tablet 200 mg Ofloxacin Tablet 400 mg																				
Gastrointestinal Medicines																					
111	Omeprazole Capsule 20 mg																				
112	Ranitidine injection																				
113	Metoclopramide Tablet 10 mg, Metoclopramide Oral Liquid 5 mg/5 ml Metoclopramide Injection 5 mg/ml																				
114	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml																				
115	Domperidone Tablet 10 mg Domperidone Oral Suspension 1 mg/ml; 30 ml bottle or 5 ml drops containing 10 mg/ml																				
116	Hyoscinebutylbromide Tablet 10 mg Hyoscinebutylbromide Injection 20 mg/ml																				
117	Ispaghula- Granules, Husk, Powder																				
118	Drotaverine Tablet 500 mg																				
119	Bisacodyl Tablet 5 mg Bisacodyl Suppository 5 mg																				
120	Oral Rehydration Salts Oral Rehydration Powder 27.5 gm WHO Formula																				

121	Zinc sulphate Dispersible Tablet 20 mg Zinc sulphate syrup																				
122	Dicyclomine Tablet 10 mg																				
123	Senna Tablet, Granules, Powder																				
124	Dioctyl sulfosuccinate sodium																				
125	Magnesium Hydroxide Liquid																				
126	Sucralfate Tablet 10 mg Sucralfate Oral Liquid 1 mg/ml																				
127	Hyoscinebutylbromide Tablet 500 mg																				
Medicines used in Diabetes mellitus																					
128	Glimepiride Tablet 2 mg																				
129	Metformin Tablet 500 mg Metformin SR Tablet 500 mg																				
130	Insulin (Soluble) Injection 40 IU/ml																				
131	Premix Insulin 30:70 Injection (Regular: NPH) Premix Insulin 30:70 Injection 40 IU/ml																				
132	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg																				
133	Glucose Packet 75 mg for OGTT Test																				
Anti-thyroid medicines																					
134	Levothyroxine Tablet 25 mcg Levothyroxine Tablet 50 mcg Levothyroxine Tablet 100 mcg																				
Immunological/Vaccines																					
135	Immunological/Vaccines, As per Current Immunization Programme Guidelines																				
136	Rabies Vaccine Anti Rabies serum																				
Oxytocic and Anti-Oxytocic Medicines																					
137	Misoprostol Tablet 200 mcg																				
138	Oxytocin Injection 5 IU/ml																				
139	Nifedipine Tablet 10 mg																				
140	Methylergometrine Injection 0.2 mg/ml																				
Psychotherapeutic Medicines																					
141	Alprazolam Tablet 0.25 mg																				
142	Clonazepam Tablet 0.5 mg																				
143	Olanzapine Tablet 5 mg																				
Medicines Acting on Respiratory Tract																					
144	Budesonide Inhalation (MDI/DPI) 100 mcg/dose Budesonide Respirator solution for use in nebulizer 0.5 mg/ml																				
145	Salbutamol Tablet 2 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Respirator solution for use in nebulizer 5 mg/ml																				
146	Montelukast Tablet Montelukast syrup																				
147	Syrup Dextromethorphan																				
148	Syrup Bromhexine Hydrochloride																				
149	Syrup Pheniramine Maleate																				
150	Ipratropium Inhalation (MDI/DPI) 20 mcg/dose Ipratropium Respirator solution for use in nebuliszer 250 mcg/ml																				

Solutions Correcting Water, Electrolyte Distribution and Acid-Base Distribution																					
151	Ringer Lactate Injection (as per IP)																				
152	Sodium Chloride Injection 0.9%																				
153	Pediatric solution like Isolyte P, N/2 & N/5																				
154	Potassium chloride Oral liquid 500 mg/5 ml																				
155	Dextrose 5% Dextrose 25%																				
Vitamins and Minerals																					
156	Ascorbic acid (Vitamin C) Tablet 100 mg																				
157	Calcium carbonate Tablet 500 mg																				
158	Cholecalciferol Tablet 60000 IU																				
159	Pyridoxine Tablet 25 mg Pyridoxine Tablet 50 mg Pyridoxine tablet 100 mg																				
160	Vitamin A Oral liquid 100000 IU/ml																				
161	B Complex Tablet, B Complex Injection																				
Ophthalmological Medicines																					
162	Lignocaine Eye Drops 4%																				
163	Tropicamide Eye Drops 1%																				
164	Ciprofloxacin Drops 0.3% Ciprofloxacin Eye/Ear Drops																				
165	Sodium cromoglycate 2% eye drop																				
166	Methylcellulose Eye Drops																				
Contraceptives																					
167	Ethinylestradiol (A) + Levonorgestrel (B) Tablet 0.03 mg (A) + 0.15 mg (B) Tablet 0.03 mg (A) + 0.15 mg (B) with Ferrous Fumarate																				
168	IUCD 380A IUCD 375																				
169	Male Condom				Y																
170	Ormeloxifene Tablet 30 mg				Y																
171	Levonorgestrel 1.5 mg				Y																
172	Medroxyprogesterone acetate Injection 150 mg				P																
Data Collected from State Essential Drugs List (EDL)																					
Sl. No.	**List of medicines not Part of IPHS but available in State Notified EDL**																				
Sl. No.	**List of Medicines Found at Health Facility but not part of IPHS EML & State Notified EDL**																				

Ayushman Arogya Mandir- Sub Health Centres (AAM-SHC): Stock Availability Data Period-Year - April 2024- September 2025

S.No.	Drug Name	IPHS medicine Notified in State EML for the facility	Currently Medicine Available (On the date of site visit) Current Quantity		Medicine Available	Stock out events	Number of stock out events	Date of stock out	Date of stock made available after stock out	Period of Stock Out/Replenishment time (In days)	Eexpired medicines (if yes then quantity)	Time taken to Dispose the expired medicines (Date of Expiry - Date of Disposal)	NSQ medicines reported (if yes then quantity/otherwise record No)	Time taken to dispose NSQ medicine (Date of NSQ reported & Date of disposal)	Annual Indent Quantity (in numbers-Tab/cap/ampoule/vial/bottle/tube)	Total quantity indented during monthly indent (Sum monthly/daily/weekly indent quantity)	Total quantity Receipt	Actual current stock (Physical count)	Quantity as per Stock ledger	Quantity as per DVDMS/ State LMIS	Locally Procured Quantity	Locally Procured Value in Rs.
	Means of verification	State notified EML	Stock ledger /Bin card/ Challan	Stock ledger	Stock ledger	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card	Stock ledger /Bin card		Stock ledger/ Physical verification at site	Stock ledger /Proceeding/ Handover document	Record, also enclose NSQ report	Stock ledger /Proceeding/ Handover document	Records	Records/LMIS	Stock ledger /LMIS	Sample drugs: (Telmisartan,Amlodipine Glimepride, Metformin, paracetamol, RL,NS,Diclofenac/Acceclofenac/Cetrizine or Levo-				
	SHC AAM	Y/N	Unit(Pack size)	Quantity (Quantity in numbers like number of Tablets/Capsules/Injections/tubes/bottles/ etc)	Y/N	Y/N																
Anesthetic Agent																						
1	Oxygen Gas for Inhalation		5 L water capacity/ 10 L water capacity/ 20–25 L water capacity/ ~ 46.7 L water capacity (D / jumbo)			Y	3	03.04.25	07.04.25	4												
								27.05.25	8.06.25	12												
								05.7.25	12.07.25	5												
2	Lignocaine Topical form 5%					N	—	—	—	—												
Non opioid Analgesic, Anti-Pyretic and Non steroidal Anti Inflammatory Medicines																						
3	Aspirin (Acetylsalicylic acid) Tablet 75 mg																					
4	Diclofenac Tablet 50 mg Diclofenac Injection 25 mg/ml																					
5	Ibuprofen Tablet 200 mg																					
6	Paracetamol tablet 250 mg Paracetamol Syrup 125 mg/5 ml Paracetamol Syrup 250 mg/5 ml																					
Anti allergics and medicines used in Anaphylaxis																						
7	Levocetirizine 5 mg Tablet Levocetirizine Oral Liquid																					
8	Hydrocortisone Succinate Injection 100 mg																					
9	Pheniramine Maleate Injection 22.75 mg/ml																					
10	Adrenaline Injection 1 mg/ml (1:1000)																					
Antidote and other Substances used in Poisioning																						
11	Atropine Injection 1 mg/ml																					
12	Activated Charcoal																					
Anti Convulsant/Anti Epileptic Medicines																						
13	Magnesium Sulfate Injection (50% solution), 2 ml ampoule																					
14	Diazepam Tablet 5 mg Diazepam Tablet 10 mg Diazepam rectal suppository(Controlled Medicine)																					
15	Midazolam Nasal Spray																					
16	Phenobarbitone Tablet 30 mg Phenobarbitone Tablet 60 mg Phenobarbitone Oral Liquid 20 mg/5 ml																					

17	Phenytoin Tablet 50 mg Phenytoin Tablet 300 mg																				
18	Sodium valproate Tablet 200 mg Sodium valproate Tablet 500 mg Sodium valproate Syrup each 5 ml contains 200 mg																				
Anti Infective Medicines																					
19	Albendazole Tablet 400 mg Albendazole Oral Liquid 200 mg/5 ml																				
20	Diethylcarbamazine Tablet 100 mg Diethylcarbamazine Oral Liquid 120 mg/5 ml																				
21	Amoxicillin Capsule 250 mg, Amoxicillin Capsule 500 mg Amoxicillin Oral liquid 250 mg/5 ml Amoxicillin Dispersible Tablet 250 mg																				
22	Gentamicin Injection 10 mg/ml Gentamicin Injection 80 mg/ml																				
23	Tab Co-trimoxazole [Sulphamethoxazol 80 mg +Trimethoprim 400 mg] Tab.20 mg trimethoprim + 100 mg sulphamethoxazole Co-trimoxazole Oral Liquid [Sulphamethoxazole 200 mg + Trimethoprim 40 mg/5 ml]																				
24	Doxycycline Capsule 100 mg																				
25	Metronidazole Tablet 200 mg Metronidazole Tablet 400 mg																				
26	Norfloxacin tab/oral liquid																				
Anti-Leprosy Medicines																					
27	Anti-leprosy medicines, As per current program guidelines (Adults and Pediatrics)																				
Anti- Tuberculosis Medicines																					
28	Anti-tuberculosis medicines, As per current program guidelines (Adults and Pediatrics)																				
Anti fungal Medicines																					
29	Clotrimazole Pessary 100 mg Clotrimazole Vaginal Tablet Clotrimazole Drops 1% Clotrimazole Cream 1%																				
30	Miconazole Ointment																				
31	Fluconazole Tablet 150 mg																				
Anti-Malarial Medicines																					
32	Anti-malarial medicines, As per program guidelines(Adults and Pediatrics)																				
Pain and Palliative Care Medicine																					
33	Lactulose Oral Liquid 10g/15 ml																				
34	Povidone Iodine Lotion and Ointment																				
Medicines Affecting Blood																					

35	Ferrous salt 100 mg + Folic acid 500 mcg Tablet Ferrous salt 20 mg + Folic acid 100 mcg Tablet Ferrous salt 60 mg + Folic acid 500 mcg Tablet Ferrous salt 45 mg + Folic acid 100 mcg Tablet Ferrous sulphate + Folic acid Syrup																				
36	Folic acid Tablet 5 mg Folic acid Tablet 400 mcg																				
37	Vitamin K Injection 1 mg/ml																				
38	Hydroxyurea capsule 100mg, 300mg, 500mg																				
Cardiovascular Medicines																					
39	Isosorbide-5- mononitrate Tablet 5 mg																				
40	Atenolol Tablet 50 mg																				
41	Metoprolol Tablet 25 mg Metoprolol SR Tablet 25 mg																				
42	Isosorbide dinitrate Tablet 5 mg (sublingual)																				
Anti Hypertensive Medicines																					
43	Amlodipine Tablet 2.5 mg Amlodipine Tablet 5 mg																				
44	Enalapril Tablet 5 mg																				
45	Telmisartan Tablet 40 mg																				
46	Hydrochlorothiazide Tablet 12.5 mg Hydrochlorothiazide Tablet 25mg																				
Hypolipidemic Medicines																					
47	Atorvastatin Tablet 10 mg																				
Medicines used in Dementia																					
48	Alprazolam Tablet 0.25 mg Alprazolam Tablet 0.5 mg																				
Dermatological Medicines (Topical)																					
49	Silver sulphadiazine Cream 1%																				
50	Betamethasone Cream 0.05%																				
51	Calamine Lotion																				
52	Benzyl Benzoate ointment/lotion																				
53	Mupirocin Ointment																				
54	Potassium Permanganate 0.1%																				
55	Zinc Oxide cream 10%																				
Disinfectants and Antiseptics																					
56	Ethyl Alcohol (denatured)) Solution 70%																				
57	Hydrogen Peroxide Solution 6%																				
58	Methylrosanilinium chloride (Gentian Violet)																				
59	Bleaching Powder containing not less than 30% w/w of available chlorine (as per I.P)																				
60	Gamma Benzene Hexachloride Lotion 100 ml																				
61	Framycetin cream 0.5%																				
Ear, Nose and Throat (ENT) Medicines																					
62	Ciprofloxacin Drops 0.3 % Ciprofloxacin Tablet 250 mg Ciprofloxacin Tablet 500 mg																				
63	Boro spirit ear drop																				
64	Wax Solvent Ear Drops: Benzocaine,Chlorobutol, Paradichlorobenzene, and Turpentine Oil																				
Gastrointestinal Medicines																					

65	Ranitidine Tablet 150 mg Ranitidine Injection				Y																
66	Omeprazole Capsule 20 mg				Y																
67	Ondansetron Tablet 4 mg Ondansetron Oral Liquid 2 mg/5 ml Ondansetron Injection 2 mg/ml				P																
68	Ispaghula- Granules, Husk, Powder				P																
69	Oral Rehydration Salts Oral Rehydration Powder 27.5 gm WHO Formula				P																
70	Zinc sulphate Dispersible Tablet 20 mg Zinc sulphate syrup				P																
71	Dicyclomine Tablet 10 mg Dicyclomine Injection				P																
72	Dioctyl sulfosuccinate sodium				P																
73	Magnesium Hydroxide Liquid				P																
74	Senna Tablet, Granules, Powder																				
75	Domperidone Tablet Domperidone Syrup																				
Hormones, other Endocrine Medicines and Contraceptives																					
76	Ethinylestradiol (A) + Levonorgestrel Tablet 0.03 mg (A) + 0.15 mg (B)				P																
77	IUCD 380A IUCD 375				P																
78	Male Condom				P																
79	Ormeloxifene Tablet 30 mg				P																
80	Levonorgestrel 1.5 mg				P																
81	Medroxyprogesterone acetate Injection 150 mg																				
82	Family Planning medicines and commodities																				
Medicines used in Diabetes Mellitus																					
83	Glimepiride Tablet 2 mg																				
84	Metformin Tablet 500 mg Metformin SR Tablet 500 mg																				
85	Glibenclamide Tablet 2.5 mg Glibenclamide Tablet 5 mg																				
Anti Thyroid medicines																					
86	Levothyroxine Tablet 25 mcg Levothyroxine Tablet 50 mcg Levothyroxine Tablet 100 mcg																				
Immunological/Vaccines																					
87	Immunological/Vaccines, As per Current Immunization Programme Guidelines																				
88	Rabies Vaccine																				
Oxytocic and Anti-Oxytocic Medicines																					
89	Misoprostol Tablet 200 mcg																				
Medicines Acting on Respiratory Tract																					
90	Budesonide Respirator solution for use in nebulizer 0.5 mg/ml																				
91	Salbutamol Tablet 2 mg Salbutamol Oral liquid 2 mg/5 ml Salbutamol Respirator solution for use in nebulizer 5 mg/ml																				
92	Normal Saline nasal drop: sodium chloride drops 0.05% w/v																				
93	Syrup Dextromethorphan																				
94	Hyoscinebutylbromide Tablet 10 mg																				

Solutions Correcting Water, Electrolyte Distribution and Acid-Base Distribution																					
95	Ringer Lactate Injection (as per IP)																				
96	Sodium Chloride Injection 0.9%																				
97	Dextrose 5% Dextrose 25%																				
Vitamins and Minerals																					
98	Ascorbic acid (Vitamin C) Tablet 100 mg																				
99	Calcium carbonate Tablet 500 mg																				
100	Cholecalciferol Tablet 60000 IU																				
101	Pyridoxine Tablet 25 mg Pyridoxine Tablet 50 mg Pyridoxine tablet 100 mg																				
102	Vitamin A Oral liquid 100000 IU/ml																				
103	B Complex Tablet																				
Ophthalmological Medicines																					
104	Sodium cromoglycate 2% eye drop																				
105	Methylcellulose Eye Drops																				
Diuretics Medicines																					
106	Furosemide Injection Furosemide Tablet 40 mg																				
Data Collected from State Essential Drugs List (EDL)																					
Sl. No.	**List of medicines not Part of IPHS but available in State Notified EDL**																				
Sl. No.	**List of Medicines Found at Health Facility but not part of IPHS EML & State Notified EDL**																				

Annexure-VIIIc

Patient Questionnaire: Medicine Availability

Name of Facility:	
Name of District	
Name of State	

		Patient Demographics	**Means of Verification**	Patient-1	Patient-2	Patient-3	Patient-4	Patient-5	Patient-6	Patient-7	Patient-8	Patient-9	Patient-10
Section-A	1	Name :											
	2	Out Patient/Inpatient											
	3	Age {Neonates (0-28 days), infants (1 month - 2 years), children (2-12 years), adolescents (12-18 years or 12-21 years) and Adult}:											
	4	Gender: Male / Female / Other											
	5	Religion (Hindu/ Muslim/ Christian/ Sikh/ Sarna/ Others)											
	6	Ethnicity (Tribal/ Non Tribal)											
	7	Socioeconomical status (BPL/ APL)											
	8	Caste (General/ OBC/ SC/ ST)											
	9	Education {Illiterate/ under matric/ Graduate/ above (Please mention the qualification)}											
	10	Rural/Urban: Rural / Urban											
	11	Employment Status (If age of the patient is less than 21 years then the employment status of the parents to be recorded) (Employed in formal organisation/ Self-employed/ Informal worker/ Unemployed											
	12	Name of the Disease diagnosed:											
	1	No. of Medicines Prescribed in the prescription	Prescription/Inpatient records										
	2	No. of medicines prescribed in Generic Name	Prescription/Inpatient records										
	3	No. of Medicines prescribed in Brand Name	Prescription/Inpatient records										

Section-B	4	No. of Medicines Dispensed by the facility	Physical verification (Patient & Dispensing personnel)										
	5	No. of Medicines Not available at the facility against Prescribed medicines	Physical verification (Patient & Dispensing personnel)										
	6	No. of Medicines purchased by the patient from outside against Prescribed medicines	Physical verification/ Bill										
	7	No. of times patient/relatives visited government health facilities for treatment (During Last one year)	Interaction with Patient & Relatives										
	8	No. of times patient/relatives visited Private / Charitable Health facilities for treatment (During Last one year)	Interaction with Patient & Relatives										
	9	Are you aware that government providing essential quality medicines free of cost at Government Health Facilities?	Interaction with Patient & Relatives										
	10	When you/relatives visit this Government Health Facility, are the medicines you need usually available? (* Always * Often * Sometimes * Rarely * Never)	Interaction with Patient & Relatives										
	11	In the past [During Last one year], have there been times when a medicine prescribed to you at this facility was not available? (* Yes * No)	Interaction with Patient & Relatives										
	12	If "Yes" to Q11, what happened when the medicine was not available? (Tick all that apply) * I was asked to purchase it from outside. * I was given an alternative medicine. * I was told to come back later. * I did not receive the medicine at all. * Other (Please specify):	Interaction with Patient & Relatives										
	13	Is there any instances that your doctor advice you/relatives to purchase medicines from the market, as free medicines provided by the government were deemed to be of substandard quality?(Y/N)	Interaction with Patient & Relatives										
Section-C	**Patients with Hypertenstion or Diabetes or both**												
	1	For your regular medications, how many days' worth of free medicine do you usually receive at one time from this facility? (* Less than 10 days * 10-30 days * More than 30 days * I have to buy my medicines.	Interaction with Patient & Relatives/Prescription/										
	2	Are you aware where to get free medicines for further refilling (* Not aware *SHC * PHC *CHC)	Interaction with Patient & Relatives										

	3	During last one year- for refilling of medicines, the quantity of medicines you receive from the health facility (* Full quantity received * Not received * Sometimes received & Sometimes purchased* full quantity purchased)	Interaction with Patient & Relatives (Supportive documents if any)										
	4	If you have not received full quantity medicines for refilling , reasons thereof (* Medicine not available at facility * Some time available & some time not available * Difficult to receive medicines * other please specify)	Interaction with Patient & Relatives (Supportive documents if any)										
Section-D	1	Overall, how satisfied are you with the availability of medicines at this Government Health Facility? (* Very Satisfied * Satisfied * Neutral * Dissatisfied * Very Dissatisfied)	Interaction with Patient & Relatives										
	2	Do you have any suggestions for improving the availability of medicines at this facility? (If yes then brief list of suggestions)	Interaction with Patient & Relatives										

Note -
1. Minimum number of patients to be intracted at AAM-SHC/USHC : 10 to 15
2. Minimum number of patients to be intracted at AAM-PHC/UPHC : 25 - 30
3. Minimum number of patients to be intracted at CHC : 30-50
4. Minimum number of patients to be intracted at DH & SDH : 40 - 50

Annexure-VIIId

Questionnaire on Knowledge, Attitude and Perception Regarding Free Essential Medicines among Caregivers (CHO at AAM SHCs, MO/ Pharmacy Officer at PHC/ UPHC AAM, MO/ Pharmacy Officer/ Nusing Officer at CHC, SDH and DH level facilities

Name of Facility:	
Name of District	
Name of State	

		Patient Demographics	Service Provider-1	Service Provider-2	Service Provider-3	Service Provider-4	Service Provider-5	Service Provider-6
Section-A (Details of the Service Provider)	1	Name :						
	2	Qualification						
	3	Designation						
	4	Age						
	5	Gender: Male/ Female/ Other						
Section-B	1	Generic medicines contain the same active ingredients as brand-name medicines. (Yes/No/Don't Know)						
	2	Generic medicines are interchangeable with brand-name medicines. (Yes/No/Don't Know)						
	3	Generic Medicines are manufactured by following the same procedure like brand name medicines. (Yes/No/Don't Know)						
	4	Does a generic medicine manufacturer need to repeat preclinical and clinical trials? (Yes/No/Don't Know)						
	5	Generic medicines are available in the Indian market also. (Yes/No/Don't Know)						
	6	Generic Medicines are less expensive than brand-name Medicines. (Yes/No/Don't Know)						
	7	Generic Medicines have the same active ingredients as the brand-name Medicines. (Yes/No/Don't Know)						

(Knowledge)	8	Generic Medicines are as effective as brand-name Medicines. (Yes/No/Don't Know)						
	9	Generic Medicines can be substituted for brand-name Medicines. (Yes/No/Don't Know)						
	10	Generic Medicines are as safe as brand-name Medicines. (Yes/No/Don't Know)						
	11	Generic Medicines have more side effects than brand-name Medicines. (Yes/No/Don't Know)						
	12	brand-name Medicines meet higher safety standards than generic Medicines. (Yes/No/Don't Know)						
	13	Generic Medicines are generally of the same quality as brand-name Medicines. (Yes/No/Don't Know)						
	14	Generic Medicines are cheaper because they are of inferior quality than the brand-name Medicines. (Yes/No/Don't Know)						
Section-C (Attitude)	1	Do you believe that, there is a lack of quality check in generic Medicines ? (Yes/No/Don't Know)						
	2	Do you believe that, there is a lack of information about efficacy and safety of generic Medicines ? (Yes/No/Don't Know)						
	3	Brand name Medicines are manufatured in modern facilities and generic Medicines are manufactured in substandard facilities. (Yes/No/Don't Know)						
	4	Only a few local companies manufacture generic medicine. (Yes/No/Don't Know)						
	5	Is it required to have guidelines on generic substitution process ? (Yes/No/Don't Know)						
	6	Do you believe that generic substitution will ensure prompt availability of Medicines to the patients like brand name medicines ? (Yes/No/Don't Know)						
	7	Generic substitution reduces drug costs in patient pharmacotherapy ? (Yes/No/Don't Know)						
	1	Do you prescribe/ advise generic Medicines to your patients? (Yes/No/Sometimes)						
	2	Have you been concerned about therapeutic failure with generic medicines after prescribing? (Yes/No/Sometimes)						
	3	Have you been hesitant to prescribe generic Medicines in life-threatening situations? (Yes/No/Sometimes)						

Section-D (Perception)	4	Will you prefer taking and recommending generics to my family members ? (Yes/No/Sometimes)						
	5	Have you ever switched a patient on brand-name Medicines to available generic Medicines? (Yes/No/Sometimes)						
	6	Have you read any article on the comparison of efficacy and safety of generic vs brand name Medicines ? (Yes/No/Sometimes)						
	7	Do you want the pharmacists to change brand name Medicines with their generic versions? (Yes/No/Sometimes)						
	8	Are the patient's demand brand name Medicines ? (Yes/No/Sometimes)						
	9	Are the prescriptions influenced by Medical Representatives (MR) ? (Yes/No/Sometimes)						
	10	Are you willing to encourage patients to use generic medicine? (Yes/No/Sometimes)						

Note -
1. Applicable for CHO at at AAM-SHC/USHC.
2. Applicable for MO and Pharmacy officer at AAM-PHC/UPHC.
3. Applicable for MO, Nursing officers & Pharmacy officer at CHC (atlest 5 service providers)
4. Applicable for MO, Nursing officers & Pharmacy officer at DH & SDH (atlest 10 service providers)